<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6155950</article-id><article-id pub-id-type="doi">10.3390/molecules22010058</article-id><article-id pub-id-type="publisher-id">molecules-22-00058</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cheuka</surname><given-names>Peter Mubanga</given-names></name><xref ref-type="aff" rid="af1-molecules-22-00058">1</xref></contrib><contrib contrib-type="author"><name><surname>Mayoka</surname><given-names>Godfrey</given-names></name><xref ref-type="aff" rid="af1-molecules-22-00058">1</xref></contrib><contrib contrib-type="author"><name><surname>Mutai</surname><given-names>Peggoty</given-names></name><xref ref-type="aff" rid="af2-molecules-22-00058">2</xref></contrib><contrib contrib-type="author"><name><surname>Chibale</surname><given-names>Kelly</given-names></name><xref ref-type="aff" rid="af1-molecules-22-00058">1</xref><xref ref-type="aff" rid="af3-molecules-22-00058">3</xref><xref ref-type="aff" rid="af4-molecules-22-00058">4</xref><xref rid="c1-molecules-22-00058" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>McPhee</surname><given-names>Derek J.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-22-00058"><label>1</label>Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa; <email>chkpet008@myuct.ac.za</email> (P.M.C.); <email>mykgod001@myuct.ac.za</email> (G.M.)</aff><aff id="af2-molecules-22-00058"><label>2</label>Department of Pharmacology and Pharmacognosy, University of Nairobi, P.O. Box 19676, 00202 KNH Nairobi, Kenya; <email>pckemei@gmail.com</email></aff><aff id="af3-molecules-22-00058"><label>3</label>Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa</aff><aff id="af4-molecules-22-00058"><label>4</label>South African Medical Research Council Drug Discovery and Development Research Unit, University of Cape Town, Rondebosch 7701, South Africa</aff><author-notes><corresp id="c1-molecules-22-00058"><label>*</label>Correspondence: <email>kelly.chibale@uct.ac.za</email>; Tel.: +27-21-6502553</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2017</year></pub-date><volume>22</volume><issue>1</issue><elocation-id>58</elocation-id><history><date date-type="received"><day>07</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>27</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 by the authors.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Endemic in 149 tropical and subtropical countries, neglected tropical diseases (NTDs) affect more than 1 billion people annually, including 875 million children in developing economies. These diseases are also responsible for over 500,000 deaths per year and are characterized by long-term disability and severe pain. The impact of the combined NTDs closely rivals that of malaria and tuberculosis. Current treatment options are associated with various limitations including widespread drug resistance, severe adverse effects, lengthy treatment duration, unfavorable toxicity profiles, and complicated drug administration procedures. Natural products have been a valuable source of drug regimens that form the cornerstone of modern pharmaceutical care. In this review, we highlight the potential that remains untapped in natural products as drug leads for NTDs. We cover natural products from plant, marine, and microbial sources including natural-product-inspired semi-synthetic derivatives which have been evaluated against the various causative agents of NTDs. Our coverage is limited to four major NTDs which include human African trypanosomiasis (sleeping sickness), leishmaniasis, schistosomiasis and lymphatic filariasis.</p></abstract><kwd-group><kwd>human African trypanosomiasis</kwd><kwd>leishmaniasis</kwd><kwd>schistosomiasis</kwd><kwd>lymphatic filariasis</kwd><kwd>natural products</kwd><kwd>antiprotozoal agents</kwd><kwd>phytotherapy</kwd></kwd-group></article-meta></front><body><sec id="sec1-molecules-22-00058"><title>1. Introduction</title><sec id="sec1dot1-molecules-22-00058"><title>1.1. Neglected Tropical Diseases: Definition, Classification and Epidemiology</title><p>According to the World Health Organization (WHO), 17 diseases caused by bacteria and parasites, are classified as neglected tropical diseases (NTDs) [<xref rid="B1-molecules-22-00058" ref-type="bibr">1</xref>]. These include Buruli ulcer, Chagas disease, dengue, chikungunya, dracunculiasis (Guinea-worm disease), echinococcosis, foodborne trematodiases, human African trypanosomiasis (sleeping sickness), and leishmaniasis. More recently, mycetoma was also officially recognized as a NTD at the 69th World Health Assembly held on 28 May 2016. Because there are still other diseases in poverty-stricken settings that remain neglected, the World Health Assembly also resolved to systematically evaluate and potentially include more diseases to the list of NTDs. Populations living in poverty with sub-standard sanitation and close contact with infectious vectors as well as domestic animals and livestock are the most affected. A general lack of attention to the developing world can explain why these diseases have been neglected for decades. More recently, diseases like HIV/AIDS, tuberculosis, and malaria have drawn much of the attention and research funding at the expense of NTDs [<xref rid="B2-molecules-22-00058" ref-type="bibr">2</xref>].</p><p>The WHO-recognized NTDs can further be categorized according to the class of the disease-causing agents. For instance, those caused by protozoan parasites include human African trypanosomiasis, otherwise called sleeping sickness. This is caused by two parasites of the genus <italic>Trypanosoma</italic>&#x02014;<italic>T. brucei gambiense</italic> and <italic>T. brucei rhodesiense</italic> [<xref rid="B2-molecules-22-00058" ref-type="bibr">2</xref>]. <italic>Trypanosoma cruzi</italic> represents another protozoan parasite that is responsible for Chagas disease, an infection that affects about 200,000 new people per year in the Americas and is one of the human parasitic conditions that is deeply concerning to the New World [<xref rid="B3-molecules-22-00058" ref-type="bibr">3</xref>]. Furthermore, leishmaniasis is also caused by a myriad of species of protozoan parasites of the genus <italic>Leishmania</italic>. These parasites have been implicated in a range of disease conditions which can be self-healing ulcers on the one hand while severe and fatal visceral disease can also occur. With the exception of malaria and lymphatic filariasis, this group of parasites has been associated with the highest mortality and morbidity among human parasitic infections [<xref rid="B4-molecules-22-00058" ref-type="bibr">4</xref>]. Another major class of NTDs is caused by helminths which include soil-transmitted helminths (STHs), schistosomiasis, lymphatic filariasis, onchocerciasis, and dracunculiasis. At least a billion people are infected by one or more of the parasitic STHs with infection being facilitated by the ingestion of, as well as direct contact with, soil contaminated with worm eggs or larvae [<xref rid="B5-molecules-22-00058" ref-type="bibr">5</xref>]. This group of parasitic infections are more devastating in children with a range of symptoms including stunted growth, compromised physical fitness, educational performance and school attendance [<xref rid="B6-molecules-22-00058" ref-type="bibr">6</xref>]. This group of infections has significant poverty-inducing impact albeit death is an unlikely outcome [<xref rid="B7-molecules-22-00058" ref-type="bibr">7</xref>]. Schistosomiasis, also known as bilharzia, represents another NTD caused by helminths with about 200 million people infected globally [<xref rid="B8-molecules-22-00058" ref-type="bibr">8</xref>]. Humans are known to be infected by five species of parasitic trematodes belonging to the family Schistosomatidae. With snails known to be intermediate hosts, their life cycle is complicated. The parasites released into bodies of water by snails invade the human host through entry via intact human skin where they undergo further development in the lungs before migration to other tissues of the human body. Fever, lethargy and eosinophilia are some of the symptoms that characterize acute illness, also known as, Katayama fever. Tissue-specific pathologies depend on the species of schistosoma responsible for infection whereby <italic>S. mansoni</italic> and <italic>S. japonicum</italic> cause intestinal manifestations whereas <italic>S. haematobium</italic> leads to urinary schistosomiasis typified by haematuria-the presence of blood in urine [<xref rid="B2-molecules-22-00058" ref-type="bibr">2</xref>]. Another psychologically and socio-economically devastating helminth infection is lymphatic filariasis, commonly known as elephantiasis. It is associated with enlargement of the limbs, genitals or breasts [<xref rid="B9-molecules-22-00058" ref-type="bibr">9</xref>]. Endemic areas harbour 20% of the global population with over 120 million people in 83 countries infected. Of these, 40 million are disfigured by the disease [<xref rid="B2-molecules-22-00058" ref-type="bibr">2</xref>]. Transmission is mediated by mosquitoes with most infections acquired remaining asymptomatic for many years. Other helminth-caused NTDs include onchocerciasis (river blindness) and dracunculiasis whose manifestation, symptoms as well as epidemiology are described elsewhere [<xref rid="B2-molecules-22-00058" ref-type="bibr">2</xref>]. Another class of NTDs which include trachoma, Buruli ulcer and leprosy are caused by bacteria. Trachoma remains a public health concern in 42 countries and inflicts blindness or visual impairment of about 1.9 million people [<xref rid="B10-molecules-22-00058" ref-type="bibr">10</xref>]. Contact with eye and nose discharges from infected individuals transmits the disease-causing bacterium <italic>Chlamydia trachomatis</italic>. Inanimate objects such as towels and/or washcloths as well as eye-seeking flies can also facilitate transmission [<xref rid="B10-molecules-22-00058" ref-type="bibr">10</xref>]. Latest estimates indicate 200 million people are resident in endemic districts and are thus at risk of trachoma blindness [<xref rid="B10-molecules-22-00058" ref-type="bibr">10</xref>].</p></sec><sec id="sec1dot2-molecules-22-00058"><title>1.2. Relative Public Health Impact</title><p>Endemic in 149 tropical and subtropical countries, NTDs affect more than 1 billion people including 875 million children, financially draining developing economies annually [<xref rid="B1-molecules-22-00058" ref-type="bibr">1</xref>,<xref rid="B11-molecules-22-00058" ref-type="bibr">11</xref>]. NTDs are responsible for over 500,000 deaths per year and are characterized by long-term disability and severe pain. Children suffer the most devastating symptoms which include malnutrition, cognitive impairment, stunted growth, and inability to attend school while infection in adults can result in social isolation as well as inability to work [<xref rid="B11-molecules-22-00058" ref-type="bibr">11</xref>]. The impact of the combined NTDs closely rivals that of malaria and tuberculosis [<xref rid="B12-molecules-22-00058" ref-type="bibr">12</xref>]. Some scholars have also argued that the reported health impact of NTDs may be underestimated due to the fact that many NTD infections are asymptomatic and are associated with longer incubation periods. In this regard, it has been argued that it is often difficult to establish a connection between a particular death and the corresponding NTD infection that has been latent over a long time [<xref rid="B13-molecules-22-00058" ref-type="bibr">13</xref>].</p></sec><sec id="sec1dot3-molecules-22-00058"><title>1.3. Challenges in Drug Discovery for NTDs and Challenges/Limitations of Current Therapies</title><p>Drug discovery and development for NTDs is faced with a number of challenges. Firstly, investment in these therapeutic areas by major pharmaceutical companies is not financially attractive owing to the prospect of poor financial returns. For this reason, drug discovery against parasitic diseases, including NTDs, has not been motivated by commercial reasons [<xref rid="B14-molecules-22-00058" ref-type="bibr">14</xref>]. Many pharmaceutical companies have adopted an opportunistic approach by utilizing drugs which were historically developed for other disease indications for repurposing against NTDs. Although such an approach has obvious advantages, which include the reduced cost of development, it does not, unfortunately, introduce chemically novel drugs on the market. Furthermore, the utility of such an approach may not be viable any more due to widespread resistance to certain chemical classes [<xref rid="B14-molecules-22-00058" ref-type="bibr">14</xref>]. Since NTDs affect resource-constrained countries, it is usually a challenge to tailor drug candidates&#x02019; target product profiles to what is required in resource-poor settings. For instance, optimising a drug candidate for safe use without close medical supervision is one such obstacle [<xref rid="B14-molecules-22-00058" ref-type="bibr">14</xref>].</p><p>Current clinically used drugs against NTDs are far from ideal. Some of the limitations associated with current chemotherapeutic agents include widespread drug resistance, severe adverse effects, lengthy treatment duration, unfavourable toxicity profiles, and complicated drug administration procedures&#x02014;which may be a challenge in the resource-poor communities affected by the NTDs. The use of some drug regimens is also jeopardized by their limited availability [<xref rid="B14-molecules-22-00058" ref-type="bibr">14</xref>].</p></sec><sec id="sec1dot4-molecules-22-00058"><title>1.4. Natural Products and Their Utility as Therapeutics: Advantages and Disadvantages</title><p>It has been estimated that approximately over half of the pharmaceuticals in clinical use today are derived from natural products [<xref rid="B15-molecules-22-00058" ref-type="bibr">15</xref>]. Some natural product-derived drugs that are a hallmark of modern pharmaceutical care include quinine, theophylline, penicillin G, morphine, paclitaxel, digoxin, vincristine, doxorubicin, cyclosporine and vitamin A among many other examples [<xref rid="B15-molecules-22-00058" ref-type="bibr">15</xref>]. For centuries, natural substances, particularly plants, have been used to control and treat diseases and this has culminated in the discovery of the majority of modern pharmaceutical agents [<xref rid="B16-molecules-22-00058" ref-type="bibr">16</xref>]. Ancient Egyptians practiced medicine from as far back as 2900 BC. The &#x0201c;Ebers Papyrus&#x0201d;, the best known first record of Egyptian pharmaceutical practice has been dated to as far back as 1500 BC. The papyrus, which describes over 700 drugs, mostly of plant origin, details different drug formulations including gargles, snuffs, poultices, infusions, pills and ointments, with beer, milk, wine and honey being commonly used as vehicles [<xref rid="B17-molecules-22-00058" ref-type="bibr">17</xref>]. Dioscorides first documented the medicinal use of natural substances as far back as 78 AD. Until now, thousands of medicinal plants described then remain relevant today in modern medicine [<xref rid="B18-molecules-22-00058" ref-type="bibr">18</xref>]. Although such plant materials are no longer used as crude drug preparations, they remain important sources of purified active principles that have become cornerstones of modern therapy [<xref rid="B15-molecules-22-00058" ref-type="bibr">15</xref>]. Between 2005 and 2007 alone, 13 natural-product-derived drugs were approved [<xref rid="B19-molecules-22-00058" ref-type="bibr">19</xref>]. Other recently approved drugs, covered extensively in specialised reviews [<xref rid="B17-molecules-22-00058" ref-type="bibr">17</xref>,<xref rid="B19-molecules-22-00058" ref-type="bibr">19</xref>,<xref rid="B20-molecules-22-00058" ref-type="bibr">20</xref>,<xref rid="B21-molecules-22-00058" ref-type="bibr">21</xref>], include compounds that are derived from plant, microbial, and animal sources as well as semi-synthetic compounds based on natural product templates. Apart from covering a wide spectrum of disease indications&#x02014;anti-cancer, anti-infective, anti-diabetic among others, they also show an exceptional diversity of chemical structures. Analysis of the chemical properties of recently developed small molecule natural-product-derived drugs has revealed that half of them were in conformity with Lipinski&#x02019;s Rule of 5 for orally available drugs [<xref rid="B22-molecules-22-00058" ref-type="bibr">22</xref>]. Although the remainder of the drugs had higher molecular weights, more rotatable bonds, and more stereogenic centres, they still exhibited relatively low log <italic>p</italic> values. Natural products, therefore, generally are more readily absorbed than synthetic drugs.</p><p>Despite such advantages and a proven track record of successes, many big pharmaceutical companies have been discouraged from pursuing natural product-based drug discovery due to perceived disadvantages of natural products. These include challenges in ensuring access and adequate supply, the complexities of natural product chemistry with associated slowness of working with natural products, and intellectual property rights concerns. Furthermore, the use of combinatorial chemistry to generate large libraries of synthetic compounds gave hope to pharmaceutical companies much to the detriment of natural products-based drug discovery research [<xref rid="B23-molecules-22-00058" ref-type="bibr">23</xref>,<xref rid="B24-molecules-22-00058" ref-type="bibr">24</xref>,<xref rid="B25-molecules-22-00058" ref-type="bibr">25</xref>]. In this article, we review different natural products from plant, microbial, and marine sources that have shown potential as lead compounds against the neglected tropical diseases. The coverage has been largely restricted to only those natural products which have exhibited substantial potency against the different disease-causing agents. Other natural products evaluated against different NTD-causative agents have been extensively reviewed elsewhere [<xref rid="B26-molecules-22-00058" ref-type="bibr">26</xref>,<xref rid="B27-molecules-22-00058" ref-type="bibr">27</xref>,<xref rid="B28-molecules-22-00058" ref-type="bibr">28</xref>,<xref rid="B29-molecules-22-00058" ref-type="bibr">29</xref>,<xref rid="B30-molecules-22-00058" ref-type="bibr">30</xref>,<xref rid="B31-molecules-22-00058" ref-type="bibr">31</xref>,<xref rid="B32-molecules-22-00058" ref-type="bibr">32</xref>,<xref rid="B33-molecules-22-00058" ref-type="bibr">33</xref>,<xref rid="B34-molecules-22-00058" ref-type="bibr">34</xref>,<xref rid="B35-molecules-22-00058" ref-type="bibr">35</xref>,<xref rid="B36-molecules-22-00058" ref-type="bibr">36</xref>,<xref rid="B37-molecules-22-00058" ref-type="bibr">37</xref>,<xref rid="B38-molecules-22-00058" ref-type="bibr">38</xref>,<xref rid="B39-molecules-22-00058" ref-type="bibr">39</xref>,<xref rid="B40-molecules-22-00058" ref-type="bibr">40</xref>,<xref rid="B41-molecules-22-00058" ref-type="bibr">41</xref>,<xref rid="B42-molecules-22-00058" ref-type="bibr">42</xref>,<xref rid="B43-molecules-22-00058" ref-type="bibr">43</xref>,<xref rid="B44-molecules-22-00058" ref-type="bibr">44</xref>,<xref rid="B45-molecules-22-00058" ref-type="bibr">45</xref>].</p></sec></sec><sec id="sec2-molecules-22-00058"><title>2. Human African Trypanosomiasis (Sleeping Sickness)</title><sec id="sec2dot1-molecules-22-00058"><title>2.1. Background of the Disease</title><p>As noted earlier in this review, the protozoan parasites of the genus <italic>Trypanosoma</italic> are responsible for the NTD human African trypanosomiasis. Commonly called sleeping sickness, the disease is transmitted by vectors&#x02014;the bites of tsetse flies (<italic>Glossina</italic> spp.) facilitate entry of the parasites into the human host [<xref rid="B46-molecules-22-00058" ref-type="bibr">46</xref>]. The parasites further invade the central nervous system upon multiplication and subsequent crossing of the blood-brain barrier. It is at this stage that the more obvious symptoms of the disease are evident: changes of behaviour, confusion, sensory disturbances and poor coordination. Another important symptom which gives the disease its name is the disruption of the sleep cycle with victims usually uncontrollably sleeping during the day [<xref rid="B47-molecules-22-00058" ref-type="bibr">47</xref>]. The disease is usually fatal if not promptly diagnosed and treated. Of the two parasite species responsible for the disease, <italic>T. brucei gambiense</italic> accounts for 98% of reported cases. Due to sustained control efforts, the number of reported cases has significantly dropped from about 10,000 in 2009 to 3796 cases in 2014 [<xref rid="B47-molecules-22-00058" ref-type="bibr">47</xref>].</p><p>The disease burden differs from one country to another with variations in different localities of the same country [<xref rid="B47-molecules-22-00058" ref-type="bibr">47</xref>]. The Democratic Republic of the Congo (DRC) accounted for over 70% of the reported cases in the last decade. Additionally, 85% (over 1000 new cases) of the reported cases in 2014 were in the DRC. In the same year, between 100 and 200 cases were declared in the Central African Republic making it the second most afflicted country after the DRC. Comfortingly, other countries (Angola, Burkina Faso, Cameroon, Chad, Congo, C&#x000f4;te d&#x02019;Ivoire, Gabon, Guinea, Malawi, South Sudan, Uganda, United Republic of Tanzania, Zambia and Zimbabwe) are reporting less than 100 cases annually [<xref rid="B47-molecules-22-00058" ref-type="bibr">47</xref>]. Other African countries have not reported any new cases for over a decade. Transmission may have stopped in some of these countries albeit it remains a challenge to assess the exact situation in some areas beset by social and political instability [<xref rid="B47-molecules-22-00058" ref-type="bibr">47</xref>].</p></sec><sec id="sec2dot2-molecules-22-00058"><title>2.2. Antitrypanosomal Drugs and Current Shortfalls</title><p>Current antitrypanosomal drugs such as pentamidine, suramin, melarsoprol, and eflornithine, (<xref ref-type="fig" rid="molecules-22-00058-f001">Figure 1</xref>) are beset by a number of challenges ranging from limited effectiveness, emergence of drug resistance, complexity of administration, and too many undesirable side effects [<xref rid="B47-molecules-22-00058" ref-type="bibr">47</xref>,<xref rid="B48-molecules-22-00058" ref-type="bibr">48</xref>]. The disease causative pathogen and the stage of disease progression are the two factors that are considered when selecting drug treatment regimens. Currently, all the drugs are donated to the WHO by pharmaceutical companies [<xref rid="B49-molecules-22-00058" ref-type="bibr">49</xref>,<xref rid="B50-molecules-22-00058" ref-type="bibr">50</xref>]. For first-stage <italic>T. brucei gambiense</italic> disease, pentamidine is the drug of choice for treatment. Administration is complicated, often requiring intravenous infusion in saline over 2 h or intramuscular administration for a week. Although generally well tolerated, when administered via intramuscular injection, adverse events including pain and swelling at the site of administration, abdominal pain, gastrointestinal problems, and hypoglycaemia (5%&#x02013;40%) have been reported [<xref rid="B51-molecules-22-00058" ref-type="bibr">51</xref>].</p><p>First stage infections with <italic>T. brucei rhodesiense</italic> disease are generally treated with suramin, whose dose regimen is complicated and lasts up to 30 days [<xref rid="B52-molecules-22-00058" ref-type="bibr">52</xref>]. Owing to its instability in air, the drug should be administered immediately upon dilution with distilled water [<xref rid="B53-molecules-22-00058" ref-type="bibr">53</xref>]. Treatment with suramin is also accompanied with adverse side effects which include nephrotoxicity, peripheral neuropathy, bone marrow toxicity coupled with agranulocytosis and thrombocytopenia [<xref rid="B54-molecules-22-00058" ref-type="bibr">54</xref>].</p><p>Second-line drugs that are used for treatment of the second phase of disease are melarsoprol and eflornithine. For treatment of second-phase disease caused by <italic>T. brucei gambiense</italic> in resource-constrained countries where availability/affordability of eflornithine is a challenge, the arsenic-containing compound, melarsoprol, is the drug of choice. It is also the only treatment option for second phase <italic>T. brucei rhodesiense</italic> infections. Treatment schedules with melarsoprol are complicated and are accompanied by severe adverse reactions which can be fatal [<xref rid="B51-molecules-22-00058" ref-type="bibr">51</xref>]. Developed nearly three decades ago, eflornithine offers a safer treatment option [<xref rid="B55-molecules-22-00058" ref-type="bibr">55</xref>] for <italic>T. brucei gambiense</italic> disease although side effects including fever, unusual bleeding and weakness, diarrhoea, nausea, stomach pain, as well as vomiting are common [<xref rid="B56-molecules-22-00058" ref-type="bibr">56</xref>]. In the context of rural Africa, the use of eflornithine is severely limited by the need to administer it as multiple daily infusions [<xref rid="B57-molecules-22-00058" ref-type="bibr">57</xref>].</p></sec><sec id="sec2dot3-molecules-22-00058"><title>2.3. Antitrypanosomal Natural Products</title><p>Natural products represent an untapped resource for novel, diverse, safe, and affordable anti-trypanosomal drug lead compounds. Nature has inspired a number of human antiprotozoal chemotherapeutics, which include antimalarials such as quinine, an alkaloid from <italic>Cinchona</italic> spp. (Rubiaceae), and artemisinin, a sesquiterpene lactone derived from <italic>Artemisia annua</italic> (Asteraceae). Used to treat amoebiasis, emetine is another antiprotozoal alkaloid from <italic>Cephaelis ipecacuanha</italic> (Rubiaceae). Additionally, these naturally-derived antiprotozoal agents have been employed as templates in the development of synthetic and semisynthetic drugs with improved efficacy, safety or pharmacokinetic properties [<xref rid="B58-molecules-22-00058" ref-type="bibr">58</xref>]. An extensive literature search revealed several natural-product-based classes of antitrypanosomal molecules albeit very few have been advanced to in vivo evaluation while none have been clinically studied [<xref rid="B32-molecules-22-00058" ref-type="bibr">32</xref>]. As we review the different antitrypanosomal natural product molecules, an attempt has been made to classify them based on chemical class. Natural products from plant, microbial and marine sources are reviewed. Total synthetic and semisynthetic compounds based on natural product scaffolds are also reviewed. All IC<sub>50</sub> values reported in this review have been harmonized by converting to micromolar (&#x003bc;&#x0039c;) values. There is also need to exercise caution in drawing comparisons between IC<sub>50</sub> values for different metabolites. This is because of variations in the nature of assays used in experimentally determining such values in different research laboratories. The review is restricted in scope, emphasising only those natural products that have exhibited significant potency in vitro (IC<sub>50</sub> &#x0003c; 1 &#x003bc;&#x0039c;) and in vivo against trypanosomes responsible for human African trypanosomiasis. A similar restriction was also applied for antileishmanial natural products, which are discussed in later sections of this review.</p><sec id="sec2dot3dot1-molecules-22-00058"><title>2.3.1. Antitrypanosomal Natural Products from Marine Sources</title><sec><title>Alkaloids</title><p>Antitrypanosomal activity of several alkaloids isolated from marine organisms which include sponges, ascidians and tunicates has been reported [<xref rid="B59-molecules-22-00058" ref-type="bibr">59</xref>,<xref rid="B60-molecules-22-00058" ref-type="bibr">60</xref>,<xref rid="B61-molecules-22-00058" ref-type="bibr">61</xref>]. In this regard, lepadins D (<bold>1</bold>), E (<bold>2</bold>), and F (<bold>3</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f002">Figure 2</xref>), isolated from the tunicate species of the genus <italic>Didemnum</italic>, and possessing a decahydroquinoline skeleton, demonstrated significant antitrypanosomal potency while retaining selectivity in vitro. While exhibiting submicromolar potency (IC<sub>50</sub> &#x0003c; 1 &#x003bc;M) on the <italic>T. brucei rhodesiense</italic> bloodstream trypomastigotes, the two diastereomers, <bold>2</bold> and <bold>3</bold>, were also found to be respectively 43- and 80-fold less toxic on L6 mammalian cells. However, on the same species of trypanosomes, the hydroxy-containing analogue, <bold>1</bold>, was only weakly active, highlighting how critical to potency the 2-<italic>E</italic>-octenoic acid ester functionality is in these decahydroquinoline alkaloids [<xref rid="B59-molecules-22-00058" ref-type="bibr">59</xref>]. Also possessing submicromolar potency (IC<sub>50</sub> = 0.6 &#x003bc;M) against the mammalian stage of <italic>T. brucei rhodesiense</italic> is fascaplysin <bold>4</bold> (<xref ref-type="fig" rid="molecules-22-00058-f002">Figure 2</xref>), a quaternary indole alkaloid isolated from the marine sponge <italic>Hyrtios erecta</italic>. Regrettably, this indole alkaloid was characterized by significant cytotoxicity on L6 cells [<xref rid="B60-molecules-22-00058" ref-type="bibr">60</xref>]. Also from a marine perspective, Copp and co-workers [<xref rid="B61-molecules-22-00058" ref-type="bibr">61</xref>] have reported the isolation of two pyridoacridone alkaloids, ascididemin (<bold>5</bold>), and 2-bromoascididemin (<bold>6</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f002">Figure 2</xref>). Being a pentacyclic DNA intercalating agent, compound <bold>5</bold> was associated with substantial cytotoxic activities. Although the two compounds were, generally, more cytotoxic to macrophages than to <italic>T. brucei rhodesiense</italic>, medicinal chemistry derivatization approaches identified very potent analogues with improved safety profiles, which are discussed in later sections of this review.</p></sec><sec><title>Peroxides and Saponins</title><p>Other marine organisms have furnished highly trypanocidal peroxides. Phytochemical investigation of the marine sponge <italic>Plakortis cfr. Lita</italic> has unraveled an ultrapotent peroxide derivative, manadoperoxide B (<bold>7</bold>, <xref ref-type="fig" rid="molecules-22-00058-f002">Figure 2</xref>) [<xref rid="B62-molecules-22-00058" ref-type="bibr">62</xref>]. Evaluation against <italic>T. brucei rhodesiense</italic> revealed that <bold>7</bold> was highly trypanocidal (IC<sub>50</sub> = 0.009 &#x003bc;M) and was equipotent to the reference drug melarsoprol (IC<sub>50</sub> = 0.008 &#x003bc;M). Although less potent than manadoperoxide B, other manadoperoxides still retained marked submicromolar potency. These include manadoperoxide I (<bold>8</bold>, IC<sub>50</sub> = 0.173 &#x003bc;M), and manadoperoxide K (<bold>9</bold>, IC<sub>50</sub> = 0.198 &#x003bc;&#x0039c;). Excitingly, the metabolites were found to be non-toxic on the human cell line HMEC-1. In the same study, Chianese and colleagues were able to draw some structure-activity relationship (SAR) profile around the peroxide <bold>7</bold> by comparing the obtained antitrypanosomal data with that reported in literature for related dioxane derivatives. Close examination of the data revealed that subtle modifications such as positional change of the methyl group on the dioxane ring can drastically influence antitrypanosomal potency [<xref rid="B62-molecules-22-00058" ref-type="bibr">62</xref>].</p><p>Steroidal saponins from marine sources have also been found to strongly inhibit <italic>Trypanosoma</italic> parasites. A noteworthy example is pandaroside G methyl ester (<bold>10</bold>, <xref ref-type="fig" rid="molecules-22-00058-f002">Figure 2</xref>) isolated from a Caribbean sponge <italic>Pandaros acanthifolium</italic>. Although this metabolite lacks selectivity against mammalian L6 cells (IC<sub>50</sub> = 0.22 &#x003bc;M), it was found to be highly trypanocidal with submicromolar potency against <italic>T. brucei rhodesiense</italic> (IC<sub>50</sub> = 0.038 &#x003bc;M) [<xref rid="B63-molecules-22-00058" ref-type="bibr">63</xref>]. On the other hand, the oroidin dimer dibromopalau&#x02019;amine (<bold>11</bold>, <xref ref-type="fig" rid="molecules-22-00058-f002">Figure 2</xref>) isolated from <italic>Axinella verrucosa</italic> has demonstrated submicromolar activity (IC<sub>50</sub> = 0.8 &#x003bc;&#x0039c;, <italic>T. brucei rhodesiense</italic>) with favourable selectivity, selectivity index of 10, against mammalian L6 cells [<xref rid="B64-molecules-22-00058" ref-type="bibr">64</xref>,<xref rid="B65-molecules-22-00058" ref-type="bibr">65</xref>].</p></sec></sec><sec id="sec2dot3dot2-molecules-22-00058"><title>2.3.2. Antitrypanosomal Natural Products from Plant and Microbial Sources</title><sec><title>Phenolic Natural Products</title><p>In another study that evaluated 132 flavonoids from different subclasses (flavone, flavonol, flavanone, isoflavone and chalcone subclasses), R&#x000e4;z [<xref rid="B66-molecules-22-00058" ref-type="bibr">66</xref>] was able to identify two trypanocidal compounds (<xref ref-type="fig" rid="molecules-22-00058-f003">Figure 3</xref>) which demonstrated submicromolar potency against <italic>T. brucei rhodesiense</italic> while maintaining exceptionally good selectivity: 7,8-dihydroxyflavone (<bold>12</bold>) and quercetagetin (<bold>13</bold>), IC<sub>50</sub> = 0.16 and 0.8 &#x003bc;M, SI = 1019 and 571 (adenocarcinoma cells (HT-29)), respectively. In addition to the two most potent compounds identified, the minimum structural requirements for potency were also noted. It was generally observed that flavones, a subclass bearing a C2-C3 double bond were more potent than flavanones, another subclass devoid of the double bond at the same position. It was also observed that the flavone derivatives which lack the hydroxyl functionality on C3 were less trypanocidal than hydroxyl-containing flavonols [<xref rid="B66-molecules-22-00058" ref-type="bibr">66</xref>].</p><p>Another class of phenolic derivatives, the chalcones, have been explored as trypanocidal agents. In one study, &#x003b2;-oxygenated chalcones, Demethylpraecansone B and praecansone B (structures not shown) were isolated from the roots of <italic>Tephrosia aequilata</italic> (Papilionaceae), and were found to exhibit modest trypanocidal potency on <italic>T. brucei rhodesiense</italic> [<xref rid="B67-molecules-22-00058" ref-type="bibr">67</xref>]. Also noteworthy amongst the trypanocidal phenolic derivatives are two arylnaphthalide lignans, justicidin B (<bold>14</bold>) and its hydroxylated derivative, piscatorin (<bold>15</bold>, <xref ref-type="fig" rid="molecules-22-00058-f003">Figure 3</xref>). When tested on the bloodstream trypomastigotes of <italic>T. brucei rhodesiense</italic>, compound <bold>14</bold> exhibited strong inhibition with submicromolar activity (IC<sub>50</sub> = 0.55 &#x003bc;M) albeit cytotoxic on different mammalian cell lines. The hydroxylated derivative <bold>15</bold> was on the other hand 11-fold less potent (IC<sub>50</sub> = 6.1 &#x003bc;M) [<xref rid="B68-molecules-22-00058" ref-type="bibr">68</xref>]. Another chalcone-flavone dimer, cissampeloflavone (<bold>16</bold>, <xref ref-type="fig" rid="molecules-22-00058-f003">Figure 3</xref>), isolated from the aerial parts of <italic>Cissampelos pareira</italic> (Menispermaceae) has been shown to exhibit good potency on the <italic>T. brucei rhodesiense</italic> bloodstream stage [<xref rid="B69-molecules-22-00058" ref-type="bibr">69</xref>].</p></sec><sec><title>Quinones</title><p>Some compounds from natural sources containing a quinone moiety have been shown to exhibit exceptionally good antitrypanosomal potency. Employing a bioactivity-guided fractionation approach, Moideen and co-workers [<xref rid="B70-molecules-22-00058" ref-type="bibr">70</xref>] were able to isolate a highly potent furanonaphthoquinone, <bold>17</bold> along with another notable naphthoquinoid, isopinnatal (<bold>18</bold>, <xref ref-type="fig" rid="molecules-22-00058-f003">Figure 3</xref>) from the stem bark and root bark extracts. The quinone-derivative <bold>17</bold>, was found to exhibit pronounced antitrypanosomal potency in the low IC<sub>50</sub> double-digit nanomolar range (IC<sub>50</sub> = 0.045 &#x003bc;M, <italic>T. brucei rhodesiense</italic>), while, albeit less potent than <bold>17</bold>, isopinnatal (<bold>18</bold>) still retained submicromolar activity on <italic>T. brucei rhodesiense</italic> (IC<sub>50</sub> = 0.73 &#x003bc;M). However, the cytotoxicity profile on KB cell lines for both compounds is relatively high (IC<sub>50</sub> = 3.9 &#x003bc;M and 14.8 &#x003bc;M for <bold>17</bold> and <bold>18</bold> respectively).</p><p>Primin (<bold>19</bold>, <xref ref-type="fig" rid="molecules-22-00058-f003">Figure 3</xref>), another quinone derivative isolated from the leaves of <italic>Miconia lepidota</italic> [<xref rid="B71-molecules-22-00058" ref-type="bibr">71</xref>] has been shown to exhibit potent antitrypanocidal activity (IC<sub>50</sub> = 0.14 &#x003bc;M) on <italic>T. brucei rhodesiense</italic> with moderate cytotoxicity (IC<sub>50</sub> = 15.4 &#x003bc;M) against mammalian L6 cell lines. When administered intraperitoneally in the <italic>T. brucei brucei</italic> rodent model, primin was ineffective in curing the infection at 20 mg/kg while higher doses proved toxic [<xref rid="B72-molecules-22-00058" ref-type="bibr">72</xref>].</p></sec><sec><title>Terpenes and Other Metabolites</title><p>Two highly trypanocidal sesquiterpene lactones (<xref ref-type="fig" rid="molecules-22-00058-f004">Figure 4</xref>) have been identified among a group of sesquiterpene lactones isolated from <italic>Arnica</italic> and <italic>Inula</italic> species (Asteraceae). Helenalin (<bold>20</bold>) and mexicanin I (<bold>21</bold>) exhibited potent activity against <italic>T. brucei rhodesiense</italic> bloodstream trypomastigotes (IC<sub>50</sub> = 0.05 and 0.32 &#x003bc;M respectively) while being reasonably devoid of cytotoxicity on mammalian L6 cells (SI = 19.5 and 7.7 for <bold>20</bold> and <bold>21</bold>, respectively). The two diastereomers have a 6-fold difference in potency, a result that shows the importance of stereochemistry for activity in this scenario. The two sesquiterpene lactones have two &#x003b1;,&#x003b2;-unsaturated carbonyl moieties which are potential alkylation sites as Michael acceptors. These sites (cyclopentenone and &#x003b1;-methylene-&#x003b3;-lactone) can covalently react with various thio groups of various enzymes. The authors observed reduced potency with other sesquiterpene lactones bearing a single alkylation site. It was, therefore, postulated that this class of molecules might be exerting their trypanocidal potency by interfering with trypanothione metabolism, thereby, inducing oxidative stress in the parasite [<xref rid="B73-molecules-22-00058" ref-type="bibr">73</xref>]. Another sesquiterpene lactone&#x02014;parthenolide (<bold>21a</bold>, <xref ref-type="fig" rid="molecules-22-00058-f004">Figure 4</xref>)&#x02014;with notable trypanocidal potency, has been isolated following a bioassay-guided fractionation of a crude extract from the plant <italic>Saussurea costus</italic> (Asteraceae) [<xref rid="B74-molecules-22-00058" ref-type="bibr">74</xref>]. Although <bold>21a</bold> had an unfavorable toxicity profile when evaluated against rat skeletal myoblast L6 cells (IC<sub>50</sub> = 5.2 &#x003bc;&#x0039c;, SI = 6.5), it was found to potently inhibit the bloodstream forms of <italic>T. brucei rhodesiense</italic> (IC<sub>50</sub> = 0.8 &#x003bc;M). More recently, five highly trypanocidal sesquiterpene lactones isolated from various plant species have been identified [<xref rid="B75-molecules-22-00058" ref-type="bibr">75</xref>]. These include <bold>21b</bold>, <bold>21c</bold>, <bold>21d</bold>, <bold>21e</bold>, and <bold>21f</bold> (<xref ref-type="fig" rid="molecules-22-00058-f004">Figure 4</xref>) isolated from <italic>Liriodendron tulipifera</italic> (Magnoliaceae) [<xref rid="B76-molecules-22-00058" ref-type="bibr">76</xref>], <italic>Lychnophora diamantinana</italic> [<xref rid="B77-molecules-22-00058" ref-type="bibr">77</xref>], <italic>Viguiera robusta</italic> [<xref rid="B78-molecules-22-00058" ref-type="bibr">78</xref>], <italic>Eremanthus goyazensis</italic> (Asteraceae) [<xref rid="B79-molecules-22-00058" ref-type="bibr">79</xref>] and <italic>Helianthus tuberosus</italic> (Asterceae) [<xref rid="B76-molecules-22-00058" ref-type="bibr">76</xref>] respectively. Evaluation against the bloodstream forms of <italic>T. brucei rhodesiense</italic> revealed that <bold>21f</bold> was the most potent (IC<sub>50</sub> = 0.015 &#x003bc;M) with favorable selectivity (SI = 77). For compounds <bold>21c</bold> and <bold>21d</bold>, it was revealed that the nature of the substituent and stereochemistry at C8 was irrelevant to potency&#x02014;the two analogues were shown to be equipotent (IC<sub>50</sub> ~ 0.07 &#x003bc;M). For compounds <bold>21f</bold> and <bold>21e</bold>, however, where the &#x003b1;,&#x003b2;,&#x003b3;,&#x003b4;-unsaturated carbonyl system is changed, the impact on potency is quiet significant. In this regard, the loss of one potential reactive site (Michael acceptor) in analogue <bold>21e</bold> (IC<sub>50</sub> = 0.20 &#x003bc;M) could explain the reduced potency. Compound <bold>21b</bold> also demonstrated a slightly inferior potency (IC<sub>50</sub> = 0.23 &#x003bc;M) [<xref rid="B75-molecules-22-00058" ref-type="bibr">75</xref>]. Although exhibiting inferior potency, it is important to note that many other terpenes and related derivatives isolated from a number of plant species including <italic>Entada abyssinica</italic> (Leguminosae) [<xref rid="B80-molecules-22-00058" ref-type="bibr">80</xref>], <italic>Vernonia guineensis</italic> (Asteraceae) [<xref rid="B81-molecules-22-00058" ref-type="bibr">81</xref>], <italic>Guarea rhophalocarpa</italic> (Meliaceae) and <italic>Galphimia glauca</italic> (Malphigeaceae) [<xref rid="B82-molecules-22-00058" ref-type="bibr">82</xref>,<xref rid="B83-molecules-22-00058" ref-type="bibr">83</xref>] have been evaluated against trypanosomes.</p><p>Another terpenoid-based metabolite that has shown high in vitro trypanocidal potency is the sesquiterpene lactone, 8-epixanthatin 1&#x003b2;,5&#x003b2;-epoxide (<bold>22</bold>, <xref ref-type="fig" rid="molecules-22-00058-f004">Figure 4</xref>). Evaluation against <italic>T. brucei rhodesiense</italic> revealed strong inhibition of the growth of <italic>Trypanosoma</italic> parasite (IC<sub>50</sub> = 0.33 &#x003bc;M). It is important to note that the same secondary metabolite has demonstrated notable leishmanicidal potency, which has been discussed in the later section of this review. Moreover, the potent sesquiterpene lactone has been characterized with a relatively favourable toxicity profile on rat myoblast cells [<xref rid="B84-molecules-22-00058" ref-type="bibr">84</xref>].</p><p>Other classes of natural products derived from microbial sources have shown potential as antitrypanosomal agents. Sinefungin (<bold>23</bold>, <xref ref-type="fig" rid="molecules-22-00058-f004">Figure 4</xref>) produced by <italic>Streptomyces grizeolus</italic> and <italic>S. incarnates</italic> is a natural nucleoside that has demonstrated potent in vitro activity against <italic>T. brucei rhodesiense</italic> bloodstream trypomastigotes in the subnanomolar range (IC<sub>50</sub> = 0.0004 &#x003bc;M) with a very high selectivity index (SI &#x0003e; 10<sup>6</sup>) [<xref rid="B85-molecules-22-00058" ref-type="bibr">85</xref>]. When progressed further to in vivo studies, <bold>23</bold> was found to cure mice infected with <italic>T. brucei brucei</italic>, <italic>T. congolense</italic> and <italic>T. vivax</italic> when administered intraperitoneally [<xref rid="B86-molecules-22-00058" ref-type="bibr">86</xref>,<xref rid="B87-molecules-22-00058" ref-type="bibr">87</xref>]. However, the compound could not be developed further due to unexpected severe nephrotoxicity in goats at subcurative doses [<xref rid="B88-molecules-22-00058" ref-type="bibr">88</xref>]. Also notable are aculeatins, another class of compounds isolated from the rhizome of <italic>Amomum aculeatum</italic> (Zingiberaceae). These are exemplified by aculeatin D (<bold>24</bold>, <xref ref-type="fig" rid="molecules-22-00058-f004">Figure 4</xref>) which exhibited strong albeit nonselective potency against bloodstream trypomastigotes of <italic>T. brucei rhodesiense</italic> (IC<sub>50</sub> = 0.5 &#x003bc;M and 0.9 &#x003bc;M on <italic>T. brucei rhodesiense</italic> and KB cells respectively) [<xref rid="B89-molecules-22-00058" ref-type="bibr">89</xref>,<xref rid="B90-molecules-22-00058" ref-type="bibr">90</xref>].</p></sec></sec><sec id="sec2dot3dot3-molecules-22-00058"><title>2.3.3. Semisynthetic Antitrypanosomal Natural Products</title><p>A number of semisynthetic compounds based on natural product scaffolds have been reported to possess noteworthy trypanocidal potency. A recent example is the semisynthetic analogue <bold>25</bold> (<xref ref-type="fig" rid="molecules-22-00058-f005">Figure 5</xref>), derived from a very potent peroxide manadoperoxide B (<bold>7</bold>, <xref ref-type="fig" rid="molecules-22-00058-f005">Figure 5</xref>, see also <xref ref-type="fig" rid="molecules-22-00058-f002">Figure 2</xref>) originally isolated from a marine sponge <italic>Plakortis cfr. Lita</italic> [<xref rid="B62-molecules-22-00058" ref-type="bibr">62</xref>,<xref rid="B91-molecules-22-00058" ref-type="bibr">91</xref>]. The semisynthetic analogue demonstrated marked trypanocidal activity against the blood stream forms of <italic>T. brucei rhodesiense</italic> in the submicromolar range (IC<sub>50</sub> = 0.43 &#x003bc;M) while displaying appreciable selectivity against the L6 cells derived from rat skeletal myoblasts (IC<sub>50</sub> = 33.82 &#x003bc;M) [<xref rid="B91-molecules-22-00058" ref-type="bibr">91</xref>].</p><p>Based on two naturally isolated pyridoacridone alkaloids, ascididemin (<bold>5</bold>), and 2-bromo-ascididemin (<bold>6</bold>, <xref ref-type="fig" rid="molecules-22-00058-f005">Figure 5</xref>, see also <xref ref-type="fig" rid="molecules-22-00058-f002">Figure 2</xref>), Copp and co-workers have synthetically generated derivatives that have demonstrated pronounced trypanocidal activity against <italic>T. brucei rhodesiense</italic> [<xref rid="B61-molecules-22-00058" ref-type="bibr">61</xref>]. The pyridoacridone analogue <bold>26</bold> (<xref ref-type="fig" rid="molecules-22-00058-f005">Figure 5</xref>), was found to be the most potent (IC<sub>50</sub> = 0.007 &#x003bc;M) of all the analogues synthesized. Despite exhibiting slightly inferior potency, other derivatives still retained submicromolar potency: <bold>27</bold> (IC<sub>50</sub> = 0.283 &#x003bc;M), <bold>28</bold> (IC<sub>50</sub> = 0.018 &#x003bc;M), <bold>29</bold> (IC<sub>50</sub> = 0.075 &#x003bc;M), <bold>30</bold> (IC<sub>50</sub> = 0.109 &#x003bc;M), <bold>31</bold> (IC<sub>50</sub> = 0.064 &#x003bc;M) and <bold>32</bold> (IC<sub>50</sub> = 0.064 &#x003bc;M). Other derivatives reported in this study were also associated with pronounced potency [<xref rid="B61-molecules-22-00058" ref-type="bibr">61</xref>]. Generally, the synthesized derivatives were less cytotoxic on the L6 mammalian cell line compared to the naturally isolated metabolites <bold>5</bold> and <bold>6</bold>. It has been speculated that the mode of action for this class of compounds may involve DNA intercalation along with DNA oxidative damage [<xref rid="B61-molecules-22-00058" ref-type="bibr">61</xref>].</p></sec></sec></sec><sec id="sec3-molecules-22-00058"><title>3. Leishmaniasis</title><sec id="sec3dot1-molecules-22-00058"><title>3.1. Background of the Disease</title><p>Leishmaniasis is a parasitic disease caused by protozoan <italic>Leishmania</italic> parasites and transmission to humans is facilitated by the bite of infected female phlebotomine sandflies. The disease pathology takes three main forms: visceral leishmaniasis (VL, also known as kala-azar), cutaneous leishmaniasis (CL), and mucocutaneous leishmaniasis (MCL) [<xref rid="B92-molecules-22-00058" ref-type="bibr">92</xref>]. <italic>Leishmania</italic> parasites are known to be transmitted by over 90 sandfly species. During a blood meal on infected humans or other terrestrial animals, the parasite enters the sandfly where it exists as an extracellular flagellated promastigote in the midgut of the vector. The parasite later develops into an infectious metacyclic promastigote, which is later inoculated into the skin of the host in the next blood meal. The parasites, then, lose their flagella as they transform into intracellular amastigotes upon internalization into macrophages, dendritic cells or neutrophils. Once in the phagolysosomes, the amastigotes can persist and reproduce via binary fusion [<xref rid="B93-molecules-22-00058" ref-type="bibr">93</xref>]. The amastigotes released from the lysis of infected phagocytotic cells then invade either additional tissue macrophages or extensively infect the reticulo-endothelial system depending upon the species of the <italic>Leishmania</italic> parasite. The <italic>Leishmania</italic> species, <italic>L. major</italic> and <italic>L. tropica</italic> are the primary causes of CL in the old world while <italic>L. braziliensis</italic> and <italic>L. mexicana</italic> are responsible for CL infections in the new world [<xref rid="B94-molecules-22-00058" ref-type="bibr">94</xref>]. MCL is principally caused by <italic>L. braziliensis</italic> although additional species (<italic>L. amazonensis</italic>, <italic>L. panamensis</italic> and <italic>L. guyanensis</italic>) have also been described [<xref rid="B95-molecules-22-00058" ref-type="bibr">95</xref>]. In the Indian subcontinent, Asia and East Africa, VL is caused by <italic>L. donovani</italic> while <italic>L. infantum</italic> is responsible for infections in Europe, North Africa and Latin America. The clinical outcome of the disease is influenced by the pathogenic species, as well as the state of host immunity. If the immune response has the capacity to fight the infection, the skin lesions associated with CL are often self-healing with concomitant development of life-long resistance to reinfection [<xref rid="B96-molecules-22-00058" ref-type="bibr">96</xref>]. In the case of immunity failure, the disease becomes chronic, with infection progressing to the eticulo-endothelial system resulting in VL which is systemic and non-healing [<xref rid="B97-molecules-22-00058" ref-type="bibr">97</xref>]. It is important to note that other parasite species that are responsible for self-healing lesions of the disease can also cause visceralizing infections.</p><p>If left untreated, VL can lead to death in over 95% of cases. Common symptoms for VL include irregular bouts of fever, weight loss, enlargement of the spleen and liver as well as anaemia [<xref rid="B92-molecules-22-00058" ref-type="bibr">92</xref>]. In the Indian sub-continent as well as East Africa, the disease is highly endemic. On a global scale, the WHO estimates that 200,000 to 400,000 new cases of VL occur each year. Of the new cases reported in 2014, 90% of the cases occurred in 6 countries: Brazil, Ethiopia, India, Somalia, South Sudan and Sudan [<xref rid="B92-molecules-22-00058" ref-type="bibr">92</xref>].</p><p>CL is characterized by skin lesions, which are largely ulcers on exposed parts of the body, resulting in life-long scars and severe disability. It is the most common version of leishmaniasis with approximately 95% of the cases occurring in the Americas, the Mediterranean basin, the Middle East and Central Asia. Six countries (Afghanistan, Algeria, Brazil, Colombia, Iran, and the Syrian Arab Republic) account for over two thirds of new CL cases [<xref rid="B92-molecules-22-00058" ref-type="bibr">92</xref>]. Between 0.7 million and 1.3 million new cases are reported globally every year [<xref rid="B92-molecules-22-00058" ref-type="bibr">92</xref>]. A partial or total destruction of nose, mouth and throat mucous membranes can result from infection with MCL. Bolivia, Brazil and Peru account for nearly 90% of the cases [<xref rid="B92-molecules-22-00058" ref-type="bibr">92</xref>].</p></sec><sec id="sec3dot2-molecules-22-00058"><title>3.2. Current Chemotherapy and Associated Challenges</title><p>The antimony-containing drugs, also known as the pentavalent antimonials, are the drugs of choice for first line treatment of Leishmaniasis where resistance has not been reported [<xref rid="B98-molecules-22-00058" ref-type="bibr">98</xref>]. These include the generic sodium stibogluconate (pentostam, <xref ref-type="fig" rid="molecules-22-00058-f006">Figure 6</xref>), the branded meglumine antimoniate (structure remains a subject of debate) which have been in use for over five decades. Regrettably, the <italic>Leishmania</italic> parasites have become increasingly resistant to the pentavalent antimonial drugs and this brought into question their use in disease-endemic areas [<xref rid="B99-molecules-22-00058" ref-type="bibr">99</xref>]. Because antimonials are administered intravenously or intramuscularly, they are not convenient for patients. They are also associated with side effects, which include chemical pancreatitis, elevations in serum aminotransferases and electro-cardiographic abnormalities [<xref rid="B40-molecules-22-00058" ref-type="bibr">40</xref>].</p><p>Second-line drugs include amphotericin B (<xref ref-type="fig" rid="molecules-22-00058-f006">Figure 6</xref>), which is used in areas where antimonial resistance is common [<xref rid="B100-molecules-22-00058" ref-type="bibr">100</xref>]. It exhibits strong binding to ergosterol, the main sterol of fungal and leishmanial cell membranes. Regrettably, amphotericin B is toxic [<xref rid="B101-molecules-22-00058" ref-type="bibr">101</xref>,<xref rid="B102-molecules-22-00058" ref-type="bibr">102</xref>] despite its high efficiency. Other formulations of amphotericin B have largely circumvented the adverse effects although some are quiet expensive [<xref rid="B103-molecules-22-00058" ref-type="bibr">103</xref>]. Other second-line antileishmanial chemotherapeutics include miltefosine (<xref ref-type="fig" rid="molecules-22-00058-f006">Figure 6</xref>), an alkylphosphocholine, originally developed as an anticancer agent. It is the first orally administered drug for the treatment of VL. Having proved its remarkable efficacy in clinical trials [<xref rid="B104-molecules-22-00058" ref-type="bibr">104</xref>,<xref rid="B105-molecules-22-00058" ref-type="bibr">105</xref>], miltefosine was considered a major breakthrough in antileishmanial chemotherapy [<xref rid="B106-molecules-22-00058" ref-type="bibr">106</xref>,<xref rid="B107-molecules-22-00058" ref-type="bibr">107</xref>]. However, serious concerns of its teratogenicity may limit its use, it has also been thought that its long half-life (152 h) could encourage the emergence of drug resistance [<xref rid="B108-molecules-22-00058" ref-type="bibr">108</xref>]. Paromomycin (<xref ref-type="fig" rid="molecules-22-00058-f006">Figure 6</xref>), another second line anti-leishmanial drug, is chemically an aminogycosidic compound which cures both VL and CL albeit its scarcity has hampered its use in endemic regions [<xref rid="B109-molecules-22-00058" ref-type="bibr">109</xref>,<xref rid="B110-molecules-22-00058" ref-type="bibr">110</xref>]. Sitamaquine (<xref ref-type="fig" rid="molecules-22-00058-f006">Figure 6</xref>), the only drug originally developed to treat VL, is an 8-aminoquinoline, which also offers an advantage of oral administration. Its efficacy and tolerability was demonstrated in a phase II clinical trial in India [<xref rid="B111-molecules-22-00058" ref-type="bibr">111</xref>]. Its efficacy has also been reported in a Kenyan clinical trial [<xref rid="B112-molecules-22-00058" ref-type="bibr">112</xref>]. However, side effects including vomiting, dyspepsia, cyanosis, nephritic syndrome, glomerulonephritis, abdominal pain, headache and kidney dysfunctioning were observed in both clinical trials. Pentamidine (<xref ref-type="fig" rid="molecules-22-00058-f006">Figure 6</xref>, also used to treat trypanosomiasis), an aromatic diamine has also been used to treat antimonial-refractory VL patients although its declining efficacy has led to its withdrawal from the market [<xref rid="B113-molecules-22-00058" ref-type="bibr">113</xref>].</p></sec><sec id="sec3dot3-molecules-22-00058"><title>3.3. Antileishmanial Natural Products</title><p>The current challenges associated with current chemotherapeutic interventions for Leishmaniasis warrant intensive research efforts into novel antileishmanial therapies. In this section, we review natural products that have demonstrated pronounced antileishmanial potency. Once again, we focus our efforts only on those isolated and characterised natural products that display submicromolar (IC<sub>50</sub> &#x0003c; 1 &#x003bc;M) potency and those that have shown promising in vivo efficacy.</p><sec id="sec3dot3dot1-molecules-22-00058"><title>3.3.1. Antileishmanial Natural Products from Plant Sources</title><sec><title>Flavonoids, Sterols, Chalcones, Coumarins, Tannins and Aurones</title><p>Despite showing a somewhat modest in vitro activity, the flavonoids, luteolin (<bold>33</bold>) and quercetin (<bold>34</bold>, <xref ref-type="fig" rid="molecules-22-00058-f007">Figure 7</xref>) displayed impressive in vivo efficacy. Luteolin showed up to 80% splenic parasite load reduction in infected rodents at a dose of 3.5 mg/kg body weight while quercetin showed a 90% parasite reduction (dose: 14 mg/kg) in the same rodent model. Although quercetin appeared to induce cell cycle arrest in normal human T-cells, such toxicity was not observed for luteolin [<xref rid="B114-molecules-22-00058" ref-type="bibr">114</xref>].</p><p>In another study, phytochemical investigation of a Mexican plant, <italic>Pentalinon andrieuxii</italic>, led to the isolation of six sterols with remarkable leishmanicidal potency. Of the six isolated sterol derivatives, 6,7-dihydroneridienone (<bold>35</bold>, <xref ref-type="fig" rid="molecules-22-00058-f007">Figure 7</xref>) displayed a combination of high leishmanicidal potency (IC<sub>50</sub> = 0.03 &#x003bc;M, <italic>L. mexicana</italic>) and negligible cytotoxicity on health bone marrow macrophages from C57BL/6 mice [<xref rid="B115-molecules-22-00058" ref-type="bibr">115</xref>].</p><p>An oxygenated chalcone, licochalcone A (<bold>36</bold>, <xref ref-type="fig" rid="molecules-22-00058-f007">Figure 7</xref>), isolated from the Chinese liquorice <italic>Glycyrrhiza</italic> spp. (Fabaceae) also exhibited moderate in vitro potency against <italic>L. major</italic> and <italic>L. donovani</italic> promastigotes and amastigotes [<xref rid="B116-molecules-22-00058" ref-type="bibr">116</xref>,<xref rid="B117-molecules-22-00058" ref-type="bibr">117</xref>] while in vivo efficacy in hamsters showed splenic and liver parasite load reduction of up to 96% (20 mg/kg body weight &#x000d7; 6 days) [<xref rid="B118-molecules-22-00058" ref-type="bibr">118</xref>]. When evaluated for cytotoxicity against human leucocytes, lymphocytes and monocytes, no cytotoxic effects were observed. Licochalcone A and related chalcones are known to exert their anti-leishmanial effect by destroying the mitochondrial ultrastructure and are capable of strongly inhibiting the enzyme fumarate reductase in <italic>L. major</italic> [<xref rid="B119-molecules-22-00058" ref-type="bibr">119</xref>]. Other chalcone derivatives have been found to demonstrate antileishmanial efficacy comparable to some first-line antileishmanial drugs. For instance, when formulated with polylactide nanoparticles (PLA), the 2&#x02032;,6&#x02032;-dihydroxy-4&#x02032;-methoxy-chalcone (DMC, <bold>37</bold>, <xref ref-type="fig" rid="molecules-22-00058-f007">Figure 7</xref>), isolated from <italic>Piper aduncum</italic> (Piperaceae), reduced cutaneous ulcers by 60% in infected BALB/c mice (440 &#x003bc;g of DMC-PLA &#x000d7; 42 days), an effect that is comparable to that of the first-line drug, glucantime<sup>&#x000ae;</sup> (meglumine antimoniate) at equivalent doses [<xref rid="B120-molecules-22-00058" ref-type="bibr">120</xref>]. The nitrosylated version of DMC also demonstrated efficacy comparable to the first-line drug pentostam<sup>&#x000ae;</sup> when administered intralesionally in mice [<xref rid="B121-molecules-22-00058" ref-type="bibr">121</xref>]. Another interesting group of metabolites that are structurally isomeric to flavones are the aurones. Aurones have demonstrated antileishmanial potency against a wide spectrum of <italic>Leishmania</italic> species albeit also toxic on bone marrow-derived macrophages. Interestingly, an aurone (<bold>38</bold>, <xref ref-type="fig" rid="molecules-22-00058-f007">Figure 7</xref>) devoid of toxicity while exhibiting antileishmanial potency (EC<sub>50</sub> = 0.33&#x02013;0.40 &#x003bc;M) across different promastigote <italic>Leishmania</italic> species has been identified [<xref rid="B122-molecules-22-00058" ref-type="bibr">122</xref>].</p><p>Impressive leishmanicidal potency has also been observed for coumarins, another class of polyphenolic compounds, isolated from various plant species [<xref rid="B123-molecules-22-00058" ref-type="bibr">123</xref>,<xref rid="B124-molecules-22-00058" ref-type="bibr">124</xref>,<xref rid="B125-molecules-22-00058" ref-type="bibr">125</xref>,<xref rid="B126-molecules-22-00058" ref-type="bibr">126</xref>]. A typical example of such coumarins, compound <bold>39</bold> (<xref ref-type="fig" rid="molecules-22-00058-f007">Figure 7</xref>) isolated from <italic>C. brasiliense</italic>, has proved highly efficacious when administered intramuscularly at a dose of 18 mg/kg/day or 0.2% topically in <italic>L. amazonensis</italic> infected mice. Interestingly, when administered intramuscularly, its efficacy was shown to be comparable to the standard drug, glucantime<sup>&#x000ae;</sup> (meglumine antimoniate) [<xref rid="B123-molecules-22-00058" ref-type="bibr">123</xref>].</p><p>Tannins represent another group of polyphenolic secondary metabolites that exhibit a broad spectrum of biochemical and pharmacological properties [<xref rid="B127-molecules-22-00058" ref-type="bibr">127</xref>,<xref rid="B128-molecules-22-00058" ref-type="bibr">128</xref>]. Kolodziej et al., have identified a potent leishmanicidal tannin, casuarinin (<bold>40</bold>, <xref ref-type="fig" rid="molecules-22-00058-f007">Figure 7</xref>) among 27 different tannins isolated from <italic>Punica granatum</italic>, <italic>Casuarina</italic>, and <italic>Stachyurus</italic> species. Casuarinin was found to be highly leishmanicidal on <italic>L. donovani</italic> parasites with EC<sub>50</sub> of 0.52 &#x003bc;M with minimal toxicity on murine host cells (EC<sub>50</sub> &#x0003e; 26.74 &#x003bc;M) [<xref rid="B129-molecules-22-00058" ref-type="bibr">129</xref>,<xref rid="B130-molecules-22-00058" ref-type="bibr">130</xref>].</p></sec><sec><title>Iridoids, Quinones, and Quinoline Alkaloids</title><p>Isolated from <italic>Swertia chirata</italic> (Gentianaceae), amarogentin (<bold>41</bold>, <xref ref-type="fig" rid="molecules-22-00058-f008">Figure 8</xref>), is a secoiridoid glycoside which is a potent topoisomerase I inhibitor and is known to exert its antileishmanial activity by interfering with the formation of the binary complex between DNA and the enzyme [<xref rid="B131-molecules-22-00058" ref-type="bibr">131</xref>]. Medda and co-workers [<xref rid="B132-molecules-22-00058" ref-type="bibr">132</xref>] were further able to demonstrate the impressive in vivo efficacy of free amarogentin, liposomal as well as niosomal formulations. When evaluated in the hamster model infected with <italic>L. donovani</italic>, the niosomal formulation reduced the splenic parasite load by 90% at a dose 2.5 mg/kg &#x000d7; 6 days. Toxicity, as assessed by blood pathology, histological tissue staining, and levels of certain liver enzymes, has not been observed [<xref rid="B132-molecules-22-00058" ref-type="bibr">132</xref>].</p><p>Noteworthy antileishmanial properties have also been observed with naphthoquinones, a special class of quinones possessing a naphthyl nucleus. A case in point is plumbagin (<bold>42</bold>, <xref ref-type="fig" rid="molecules-22-00058-f008">Figure 8</xref>), a naphthoquinone isolated from a Bolivian plant <italic>Pera benensis</italic> (Euphorbiaceae). Metabolite <bold>42</bold> displayed remarkable inhibition of <italic>L. donovani</italic> promastigotes (IC<sub>50</sub> = 0.21 &#x003bc;M) [<xref rid="B133-molecules-22-00058" ref-type="bibr">133</xref>,<xref rid="B134-molecules-22-00058" ref-type="bibr">134</xref>]. Plumbagin has also been shown to interfere with development of <italic>L. amazonensis</italic> and <italic>L. venezuelensis</italic> in vivo. Additionally, at a much lower dose than that of the first-line drug, glucantime<sup>&#x000ae;</sup> the plumbagin dimer, 8,8&#x02032;-biplumbagin has been shown to locally treat localized single lesions [<xref rid="B135-molecules-22-00058" ref-type="bibr">135</xref>]. Plumbagin has been shown to promote DNA cleavage mediated by topoisomerase II [<xref rid="B136-molecules-22-00058" ref-type="bibr">136</xref>]. A synthetic derivative of plumbagin, the hydroquinoid <bold>43</bold> (<xref ref-type="fig" rid="molecules-22-00058-f008">Figure 8</xref>) has also displayed submicromolar antileishmanial inhibitory activity (IC<sub>50</sub> = 0.33 &#x003bc;&#x0039c;, promastigote forms of <italic>L. donovani</italic>) [<xref rid="B134-molecules-22-00058" ref-type="bibr">134</xref>]. Other naphthoquinones with noteworthy leishmanicidal potency include burmanin A (<bold>44</bold>), B (<bold>45</bold>), and C (<bold>46</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f008">Figure 8</xref>), all isolated from <italic>Diospyros burmanica</italic>. Burmanin A (<bold>44</bold>), was found to display the most potent inhibition of <italic>L. major</italic> in the low double digit nanomolar range (IC<sub>50</sub> = 0.053). Burmanin B (<bold>45</bold>) and C (<bold>46</bold>), exhibited slightly inferior potency to burmanin A. However, their potencies were still in the submicromolar range, IC<sub>50</sub> = 0.18 &#x003bc;&#x0039c;, and 0.15 &#x003bc;&#x0039c; respectively [<xref rid="B137-molecules-22-00058" ref-type="bibr">137</xref>]. Primin (<bold>19</bold>, <xref ref-type="fig" rid="molecules-22-00058-f003">Figure 3</xref>), a quinone isolated from the leaves of <italic>Miconia lepidota</italic> and known to strongly inhibit trypanosomes (see <xref ref-type="sec" rid="sec2dot3dot2-molecules-22-00058">Section 2.3.2</xref>), has also been associated with strong antileishmanial potency against <italic>L. donovani</italic> (IC<sub>50</sub> = 0.71 &#x003bc;M) while possessing only moderate cytotoxicity (IC<sub>50</sub> = 15.4 &#x003bc;&#x0039c;) on mammalian cells (L6 cell line) [<xref rid="B71-molecules-22-00058" ref-type="bibr">71</xref>,<xref rid="B72-molecules-22-00058" ref-type="bibr">72</xref>]. Other natural product-based quinones, including pendulone, possessing impressive antileishmanial potencies, have been reported [<xref rid="B138-molecules-22-00058" ref-type="bibr">138</xref>].</p><p>Quinoline alkaloids have also shown promise as antileishmanial agents exhibiting notable in vivo efficacy in different <italic>Leishmania</italic> disease models. Chimanine B (<bold>47</bold>, <xref ref-type="fig" rid="molecules-22-00058-f008">Figure 8</xref>) and chimanine D (<bold>48</bold>, <xref ref-type="fig" rid="molecules-22-00058-f008">Figure 8</xref>) which are 2-substituted quinolines isolated from <italic>Galipea longiflora</italic> (Rutaceae) have demonstrated strong therapeutic efficacy against experimental CL and VL. When administered to <italic>L. amazonensis</italic> infected BALB/c mice (50 mg/kg body weight &#x000d7; 5 injections at intervals of 4 days), chimanine B reduced the parasite load by 90% while the lesion weight was reduced by 74% [<xref rid="B139-molecules-22-00058" ref-type="bibr">139</xref>]. Chimanine D also exhibited substantial parasite reduction (87%) when administered at a dose 100 mg/kg body weight for 5 days. Furthermore, a dihydro version of chimanine B, 2-<italic>n</italic>-propylquinoline (<bold>49</bold>, <xref ref-type="fig" rid="molecules-22-00058-f008">Figure 8</xref>) almost eliminated the liver parasite load (99.9% reduction in an experimental VL model; 94 mg/kg body weight &#x000d7; 10 days; oral administration) [<xref rid="B140-molecules-22-00058" ref-type="bibr">140</xref>]. Phytochemical exploration of the tropical plant <italic>Psychotria klugii</italic> by Muhammad and colleagues [<xref rid="B141-molecules-22-00058" ref-type="bibr">141</xref>] has revealed highly potent antileishmanial alkaloids. In this study, klugine (<bold>50</bold>), cephaeline (<bold>51</bold>), and isocephaeline (<bold>52</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f008">Figure 8</xref>) were isolated and profiled for leishmanicidal potency. When evaluated against <italic>L. donovani</italic> parasites, cephaeline (<bold>51</bold>) was found to be &#x0003e;20- and &#x0003e;5-fold more potent (IC<sub>50</sub> = 0.06 &#x003bc;M) than the standard drugs pentamidine and amphotericin B, respectively. On the other hand, klugine (<bold>50</bold>), demonstrated slightly inferior potency (IC<sub>50</sub> = 0.85 &#x003bc;&#x0039c;) to cephaeline. Submicromolar potency (IC<sub>50</sub> = 0.96 &#x003bc;M) was also observed for isocephaeline (<bold>52</bold>). Compound <bold>51</bold> also proved to be cytotoxic against SK-MEL, KB, BT-549, and SK-OV-3 human cancer cells while <bold>50</bold> was devoid of such cytotoxicity [<xref rid="B141-molecules-22-00058" ref-type="bibr">141</xref>].</p><p>Alkaloids of the &#x003b2;-carboline amine class have also been shown to potently inhibit the growth of leishmania parasites. These are exemplified by harmine (<bold>53</bold>, <xref ref-type="fig" rid="molecules-22-00058-f008">Figure 8</xref>), an alkaloid isolated from <italic>Peganum harmala</italic> [<xref rid="B142-molecules-22-00058" ref-type="bibr">142</xref>]. Harmine&#x02019;s impressive in vitro antileishmanial potency prompted in vivo evaluation in hamster models. In this study [<xref rid="B142-molecules-22-00058" ref-type="bibr">142</xref>], Lala and co-workers subcutaneously administered harmine (<bold>53</bold>) in free form as well as three vesicular forms&#x02014;liposomes, niosomes and nanoparticles. At a dose of 1.5 mg/kg body weight administered 6 times for 15 days, the free, liposomal, niosomal, and nanoparticular forms of harmine reduced splenic parasitemia by 40%, 60%, 70% and 80% respectively. Excitingly, only marginal nephrotoxicity and hepatotoxicity were observed for vesicular forms of harmine. Due to substantial efficacy against intracellular parasites coupled with a clean hepatotoxicity and nephrotoxicity profile, the vesicular forms of this alkaloid may be considered for clinical application in humans [<xref rid="B142-molecules-22-00058" ref-type="bibr">142</xref>]. Regrettably, DNA-binding-related toxicity is well known for harmine and its analogues [<xref rid="B143-molecules-22-00058" ref-type="bibr">143</xref>].</p></sec><sec><title>Saponins</title><p>Among this class of natural products, some noteworthy highly leishmanicidal metabolites are the two saponins, maesabalides III (<bold>54</bold>) and IV (<bold>55</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f009">Figure 9</xref>) which were isolated from the Vietnamese medicinal plant <italic>Maesa balansae</italic> (Myrsinaceae). Both secondary metabolites exhibited single digit nanomolar range IC<sub>50</sub> values, 0.005 and 0.009 &#x003bc;M, respectively against <italic>L. infantum</italic> intracellular amastigotes [<xref rid="B144-molecules-22-00058" ref-type="bibr">144</xref>]. These two compounds were, interestingly, found to be more potent than the clinically used antileishmanial drug, sodium stibogluconate. When evaluated against human fibroblast (MRC-5) cell line, cytotoxicity was not observed. In vivo investigation showed that a single subcutaneous dose of 0.2 and 0.4 mg/kg for <bold>54</bold> and <bold>55</bold> respectively reduced liver amastigote parasitemia by 90% one week post dosing in the BALB/c mouse model. Another saponin of the steroidal class racemoside A (<bold>56</bold>, <xref ref-type="fig" rid="molecules-22-00058-f009">Figure 9</xref>), isolated from <italic>Asparagus racemosus</italic> (Liliaceae), has shown remarkable potency against <italic>L. donovani</italic> amastigotes with submicromolar activity (IC<sub>50</sub> = 0.15 &#x003bc;M). Even up to a concentration of 10 &#x003bc;g/mL in murine macrophages, cytotoxicity was not observed [<xref rid="B145-molecules-22-00058" ref-type="bibr">145</xref>]. Delmas and colleagues [<xref rid="B146-molecules-22-00058" ref-type="bibr">146</xref>] also reported isolation of three saponins from ivy <italic>Hedera helix</italic> (Araliaceae) with notable antileishmanial activity. Hederacholchiside A<sub>1</sub>, <bold>57</bold> (<xref ref-type="fig" rid="molecules-22-00058-f009">Figure 9</xref>) was the most potent exhibiting strong double digit nanomolar range activity (IC<sub>50</sub> = 0.053 &#x003bc;&#x0039c;), against <italic>L. infantum</italic> intracellular amastigotes albeit moderate toxicity on human monocytes was also observed [<xref rid="B146-molecules-22-00058" ref-type="bibr">146</xref>].</p></sec><sec><title>Lignans, Taxoids, Terpenes, Anthranoids and Miscellaneous Antileishmanial Natural Products</title><p>Isolated from <italic>Haplophyllum bucharicum</italic> (Rutaceae), the lignan, diphyllin (<bold>58</bold>, <xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>) has been shown to strongly inhibit (IC<sub>50</sub> = 0.2 &#x003bc;&#x0039c;) the growth of <italic>L. infantum</italic> intracellular amastigotes while only moderately inhibiting promastigotes of the same parasite species. Diphyllin has, however, been shown to be antiproliferative on human monocytes [<xref rid="B147-molecules-22-00058" ref-type="bibr">147</xref>]. Taxoid compounds like paclitaxel, isolated from <italic>Taxus baccata</italic> (Taxaceae) are well known in anticancer therapy. From an antileishmanial perspective, another taxoid compound, 10-Deacetylbaccatin III, <bold>59</bold> (<xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>), isolated from the same plant, has demonstrated strong inhibition of the growth of intracellular <italic>L. donovani</italic> amastigotes with an IC<sub>50</sub> value of 0.07 &#x003bc;M. Cytotoxic evaluation showed that the compound was well tolerated in macrophages up to a concentration of 5 &#x003bc;M. The mode of action for this taxoid compound has been thought to involve stimulation of nitric oxide production in macrophages and not inhibition of microtubule depolymerisation, which is the mechanism of action of paclitaxel in cancer cells [<xref rid="B148-molecules-22-00058" ref-type="bibr">148</xref>]. Impressive leishmanicidal activity has been observed for the monoterpene linalool (<bold>60</bold>, <xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>) isolated from a plant <italic>Croton cajucara</italic> (Euphorbiaceae). It has shown strong antileishmanial activity against <italic>L. amazonensis</italic> promastigotes and intracellular amastigotes&#x02014;LD<sub>50</sub> = 0.028 and 0.14 &#x003bc;M respectively. Exposure of preinfected macrophages to 15 ng/mL of linalool-rich essential oil was found to discourage macrophage-parasite interaction while nitric oxide production was stimulated. Both promastigotes and intracellular amastigotes were completely destroyed upon exposure for 1 h while no cytotoxicity to murine macrophages was observed [<xref rid="B149-molecules-22-00058" ref-type="bibr">149</xref>].</p><p>Other notable terpene metabolites that have demonstrated strong leishmanicidal potency include two diterpenes: 7-hydroxy-12-methoxy-20-nor-abieta-1,5(10),7,9,12-pentaen-6,14-dione (<bold>61</bold>) and abieta-8,12-dien-11,14-dione (<bold>62</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>), both isolated from the roots of <italic>Salvia cilicica</italic> (Lamiaceae). Both diterpene derivatives, <bold>61</bold> and <bold>62</bold>, exhibited strong leishmanicidal potency against intracellular amastigote forms of both <italic>L. donovani</italic> (IC<sub>50</sub> = 0.17 and 0.12 &#x003bc;M, respectively) and <italic>L. major</italic> (IC<sub>50</sub> = 0.29 and 0.18 &#x003bc;M, respectively) [<xref rid="B150-molecules-22-00058" ref-type="bibr">150</xref>]. In another study, Danelli and co-workers [<xref rid="B151-molecules-22-00058" ref-type="bibr">151</xref>] have reported a strongly leishmanicidal nor-triterpene, <bold>63</bold> (<xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>), isolated from <italic>Lophanthera lactescens</italic>. The metabolite, <bold>63</bold>, strongly inhibits the amastigote forms of <italic>L. amazonensis</italic> with an IC<sub>50</sub> value of 0.5 &#x003bc;&#x0039c;. Two other terpenoid metabolites, isoiguesterin (<bold>64</bold>) and its analogue, 20-epi-isoiguesterinol (<bold>65</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>), both isolated from <italic>Salacia madagascariensis</italic> (Celastraceae), have strong submicromolar leishmanicidal potency. Isoiguesterin (<bold>64</bold>) was highly leishmanicidal against both <italic>L. donovani</italic> and <italic>L. mexicana</italic>&#x02014;IC<sub>50</sub> = 0.20 and 0.082 &#x003bc;M, respectively. Evaluation of analogue <bold>65</bold> against <italic>L. donovani</italic> revealed that it was almost three-fold more potent (IC<sub>50</sub> = 0.079 &#x003bc;M) than metabolite <bold>64</bold> [<xref rid="B152-molecules-22-00058" ref-type="bibr">152</xref>].</p><p>A sesquiterpene lactone, 8-epixanthatin 1&#x003b2;,5&#x003b2;-epoxide (<bold>66</bold>, <xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>) isolated from the Sudanese plant <italic>Xanthium brasilicum Vell</italic> is another terpenoid metabolite that has displayed noteworthy leishmanicidal in vitro potency against <italic>L. donovani</italic> with a submicromolar IC<sub>50</sub> value of 0.6 &#x003bc;M. The analogue also exhibited fairly minimal cytotoxicity on rat myoblast cells [<xref rid="B84-molecules-22-00058" ref-type="bibr">84</xref>]. Two other sesquiterpene lactones isolated from the Brazilian plant <italic>Elephantopus mollis</italic> have exhibited strong inhibition of <italic>L. major</italic> promastigotes. Elephantopin (<bold>67</bold>) and 2-deethoxy-2&#x003b2;-methoxyphantomolin (<bold>68</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>) possessed good potencies (IC<sub>50</sub> &#x02264; 0.28 &#x003bc;M) against the extracellular promastigote forms of <italic>L. major</italic> [<xref rid="B153-molecules-22-00058" ref-type="bibr">153</xref>]. Furthermore, bioassay-guided fractionation of an organic extract from an Argentine plant, <italic>Ambrosia tenuifolia</italic>, led to isolation of a significantly leishmanicidal sesquiterpene lactone&#x02014;psilostachyin (<bold>68a</bold>, <xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>) [<xref rid="B154-molecules-22-00058" ref-type="bibr">154</xref>]. When tested against the promastigote forms of <italic>Leishmania</italic> parasites, <bold>68a</bold> displayed submicromolar potency (IC<sub>50</sub> = 0.43 &#x003bc;M). Excitingly, toxicity evaluation against the T lymphocytic cells showed high selectivity [<xref rid="B154-molecules-22-00058" ref-type="bibr">154</xref>].</p><p>Simalikalactone D (<bold>69</bold>, <xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>), also a terpenoid metabolite belonging to the decanortriterpenoid subcategory and isolated from the root bark of <italic>Simaba orinocensis</italic> (Simaroubaceae) has shown impressive leishmanicidal potency. It was found to be highly leishmanicidal on <italic>L. donovani</italic> promastigotes (IC<sub>50</sub> = 0.07 &#x003bc;&#x0039c;). Moreover, under the assay conditions, the decanortriterpenoid metabolite, <bold>69</bold>, was &#x0003e;46- and &#x0003e;31-fold more potent than the two standard antileishmanial drugs, pentamidine and amphotericin B. When further screened for cytotoxicity against Vero cells, <bold>69</bold>, displayed a fairly favourable selectivity (IC<sub>50</sub> on Vero cells = 4.8 &#x003bc;M). The authors also explored some structure-activity relationships around metabolite <bold>69</bold>. When the two hydroxyl groups on the northern cyclohexyl ring were acetylated, antileishmanial activity was completely eliminated. The Michael acceptor carbonyl group on the western portion of the molecule was also very critical to potency [<xref rid="B155-molecules-22-00058" ref-type="bibr">155</xref>].</p><p>More recently, Lenta et al., have reported strong antileishmanial potency of an anthranoid, acetylvismione D (<bold>70</bold>) isolated from <italic>Psorospermum glaberrimum</italic> (Clusiaceae), a Cameroonian plant traditionally used for treatment of parasitic diseases. The anthranoid compound exhibited strong in vitro leishmanicidal activity (IC<sub>50</sub> = 0.09 &#x003bc;M) against <italic>L. donovani</italic>, which was far more superior than the reference drug miltefosine (IC<sub>50</sub> = 0.46 &#x003bc;M). In vitro cytotoxicity, as tested against mammalian cell lines (L6), was minimal [<xref rid="B156-molecules-22-00058" ref-type="bibr">156</xref>]. Dicentrinone (<bold>71</bold>, <xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>), is one alkaloid among many others successfully isolated from <italic>Duguetia furfuracea</italic> (Annonaceae) which has demonstrated high leishmanicidal potency against promastigote forms of <italic>L. braziliensis</italic> (IC<sub>50</sub> = 0.01 &#x003bc;M). Promising leishmanicidal potency (IC<sub>50</sub> = 0.11 &#x003bc;M) against the same <italic>Leishmania</italic> species was also observed for the charged alkaloid, duguetine &#x003b2;-N-oxide (<bold>72</bold>, <xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>) [<xref rid="B157-molecules-22-00058" ref-type="bibr">157</xref>].</p><p>Potent antileishmanial terpenoid derivatives have also been isolated from <italic>Jatropha</italic> species [<xref rid="B158-molecules-22-00058" ref-type="bibr">158</xref>]. In this regard, phytochemical investigation of <italic>Jatropha grossidentata</italic> led to isolation of a highly potent leishmanicidal diterpene, jatrogrossidione (<bold>73</bold>, <xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>). In vitro leishmanicidal evaluation, as determined using an IC<sub>100</sub> value, shows strong potency (IC<sub>100</sub> = 2.4 &#x003bc;&#x0039c;). The Jatropha-derived metabolite was, interestingly, found to be more potent than the standard drugs glucantime and pentamidine against <italic>Leishmania</italic> parasites. When evaluated against the amastigote forms of the <italic>Leishmania</italic> parasites, jatrogrossidione exhibited a submicromolar potency (IC<sub>50</sub> = 0.8 &#x003bc;M) with toxic concentrations being slightly higher than the IC<sub>50</sub> value. Jatrophone (<bold>74</bold>, <xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>), another diterpene isolated from <italic>Jatropha isabellii</italic>, was found to significantly suppress parasitemia in <italic>L. amazonensis</italic> (pH 8) infected BALB/c mice when administered subcutaneously at 25 mg/kg/day for 13 consecutive days. When compared to glucantime administered at a much higher dose (112 mg Sb<sup>V</sup>/kg/day), jatrophone still possessed superior efficacy [<xref rid="B158-molecules-22-00058" ref-type="bibr">158</xref>]. Regrettably, such subcutaneous administration of jatrophone proved too toxic, with half of the animals dying during the experiment [<xref rid="B158-molecules-22-00058" ref-type="bibr">158</xref>].</p><p>In another study and employing a bioguided fractionation approach, Tan and co-workers have reported the isolation and antileishmanial evaluation of two triterpenoic acids [<xref rid="B150-molecules-22-00058" ref-type="bibr">150</xref>]. Oleanolic acid (<bold>75</bold>), and ursolic acid (<bold>76</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f010">Figure 10</xref>), both isolated from the roots of <italic>Salvia cilicica</italic> (Lamiaceae), proved highly potent against the amastigote forms of <italic>L. donovani</italic> and <italic>L. major</italic> (IC<sub>50</sub> = 0.007&#x02013;0.12 &#x003bc;M). The two metabolites also exhibited marked potency (IC<sub>50</sub> = 0.051&#x02013;0.137 &#x003bc;M) against the promastigote forms of <italic>L. donovani</italic> and <italic>L. major</italic>. Cytotoxicity, as measured on non-parasitised macrophage-like RAW 264.7 cells for both <bold>75</bold> and <bold>76</bold> (IC<sub>50</sub> = 0.13 and 0.016 &#x003bc;M respectively) remains a serious concern.</p></sec></sec><sec id="sec3dot3dot2-molecules-22-00058"><title>3.3.2. Antileishmanial Natural Products from Marine Sources</title><p>Although there seems to be a paucity of information on marine-based isolation of Antileishmanial metabolites, some potent leishmanicidal marine-derived metabolites have been reported. A marine-derived alkaloid, renieramycin A (<bold>77</bold>, <xref ref-type="fig" rid="molecules-22-00058-f011">Figure 11</xref>), isolated from <italic>Neopetrosia</italic> species has been reported to significantly inhibit <italic>L. amazonensis</italic> with an IC<sub>50</sub> value of 0.35 &#x003bc;M [<xref rid="B159-molecules-22-00058" ref-type="bibr">159</xref>]. Furthermore, phytochemical investigation of the Palauan sponge <italic>Plakortis aff angulospiculatus</italic> led to the isolation of a potent cyclic peroxide <bold>78</bold> (<xref ref-type="fig" rid="molecules-22-00058-f011">Figure 11</xref>) with submicromolar activity against <italic>L. mexicana</italic> (LD<sub>50</sub> = 0.97 &#x003bc;M). At a concentration of 3.4 &#x003bc;&#x0039c;, the cyclic peroxide induces cell membrane lysis after 24 h with a drastic decrease in motility after 0.5 h [<xref rid="B160-molecules-22-00058" ref-type="bibr">160</xref>]. Marine-based microbes have also inspired natural products that have shown relevance as antileishmanial agents. In this context, and relatively recently, Linington and co-workers have reported the isolation of valinomycin (<bold>79</bold>, <xref ref-type="fig" rid="molecules-22-00058-f011">Figure 11</xref>), from <italic>Streptomyces</italic> strains. Valinomycin was found to be highly potent against <italic>L. major</italic> promastigotes (EC<sub>50</sub> &#x0003c; 0.11 &#x003bc;M) [<xref rid="B161-molecules-22-00058" ref-type="bibr">161</xref>]. Unfortunately, the peptide metabolite exhibited an unfavourable toxicity profile against 293T kidney epithelial cells and J774.1 macrophages [<xref rid="B162-molecules-22-00058" ref-type="bibr">162</xref>].</p></sec><sec id="sec3dot3dot3-molecules-22-00058"><title>3.3.3. Semi-Synthetic Antileishmanial Natural Products</title><p>A limited number of potent antileishmanial semisynthetic compounds inspired by natural product scaffolds have been reported in literature. In a recent study, Vik and co-workers have reported the total synthesis of agelasine D (<bold>80</bold>, <xref ref-type="fig" rid="molecules-22-00058-f012">Figure 12</xref>), a marine natural product originally isolated from the marine sponge <italic>Agelas nakamurai</italic> [<xref rid="B163-molecules-22-00058" ref-type="bibr">163</xref>].</p><p>Various derivatives of <bold>80</bold> (<xref ref-type="fig" rid="molecules-22-00058-f012">Figure 12</xref>) were also synthesized and evaluated for leishmanicidal activity against amastigote forms of <italic>L. infantum</italic>. Among the most potent derivatives were <bold>81</bold> (IC<sub>50</sub> = 0.20 &#x003bc;M), <bold>82</bold> (IC<sub>50</sub> = 0.54 &#x003bc;M), <bold>83</bold> (IC<sub>50</sub> = 0.50 &#x003bc;M), and <bold>84</bold> (IC<sub>50</sub> &#x0003c; 0.25 &#x003bc;M). Regrettably, with the exception of analogues <bold>81</bold> and <bold>84</bold>, most evaluated analogues were also highly toxic on MRC-5 fibroblast cells. In another study inspired by quinazolinone-containing natural products with pharmacological relevance, Sharma et al., have synthesised leishmanicidal quinazolinones hybridized with heterocyclic moieties and other substructures [<xref rid="B164-molecules-22-00058" ref-type="bibr">164</xref>]. The study identified four significantly potent analogues (<bold>85</bold>, <bold>86</bold>, <bold>87</bold> and <bold>88</bold>, <xref ref-type="fig" rid="molecules-22-00058-f012">Figure 12</xref>) in vitro and in vivo. Although analogues <bold>85</bold> and <bold>86</bold> exhibited moderate potency in vitro, IC<sub>50</sub> = 3.95 and 4.39 &#x003bc;M, respectively, against intracellular amastigote forms of <italic>L. donovani</italic>, they both possessed pronounced in vivo efficacy (73.2% and 80.9% reduction in parasitemia) in <italic>L. donovani</italic> infected hamster models. The ferrocene-containing analogue <bold>87</bold>, possessed submicromolar potency in vitro (IC<sub>50</sub> = 0.73 &#x003bc;M) but only moderately efficacious in vivo. Additionally, analogue <bold>88</bold> also demonstrated good potency in vitro (IC<sub>50</sub> = 0.65 &#x003bc;M) although its unfavourable toxicity profile discouraged further investigation in vivo.</p></sec></sec></sec><sec id="sec4-molecules-22-00058"><title>4. Schistosomiasis</title><sec id="sec4dot1-molecules-22-00058"><title>4.1. Background of the Disease</title><p>Schistosomiasis, also known as bilharzia, is a parasitic disease caused by flatworms of the genus <italic>Schistosoma</italic>. The public health impact of schistosomiasis is revealed by records showing that the infection is only second to malaria with respect to epidemiology and morbidity among the parasitic diseases [<xref rid="B165-molecules-22-00058" ref-type="bibr">165</xref>]. Statistics indicate that close to 260 million people required preventive chemotherapy in 2014, the majority of which are in Africa, Asia and South America [<xref rid="B166-molecules-22-00058" ref-type="bibr">166</xref>,<xref rid="B167-molecules-22-00058" ref-type="bibr">167</xref>].</p><p>Three types of <italic>Schistosoma</italic> species are largely responsible for human schistosomiasis: <italic>Schistosoma mansoni</italic>, <italic>Schistosoma japonicum</italic> and <italic>Schistosoma haematobium</italic> [<xref rid="B168-molecules-22-00058" ref-type="bibr">168</xref>]. The human infection occurs when the intermediate fresh water snail releases the larva form known as cercaria that penetrates the skin of humans in contact with the infected water during water-related activities. The larva then transforms and migrates through systemic circulation to lodge in the portal veins where the paired parasites mature and migrate to the mesenteric venules (<italic>S. mansoni</italic> and <italic>S. japonicum</italic>) and urinary bladder plexus (<italic>S. haematobium</italic>) where the female lay eggs. The eggs passed through faeces or in urine, hatch into the ciliated larval form referred to as miracidia in fresh water, infect the appropriate intermediate snail host and transform into the free swimming larva, cercaria, which are then ready to infect the next human, thus completing the cycle [<xref rid="B8-molecules-22-00058" ref-type="bibr">8</xref>,<xref rid="B169-molecules-22-00058" ref-type="bibr">169</xref>].</p><p>Host immune reactions to the schistosome eggs contribute to disease pathology which runs a chronic and debilitating course and is often insidious, with diagnosis only realised after severe organ damage or complications [<xref rid="B170-molecules-22-00058" ref-type="bibr">170</xref>]. In the case of intestinal schistosomiasis, gastrointestinal bleeding, obstruction, portal hypertension, hepatomegaly and splenomegaly may arise while with urinary schistosomiasis, haematuria, obstructive uropathy and cancer of the urinary tract are possible outcomes [<xref rid="B171-molecules-22-00058" ref-type="bibr">171</xref>]. Moreover, schistosomiasis can worsen prognosis with co-infections and is known to increase HIV/AIDS transmission due to the urogenital pathology by <italic>S. haematobium</italic>, further affirming the public health significance of this parasitic disease [<xref rid="B172-molecules-22-00058" ref-type="bibr">172</xref>,<xref rid="B173-molecules-22-00058" ref-type="bibr">173</xref>,<xref rid="B174-molecules-22-00058" ref-type="bibr">174</xref>].</p></sec><sec id="sec4dot2-molecules-22-00058"><title>4.2. Intervention Strategies and Challenges</title><p>Approaches to the control of schistosomiasis include snail vector control, preventive chemotherapy and treatment of the disease to control morbidity. For over four decades, praziquantel (<xref ref-type="fig" rid="molecules-22-00058-f013">Figure 13</xref>) has remained the drug of choice for the treatment of all types of human schistosomiasis [<xref rid="B175-molecules-22-00058" ref-type="bibr">175</xref>,<xref rid="B176-molecules-22-00058" ref-type="bibr">176</xref>]. The other two drugs-oxamniquine and metrifonate (<xref ref-type="fig" rid="molecules-22-00058-f013">Figure 13</xref>) are only singly active against <italic>S. mansoni</italic> and <italic>S. haematobium</italic>, respectively and are no longer preferred for clinical use.</p><p>Despite the success and notable advantages with the use of praziquantel that include its low cost and possessing activity against all the three species of schistosomes, there are nonetheless some limitations. The drug is only active against the mature worms and not the newly transformed worms hence cannot prevent disease re-infection and, therefore, repeated drug administration is necessary [<xref rid="B177-molecules-22-00058" ref-type="bibr">177</xref>].</p><p>Furthermore, commercial praziquantel is a racemate, comprising both the <italic>R</italic> and <italic>S</italic> isomers yet only the (<italic>R</italic>) isomer is responsible for antischistosomal activity. It has a bitter taste and may contribute to drug non-compliance especially in the mass drug administration programs and, importantly, has been reported to have reduced efficacy in some schistosome strains raising worries of development of resistance [<xref rid="B178-molecules-22-00058" ref-type="bibr">178</xref>,<xref rid="B179-molecules-22-00058" ref-type="bibr">179</xref>,<xref rid="B180-molecules-22-00058" ref-type="bibr">180</xref>].</p><p>On the basis of the public health impact and the paucity of drug discovery efforts for schistosomiasis, there exists a clear and urgent need for newer drugs as alternatives to praziquantel should the resistance reported in other areas rise or spread to clinically significant levels. In this quest, the antischistosomal effects of natural products have been investigated and several in vitro and in vivo evaluations pursued. Moreover, there are several reports of exploratory clinical trials for schistosomiasis involving drugs of natural product origin.</p><sec><title>Parameters Assessed</title><p>In evaluating the in vitro and in vivo activities of potential antischistosomal agents, important parameters assessed include effects on features that interfere with reproduction ability: worm pairing, worm migration, egg laying, surface changes that impede adherence within the gynaecophoric groove, motility and the ability of the parasites to attach to the host tissues. Among the common morphological features assessed is the tegument, which is vital for the parasite attachment to the host, nutrition and the circumventing of host immune response to the parasite [<xref rid="B181-molecules-22-00058" ref-type="bibr">181</xref>,<xref rid="B182-molecules-22-00058" ref-type="bibr">182</xref>]. Other observations include comparing pathological changes between controls and treated animals&#x02014;mainly regarding the liver and spleen- the ability to kill worms, time taken to kill the worms and the reversibility of effects upon withdrawal of the agent under investigation [<xref rid="B176-molecules-22-00058" ref-type="bibr">176</xref>].</p></sec></sec><sec id="sec4dot3-molecules-22-00058"><title>4.3. Examples of Natural Product Leads or Drugs with Antischistosomal Activities</title><sec id="sec4dot3dot1-molecules-22-00058"><title>4.3.1. Epiisopilotulorine</title><p>The imidazole alkaloid from <italic>Pilocarpus microphylus</italic>, epiisopilotulorine (<bold>89</bold>, <xref ref-type="fig" rid="molecules-22-00058-f014">Figure 14</xref>) has been shown to elicit in vitro activity at a concentration of 524 &#x000b5;M. In addition to inhibiting the ability to lay eggs at below lethal dose, the compound had antiinflammatory action, which would be beneficial in resolution of granulomas, a feature of chronic schistosomal infections.</p><p>With a safe toxicity profile (530 mg/kg) and accompanying spontaneous resolution of effects; in vivo efficacy studies were pursued at doses of 40, 100 and 300 mg/kg. Epiisopilotulorine displayed inverse dose-response relationship prompting the researchers to propose pharmacokinetics studies of this compound [<xref rid="B183-molecules-22-00058" ref-type="bibr">183</xref>].</p></sec><sec id="sec4dot3dot2-molecules-22-00058"><title>4.3.2. Piplartine</title><p>Piplartine (5,6-dihydro-1-[(2<italic>E</italic>)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-2(1<italic>H</italic>)-pyridinone <bold>90</bold>, <xref ref-type="fig" rid="molecules-22-00058-f014">Figure 14</xref>), the principal alkaloid from long pepper, <italic>Piper tuberculatum</italic> and other species of the Piperaceae family [<xref rid="B184-molecules-22-00058" ref-type="bibr">184</xref>,<xref rid="B185-molecules-22-00058" ref-type="bibr">185</xref>], is an amide with an array of activities both against infectious and non-infectious agents, including promising in vitro antischistosomal activity [<xref rid="B186-molecules-22-00058" ref-type="bibr">186</xref>,<xref rid="B187-molecules-22-00058" ref-type="bibr">187</xref>,<xref rid="B188-molecules-22-00058" ref-type="bibr">188</xref>]. At a sublethal concentration of 6.3 &#x000b5;M, egg-laying was inhibited whereas at 15.8 &#x000b5;M, piplartine caused death of worms within a day. In another study [<xref rid="B187-molecules-22-00058" ref-type="bibr">187</xref>], piplartine killed 50% of worms after 2 h at a dose of 393.9 &#x000b5;M while it took 24 h at a dose of 12.6 &#x000b5;M to produce the same effect. Praziquantel, used as a positive control in this experiment, produced this effect in 2 h at 10 &#x000b5;M. Other extensive studies reveal the genotoxic potential [<xref rid="B189-molecules-22-00058" ref-type="bibr">189</xref>] and low systemic toxicity of piplartine. Further safety profiling carried out on Vero cells and human peripheral blood mononuclear cells [<xref rid="B190-molecules-22-00058" ref-type="bibr">190</xref>] failed to show cytotoxicity at the maximum tested concentration at which piplartine is known to be toxic to schistosomes. Mouse pharmacokinetics studies indicate that piplartine has moderate bioavailability and with additional metabolic stability studies, this compound can form a starting point for antischistosomal drug discovery [<xref rid="B189-molecules-22-00058" ref-type="bibr">189</xref>,<xref rid="B191-molecules-22-00058" ref-type="bibr">191</xref>,<xref rid="B192-molecules-22-00058" ref-type="bibr">192</xref>].</p></sec><sec id="sec4dot3dot3-molecules-22-00058"><title>4.3.3. Ginger</title><p>A rhizome from the Zingiberaceae family, ginger (<italic>Zingiber Officinale</italic>) has numerous culinary and medicinal uses [<xref rid="B193-molecules-22-00058" ref-type="bibr">193</xref>,<xref rid="B194-molecules-22-00058" ref-type="bibr">194</xref>]. Documented effects, believed to be chiefly owed to the volatile oils Gingerol (<bold>91</bold>), zingerone (<bold>92</bold>) and shogaol (<bold>93</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f014">Figure 14</xref>), range from antiinflammatory, antiarthritic, antidiabetic, hypolipidaemic and hypocholesterolaemic.</p><p>In one study, although in vitro activity was demonstrated with the aqueous extract, there was no observed in vivo activity. On the other hand, an organic extract using ethyl acetate dosed at 500 mg/kg resulted in the decrease in worm recovery and egg production [<xref rid="B178-molecules-22-00058" ref-type="bibr">178</xref>] and at 200 mg/L killed adult worms [<xref rid="B193-molecules-22-00058" ref-type="bibr">193</xref>]. The failure to replicate the observed in vitro effects of the ginger extracts in in vivo studies is not a surprising occurrence in drug discovery and presents an opportunity for medicinal chemistry, formulation or dose optimisation studies in surmounting the possible pharmacokinetics hurdles.</p></sec><sec id="sec4dot3dot4-molecules-22-00058"><title>4.3.4. Phytol</title><p>The ubiquitous diterpene alcohol 3,7,11,15-tetramethyl-2-hexadecen-1-ol (phytol, <bold>94</bold>, <xref ref-type="fig" rid="molecules-22-00058-f015">Figure 15</xref>), found in chlorophyll, possesses diverse biological and pharmacological activities including immunomodulatory, antiallergic, antinociceptive and antioxidant [<xref rid="B42-molecules-22-00058" ref-type="bibr">42</xref>,<xref rid="B195-molecules-22-00058" ref-type="bibr">195</xref>,<xref rid="B196-molecules-22-00058" ref-type="bibr">196</xref>]. Besides, phytol is frequently used as a food additive, inferring that it is tolerable and hence safe in humans, a pivotal concern in drug discovery programs. In a murine model of schistosomiasis, phytol, at 40 mg/kg dose, killed adult worms while at sublethal doses, it produced changes consistent with antischistosomal activity including: reduced worm motility, decreased egg production and total worm reduction, in a dose dependent manner [<xref rid="B195-molecules-22-00058" ref-type="bibr">195</xref>].Since the mechanism of possible toxicity with the use of phytol is predictable [<xref rid="B197-molecules-22-00058" ref-type="bibr">197</xref>,<xref rid="B198-molecules-22-00058" ref-type="bibr">198</xref>] and that it has a tractable chemical structure, structure-activity and structure-property relationship studies can be readily pursued. Moreover, due to its ubiquitous distribution, costs of production can be projected to be low and this might translate into an affordable drug product, an attractive end point since the disease affects mostly the poor people to whom the cost of medication is out of reach.</p></sec><sec id="sec4dot3dot5-molecules-22-00058"><title>4.3.5. Curcumin</title><p>A rhizome of the Zingiberaceae family, curcumin (turmeric, <bold>95</bold>, <xref ref-type="fig" rid="molecules-22-00058-f015">Figure 15</xref>), although commonly used as a cooking component, has proven biological activities, including antiprotozoal activity [<xref rid="B199-molecules-22-00058" ref-type="bibr">199</xref>,<xref rid="B200-molecules-22-00058" ref-type="bibr">200</xref>]. Curcumin has been shown to possess activity against <italic>L. donovani</italic> while Magalh&#x000e3;es and colleagues profiled this compound for antischistosomal activity at doses between 5 and 100 &#x000b5;M where a dose-response relationship was obtained [<xref rid="B201-molecules-22-00058" ref-type="bibr">201</xref>].</p></sec><sec id="sec4dot3dot6-molecules-22-00058"><title>4.3.6. Phloroglucinols</title><p>Phloroglucinols from the Dryopteris species elicit antibacterial, antioxidant and antitumour enhancing, vermifuge and antihelminthic activities [<xref rid="B202-molecules-22-00058" ref-type="bibr">202</xref>,<xref rid="B203-molecules-22-00058" ref-type="bibr">203</xref>]. Principal components associated with the antischistosomal action of phloroglucinols include the structurally related compounds: aspidin (<bold>96</bold>), desaspidin (<bold>97</bold>), flavaspidic acid (<bold>98</bold>) and methylene-bis-aspidinol (<bold>99</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f015">Figure 15</xref>) [<xref rid="B202-molecules-22-00058" ref-type="bibr">202</xref>,<xref rid="B203-molecules-22-00058" ref-type="bibr">203</xref>,<xref rid="B204-molecules-22-00058" ref-type="bibr">204</xref>]. In one in vitro study, whereas aspidin and desaspidin were observed to kill worms at concentrations of between 25 and 100 &#x000b5;M, flavaspidic acid and methylene-bis-aspidinol required higher concentrations of 50&#x02013;100 &#x000b5;M and 100 &#x000b5;M respectively to elicit the same effect. Interestingly, these compounds appear to induce different morphological effects in the parasite since desaspidin failed to cause decoupling of worms while methylene-bis-aspidinol did not reduce worm viability [<xref rid="B205-molecules-22-00058" ref-type="bibr">205</xref>] and may suggest divergent modes of action of these constituent compounds.</p></sec><sec id="sec4dot3dot7-molecules-22-00058"><title>4.3.7. Cinchona Alkaloids&#x02014;Quinine and Derivatives</title><p>The bark of the cinchona tree is a rich source of alkaloids including the antimalarial agent quinine. Chloroquine, a synthetic analogue of quinine was previously successful in the treatment of malaria and its use only decimated with the advent of widespread resistance of plasmodia parasites to its use [<xref rid="B206-molecules-22-00058" ref-type="bibr">206</xref>,<xref rid="B207-molecules-22-00058" ref-type="bibr">207</xref>]. Together with mefloquine and primaquine, these quinine-based drugs (<xref ref-type="fig" rid="molecules-22-00058-f016">Figure 16</xref>) have been evaluated for their antischistosomal properties, yielding attractive results [<xref rid="B208-molecules-22-00058" ref-type="bibr">208</xref>,<xref rid="B209-molecules-22-00058" ref-type="bibr">209</xref>,<xref rid="B210-molecules-22-00058" ref-type="bibr">210</xref>].</p><p>Both in vitro and in vivo studies of mefloquine reveal the ability to reduce the worm burden in infected mice with notable synergy when used together with the artemisinin derivative, artesunate. Mefloquine and primaquine, in a study by Holtfreter and co-workers, showed time- and dose-dependent in vitro antischistosomal activities in the tested concentration range 0.5&#x02013;2 &#x000b5;g/mL [<xref rid="B211-molecules-22-00058" ref-type="bibr">211</xref>]. In an exploratory clinical trial in West Africa, mefloquine produced equal cure rates with artesunate at 21% and 25% respectively and was synergistic with artesunate whereby a three-fold increase in effect was observed (61%) and a 95% reduction in eggs [<xref rid="B212-molecules-22-00058" ref-type="bibr">212</xref>]. In this study, the standard treatment for schistosomiasis, praziquantel, proved to be the most effective drug with 88% cure rate. Given the observation that mefloquine is more effective against the immature schistosomulae stage as compared to the adult worms [<xref rid="B208-molecules-22-00058" ref-type="bibr">208</xref>,<xref rid="B211-molecules-22-00058" ref-type="bibr">211</xref>], combined therapy with praziquantel has been evaluated. As predicted, this combination was synergistic when the two drugs were used in the ratio of their medium effective concentrations [<xref rid="B213-molecules-22-00058" ref-type="bibr">213</xref>].</p><p>The mechanism of antimalarial action of chloroquine and mefloquine is yet to be fully known. However, it at least consist, in part, of the interference with the haemoglobin degradation pathway where it causes the built up of toxic heme [<xref rid="B206-molecules-22-00058" ref-type="bibr">206</xref>,<xref rid="B208-molecules-22-00058" ref-type="bibr">208</xref>]. Schistosoma parasite biology contain this pathway also and is a possible drug target in antischistosomal drug discovery [<xref rid="B165-molecules-22-00058" ref-type="bibr">165</xref>]. On the other hand, primaquine is known to interfere with mitochondrion function leading to oxidative damage while both primaquine and mefloquine might cause influx of calcium ions into cells leading to spasms [<xref rid="B211-molecules-22-00058" ref-type="bibr">211</xref>].</p></sec><sec id="sec4dot3dot8-molecules-22-00058"><title>4.3.8. Artemisinins and Derivatives</title><p>The discovery of the antimalarial properties of artemisinin (<xref ref-type="fig" rid="molecules-22-00058-f017">Figure 17</xref>), a sesquiterpene lactone, from Sweet wormwood, <italic>Artemisia annua</italic> L. (Asteraceae) has revolutionized malaria treatment [<xref rid="B214-molecules-22-00058" ref-type="bibr">214</xref>,<xref rid="B215-molecules-22-00058" ref-type="bibr">215</xref>,<xref rid="B216-molecules-22-00058" ref-type="bibr">216</xref>]. Subsequently, derivatives of artemisinin such as artemether, arteether and artesunate have been developed with improved potency, pharmacokinetics profile and chemical stability and are part of the components of the first line treatment regime in malaria endemic regions [<xref rid="B176-molecules-22-00058" ref-type="bibr">176</xref>]. Just as with antimalarial activity, the antischistosomal properties of artemisinins were first reported in China [<xref rid="B217-molecules-22-00058" ref-type="bibr">217</xref>]. In that country, artemisinin-derived agents, mainly artemether, were used extensively to control infections in the regions where <italic>S. japonicum</italic> infections were endemic [<xref rid="B167-molecules-22-00058" ref-type="bibr">167</xref>]. Studies have followed in other geographical regions and including tests on other <italic>Schistosoma</italic> species [<xref rid="B218-molecules-22-00058" ref-type="bibr">218</xref>].</p><p>In a study by Le and co-workers, artemether tested experimentally in dogs or mice decreased worm burden and was effective against the migratory larval forms&#x02014;schistosomula [<xref rid="B217-molecules-22-00058" ref-type="bibr">217</xref>]. Later studies reported that schistosome eggs were unresponsive to artemether treatment [<xref rid="B219-molecules-22-00058" ref-type="bibr">219</xref>,<xref rid="B220-molecules-22-00058" ref-type="bibr">220</xref>]. Other studies followed confirming antischistosomal properties of other artemisinin derivatives&#x02014;artesunate [<xref rid="B221-molecules-22-00058" ref-type="bibr">221</xref>], arteether [<xref rid="B222-molecules-22-00058" ref-type="bibr">222</xref>] and dihydroartemisinin [<xref rid="B223-molecules-22-00058" ref-type="bibr">223</xref>]. Artemether produced greater effects against female worms compared to the males and induced hepatic shift in worms from mesenteric venules to the liver [<xref rid="B219-molecules-22-00058" ref-type="bibr">219</xref>,<xref rid="B220-molecules-22-00058" ref-type="bibr">220</xref>]. Moreover, several studies have confirmed that artemether in vivo is more active against the schistosomulae stage than the adult stage [<xref rid="B224-molecules-22-00058" ref-type="bibr">224</xref>,<xref rid="B225-molecules-22-00058" ref-type="bibr">225</xref>]; an effect that was not only dose-dependent but also influenced by frequency of administration and the route used whereby the intragrastric route appeared more effective than the intramuscular one [<xref rid="B226-molecules-22-00058" ref-type="bibr">226</xref>]. In another study, artemether administered intramuscularly at 50 and 100 mg/kg decreased egg-laying and total worms, particularly females in infections with <italic>S. mansoni</italic>. The liver and spleen of the treated animals were noticed to decrease in weight [<xref rid="B167-molecules-22-00058" ref-type="bibr">167</xref>].</p><p>Since the artemisinins are already in clinical use, and there is geographical overlap between malaria- and schistosomiasis-endemic regions, exploratory clinical trials have been undertaken to ascertain the clinical efficacy and potential of the artemisinins to prevent transmission and contribute to the treatment of schistosomiasis. In clinical trials carried out in West Africa, artemether reduced the incidence and intensity of infection among the study participants-mostly school-going children [<xref rid="B227-molecules-22-00058" ref-type="bibr">227</xref>,<xref rid="B228-molecules-22-00058" ref-type="bibr">228</xref>]. Due to the activity of artemether in preventing the maturation of schistosomes, adult worms are prevented from developing and hence egg-laying precluded. This decreases the transmission of the disease as well as pathology due to presence of eggs and the adult worms in the organs. For this reason, artemether has been proposed as a potential chemoprophylactic agent among high risk groups [<xref rid="B228-molecules-22-00058" ref-type="bibr">228</xref>,<xref rid="B229-molecules-22-00058" ref-type="bibr">229</xref>]. Furthermore, studies comprising combined administration of an artemisinin-derived drugs with praziquantel have been explored [<xref rid="B230-molecules-22-00058" ref-type="bibr">230</xref>]. In this approach, synergy is envisaged whereby praziquantel would produce greater activity against the adult stage of the parasites while the artemisinin component would be more active against the schistosomulae. This combined effect should translate into the ability to prevent re-infection; an outcome that is not possible in the present use of praziquantel alone. The benefit of having an antimalarial drug possessing antischistosomal property is that with a single drug administration, two diseases can be targeted [<xref rid="B228-molecules-22-00058" ref-type="bibr">228</xref>,<xref rid="B231-molecules-22-00058" ref-type="bibr">231</xref>] which is an advantage from an economic point of view as well as compliance to medication, due to the decreased pill burden. However, this benefit has a serious potential downside: the use of an antimalarial drug in schistosomiasis raises concern for the potential selection of resistance by the plasmodia parasites&#x02014;a dangerous scenario especially in the face of limited range of antimalarial drugs [<xref rid="B176-molecules-22-00058" ref-type="bibr">176</xref>,<xref rid="B232-molecules-22-00058" ref-type="bibr">232</xref>]. Thus, it has been recommended that artemether might be used safely in areas where schistosomiasis is endemic but where malaria is not, to reduce incidence of infection [<xref rid="B176-molecules-22-00058" ref-type="bibr">176</xref>].</p><p>Artemisinins are believed to achieve their toxicity to plasmodia parasites, as well as to schistosomes, due to the labile endoperoxide group which cleaves to generate reactive oxygen species that interact with biomolecules within the parasite leading to parasite death [<xref rid="B233-molecules-22-00058" ref-type="bibr">233</xref>,<xref rid="B234-molecules-22-00058" ref-type="bibr">234</xref>]. Medicinal chemistry optimisation of related chemical classes that incorporate the peroxide moiety such as 1,2,4 trioxanes have been explored and present the artemisinins as viable templates for lead development [<xref rid="B235-molecules-22-00058" ref-type="bibr">235</xref>].</p></sec><sec id="sec4dot3dot9-molecules-22-00058"><title>4.3.9. Allicin</title><p>Garlic (<italic>Allium sativum</italic>; Liliaceae) possesses numerous anti-infective properties, among them, antiparasitic [<xref rid="B236-molecules-22-00058" ref-type="bibr">236</xref>]. Allicin (<bold>100</bold>, <xref ref-type="fig" rid="molecules-22-00058-f018">Figure 18</xref>), a simple molecule comprising of an unsaturated aliphatic system is identified as the major component and is responsible for the reported antischistosomal activity of garlic. Lima et al., 2011 reported on the effect of incremental doses of allicin (up to 20 mg/mL) on the tegument of adult worms. This effect was dose-dependent and, higher than therapeutic concentrations were required to produce detrimental effects [<xref rid="B237-molecules-22-00058" ref-type="bibr">237</xref>]. In earlier findings, Riad and colleagues reported on the curative parasitological effects, against <italic>S. mansoni</italic>, of garlic extract at 50 mg/kg. Interestingly, the observed antischistosomal effects were reversed at a higher dose of 100 mg/kg [<xref rid="B238-molecules-22-00058" ref-type="bibr">238</xref>,<xref rid="B239-molecules-22-00058" ref-type="bibr">239</xref>].</p></sec><sec id="sec4dot3dot10-molecules-22-00058"><title>4.3.10. <italic>Vernonia amygdalina</italic></title><p>The tropical plant <italic>Vernonia amygdalina</italic> (Asteraceae) is a rich source of sesquiterpene lactones and steroidal glucosides with their corresponding aglycones [<xref rid="B240-molecules-22-00058" ref-type="bibr">240</xref>], which have been investigated for antischistosomal activity. In the study led by Jisaka, despite failing to produce significant effects at 2 ppm&#x02014;the concentration at which praziquantel is effective&#x02014;the sesquiterpene lactones and steroidal glucosides from this plant inflicted changes at 200 ppm with vernodalin (<bold>101</bold>, <xref ref-type="fig" rid="molecules-22-00058-f018">Figure 18</xref>) being most potent, as it produced detrimental effects at 20 ppm [<xref rid="B241-molecules-22-00058" ref-type="bibr">241</xref>].</p></sec><sec id="sec4dot3dot11-molecules-22-00058"><title>4.3.11. Emetine</title><p>Emetine (<bold>102</bold>, <xref ref-type="fig" rid="molecules-22-00058-f018">Figure 18</xref>) is the major alkaloid found in the root of the plant <italic>Cephaelis ipecacuanha</italic> (Rubiciae) with clinical use in amoebiasis and for inducing emesis. Dehydroemetine (<bold>103</bold>, <xref ref-type="fig" rid="molecules-22-00058-f018">Figure 18</xref>) is a closely related analogue resulting from unsaturation of emetine [<xref rid="B242-molecules-22-00058" ref-type="bibr">242</xref>,<xref rid="B243-molecules-22-00058" ref-type="bibr">243</xref>]. These compounds have been shown to possess antitumour activity and are believed to function via inhibition of protein synthesis [<xref rid="B244-molecules-22-00058" ref-type="bibr">244</xref>,<xref rid="B245-molecules-22-00058" ref-type="bibr">245</xref>,<xref rid="B246-molecules-22-00058" ref-type="bibr">246</xref>]. Evaluation of emetine for antischistosomal activity suggested that double the dose used in amoebic infections would be necessary, an unfavourable profile given the high toxicity of the compound. Dehydroemetine, although possessing a better safety profile than emetine, required prolonged administration&#x02014;given for 30 days intravenously. These features make the drug expensive for a population that is already impoverished making it less affordable hence not favourable [<xref rid="B175-molecules-22-00058" ref-type="bibr">175</xref>,<xref rid="B247-molecules-22-00058" ref-type="bibr">247</xref>].</p></sec><sec id="sec4dot3dot12-molecules-22-00058"><title>4.3.12. Other Natural Product Leads: Mevinolin (Lovastatin), Plumbagin and Sanguinarine</title><p>Mevinolin (<bold>104</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f019">Figure 19</xref>) is the template cholesterol lowering drug from which newer generation derivatives have been synthesised. The compound is produced by the fungus <italic>Aspergillus terreus</italic> and is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase involved in the cholesterol synthesis pathway [<xref rid="B248-molecules-22-00058" ref-type="bibr">248</xref>]. In an Antischistosomal assay, mevinolin was found to decrease the production of eggs, an action thought to arise from inhibition of the synthesis of dolichol-like compounds crucial to the modification (mannosylation) of proteins in the schistosomes, hence impairing their activities. Mevinolin, on prolonged exposure, displayed activity on both adult and juvenile worms [<xref rid="B249-molecules-22-00058" ref-type="bibr">249</xref>,<xref rid="B250-molecules-22-00058" ref-type="bibr">250</xref>].</p><p>When tested at 10 &#x000b5;M&#x02014;the WHO recommended cut-off for an antischistosomal hit-plumbagin (<bold>42</bold>) and sanguinarine (<bold>105</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f019">Figure 19</xref>) produced various morphological changes resulting in parasite death. In addition to the greater potency of sanguinarine over plumbagin against adult worms, the diversity of detrimental alterations produced suggest that the two compounds may have different modes of antischistosomal action [<xref rid="B251-molecules-22-00058" ref-type="bibr">251</xref>].</p></sec><sec id="sec4dot3dot13-molecules-22-00058"><title>4.3.13. Summary</title><p>Despite the considerable public health effect of schistosomiasis, drug discovery efforts remain disproportionate. Natural products have been explored with the aim of identifying novel leads for this parasitic disease. Many of the tested agents derive their history from culinary and other medicinal uses while for others, only crude extracts have been investigated. Major efforts are still needed to identify isolated chemical compounds responsible for antischistosomal activity. Moreover, further assays to evaluate cytotoxicity and pharmacokinetics are requisite to be able to identify potential antischistosomal drug leads. The most advanced agents tested for potential use in the treatment of schistosomiasis hitherto are the quinine analogues and artemisinin-based antimalarial drugs, inspired mainly by their established use in the treatment of malaria. The successful clinical trials by these agents provide confidence in the use of natural products in this parasitic disease.</p></sec></sec></sec><sec id="sec5-molecules-22-00058"><title>5. Lymphatic Filariasis</title><sec id="sec5dot1-molecules-22-00058"><title>5.1. Background of the Disease</title><p>Lymphatic filariasis, commonly referred to as elephantiasis is a parasitic infection caused by the <italic>Wuchereria bancrofti</italic>, <italic>Brugia malayi</italic> and <italic>Brugia timori</italic> filarial worms [<xref rid="B252-molecules-22-00058" ref-type="bibr">252</xref>]. The World Health Organization estimated in October 2016 that 947 million people living in 54 countries worldwide are at risk of contracting lymphatic filariasis with the highest burden being in African countries [<xref rid="B253-molecules-22-00058" ref-type="bibr">253</xref>]. Current treatment involves the use of ivermectin, diethylcarbamaine and albendazole. Public health efforts to eliminate lymphatic filariasis have involved the use of mass drug administration of combinations of the three drugs. However, these drugs mainly target the microfilarial stages of the parasite and are not effective on the adult worm [<xref rid="B254-molecules-22-00058" ref-type="bibr">254</xref>]. There is, therefore, a need to develop drugs for this neglected tropical disease.</p></sec><sec id="sec5dot2-molecules-22-00058"><title>5.2. Naturally Derived Compounds for Lymphatic Filariasis</title><sec id="sec5dot2dot1-molecules-22-00058"><title>5.2.1. Plant Origin</title><p><italic>Lantana camara</italic>, a common plant that is native to tropical America and now regarded as a global weed was investigated for antifilarial activity. The crude extract administered in vivo to the <italic>Mastomys coucha</italic> rodent model at a high dose of 1 g/kg body weight for five days killed 43.05% of the adult <italic>Brugia malayi</italic>. Two compounds&#x02014;oleanolic acid (<bold>75</bold>) and oleononic acid (<bold>106</bold>) (<xref ref-type="fig" rid="molecules-22-00058-f020">Figure 20</xref>)&#x02014;isolated from <italic>L. camara</italic> exhibited antifilarial activity with an LC<sub>100</sub> at 68.4 and 137 &#x000b5;M respectively [<xref rid="B255-molecules-22-00058" ref-type="bibr">255</xref>].</p><p>The methanolic extract of <italic>Trachyspermum ammi</italic> fruits was found to possess activity against the adult bovine filarial worm, <italic>Setaria digitata</italic>. The crude extract had an IC<sub>50</sub> of 0.067 mg/mL at 24 h and an IC<sub>50</sub> of 0.019 mg/mL at 48 h. Higher potency was observed after a longer exposure period implying that this extract was slow acting [<xref rid="B256-molecules-22-00058" ref-type="bibr">256</xref>]. Bioassay guided fractionation was carried out and thymol (<bold>107</bold>, <xref ref-type="fig" rid="molecules-22-00058-f020">Figure 20</xref>), a monoterpene phenolic compound was isolated. Like the crude extract, thymol was slow acting with an IC<sub>50</sub> of 160 &#x003bc;M at 24 h and 13.3 &#x003bc;M at 48 h. The in vivo effect of thymol was tested against <italic>Brugia malayi</italic> in a <italic>Mastomys coucha</italic> model and the mean percentage of parasite mortality was 58.93% following a 50 mg/kg dose, while the control group had a mean percentage mortality of 19.05% [<xref rid="B256-molecules-22-00058" ref-type="bibr">256</xref>].</p><p>A steroidal glycoalkaloid, solamargine (<bold>108</bold>, <xref ref-type="fig" rid="molecules-22-00058-f020">Figure 20</xref>), isolated from the ripe fruits of <italic>Solanum khasianum</italic> displayed in vitro activity against the adult worms and microfilaria of <italic>Brugia malayi</italic>, killing 100% at a concentration of 4 mg/mL in 60 min for the adult and 88 min for the microfilaria [<xref rid="B252-molecules-22-00058" ref-type="bibr">252</xref>]. Total synthesis of solamargine and its analogues has been achieved thus it is possible to further explore this compound with the aim of improving activity and its drug like properties [<xref rid="B257-molecules-22-00058" ref-type="bibr">257</xref>].</p><p>The crude aqueous and methanolic extracts of <italic>Xylocarpus granatum</italic> commonly referred to as the mangrove plant demonstrated in vitro antifilarial activity against the adult worm. Two compounds isolated from this plant displayed good antifilarial activity: Gedunin (<bold>109</bold>) IC<sub>50</sub> value: 0.50 &#x000b5;M; photogedunin (<bold>110</bold>) IC<sub>50</sub> 0.41 &#x000b5;M (<xref ref-type="fig" rid="molecules-22-00058-f020">Figure 20</xref>) [<xref rid="B258-molecules-22-00058" ref-type="bibr">258</xref>].</p><p>Other drug discovery approaches that have been explored from plant sources include the synergistic effects of conventional and herbal therapy. Sharma et al., tested the effects of the methanolic extracts of <italic>Vitex negundo</italic> and <italic>Aegle marmelos</italic> when administered with diethylcarbamazine (DEC) and found that the extracts enhanced the microfilarial effects of DEC. However, attempts to fractionate the extracts led to loss of activity thus implying that the activity of the extracts may be due to synergism of the phytochemicals present as opposed to a single compound [<xref rid="B259-molecules-22-00058" ref-type="bibr">259</xref>].</p><p>Another drug discovery approach that has been attempted is the target based drug discovery targeting the glutathione <italic>S</italic>-transferase (GST) enzyme found in filarial worms. Glutathione S transferase inhibitors obtained from plant sources such as ethacrynic acid, plumbagin and curcumin were found to inhibit the GST enzyme isolated from the female adult bovine filarial worm, <italic>Setaria digitata</italic> [<xref rid="B260-molecules-22-00058" ref-type="bibr">260</xref>]</p></sec><sec id="sec5dot2dot2-molecules-22-00058"><title>5.2.2. Microbial Sources</title><p>The discovery of <italic>Wolbachia</italic>, an endobacterium found in filarial worms provided a promising target for chemotherapy by opening up the possibility of antibiotic therapy in the management of filariasis. Anti-rickettsial agents like tetracycline, doxycycline (<xref ref-type="fig" rid="molecules-22-00058-f020">Figure 20</xref>) and ciprofloxacin have been shown to deplete Wolbachia from the worms [<xref rid="B261-molecules-22-00058" ref-type="bibr">261</xref>]. Doxycycline, a synthetic derivative of Terramycin, an antibiotic isolated from soil bacterium <italic>Streptomyces rimosus</italic> has demonstrated significant activity against macrofilaria. A daily dose of 200 mg was administered in a 3-, 4- and 6-week regimen. The 6-week regimen showed microfilaricidal activity of 92%, the 4-week regimen had 83% while no activity was observed in the 3-week regimen implying that there may be a minimum cumulative dose required for activity [<xref rid="B262-molecules-22-00058" ref-type="bibr">262</xref>].</p></sec><sec id="sec5dot2dot3-molecules-22-00058"><title>5.2.3. Marine Sources</title><p>The marine sponge, <italic>Haliclonia exigua</italic> was investigated for antifilarial activity. The crude methanolic extract and the <italic>n</italic>-butanol soluble fractions killed the adult <italic>Brugia malayi</italic> worm at 31.25 &#x000b5;g/mL while the chloroform extract exhibited higher activity, killing the worms at 15.6 &#x000b5;g/mL. Araguspongin C (<bold>111</bold>, <xref ref-type="fig" rid="molecules-22-00058-f020">Figure 20</xref>) was isolated from this organism and found to have activity that was similar to that of the crude extract (IC<sub>50</sub> = 34.9 &#x000b5;M). When tested in vivo, both the crude extract and Araguspongin C did not exhibit any significant activity [<xref rid="B263-molecules-22-00058" ref-type="bibr">263</xref>]. The related species, <italic>Haloclonia oculata</italic> chloroform extract exhibited in vitro activity against the adult <italic>Brugia malayi</italic> with an IC<sub>50</sub> value of 1.80 &#x000b5;g/mL. Unlike the <italic>H. exigua</italic> extract, the <italic>H. oculata</italic> extract exhibited significant in vivo microfilarial efficacy (64%) on the <italic>B. malayi</italic> intraperitoneal transplanted jird model [<xref rid="B264-molecules-22-00058" ref-type="bibr">264</xref>].</p></sec></sec><sec id="sec5dot3-molecules-22-00058"><title>5.3. Semi-Synthetic/Total Synthetic Compounds Based on Natural Compound Templates</title><sec id="sec5dot3dot1-molecules-22-00058"><title>Pre-Clinical Compounds</title><p>A bioactive anthraquinone, anthraquinone J (<bold>112</bold>, <xref ref-type="fig" rid="molecules-22-00058-f021">Figure 21</xref>) isolated from daylily roots exhibited significant activity against <italic>B. malayi</italic> and was thus synthesized alongside a number of its analogues. Anthraquinones A&#x02013;S were synthesized and tested against microfilaria and adult worms. Anthraquinone K (<bold>113</bold>, <xref ref-type="fig" rid="molecules-22-00058-f021">Figure 21</xref>) showed 100% mortality in 1 day against microfilaria; 3 days against female worms and 5 days against the adult male worms [<xref rid="B265-molecules-22-00058" ref-type="bibr">265</xref>].</p></sec></sec></sec><sec id="sec6-molecules-22-00058"><title>6. Concluding Remarks</title><p>NTDs remain a public health issue for emerging countries. As pointed out in the earlier sections of this review, their public health impact may well have been underestimated. Despite being ancient diseases, they have continued afflicting significant proportions of the world especially the world&#x02019;s poorest. Investment, financial and otherwise, in the development of chemotherapeutic interventions against NTDs has been hampered, in part, by the general disregard of diseases afflicting poor populations as well as a prospect of limited financial returns on investment.</p><p>Current clinically used drugs against NTDs are beset by numerous shortfalls including toxicity, complicated administration procedures, limited availability and emergence of resistance. Natural products represent an untapped source of novel and structurally diverse chemotypes with potential to act via novel mechanisms of action against various causative agents of NTDs. In this review article we have reviewed natural products and their derivatives as potential leads for new therapies against NTDs. We have highlighted the immense therapeutic potential that remains untapped in natural product-derived compounds. Numerous metabolites isolated from plant, microbial and marine sources have been discussed. A limited number of synthetic and semisynthetic compounds motivated by natural product scaffolds have also been covered. Highly potent classes of metabolites from different chemical classes&#x02014;alkaloids, phenolic compounds, quinones, terpenes, saponins, lignans, taxoids, anthranoids among others, have been discussed. Although a myriad of different classes of metabolites have demonstrated comparable and, in some cases, superior potency along with better toxicity profiles, compared to standard drugs, none of the promising leads have been progressed further into clinical development. There is need to seriously consider further clinical development of some promising natural products. The natural product compounds covered in this review could be clinical candidates in their own right or could provide templates for further medicinal chemistry optimization programmes.</p></sec></body><back><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-molecules-22-00058"><label>1.</label><element-citation publication-type="webpage">
<article-title>Neglected Tropical Diseases</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.webcitation.org/6kb2aMCKW">http://www.webcitation.org/6kb2aMCKW</ext-link></comment>
<date-in-citation>(accessed on 17 September 2016)</date-in-citation>
</element-citation></ref><ref id="B2-molecules-22-00058"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feasey</surname><given-names>N.</given-names></name><name><surname>Wansbrough-Jones</surname><given-names>M.</given-names></name><name><surname>Mabey</surname><given-names>D.C.W.</given-names></name><name><surname>Solomon</surname><given-names>A.W.</given-names></name></person-group>
<article-title>Neglected tropical diseases</article-title>
<source>Br. Med. Bull.</source>
<year>2010</year>
<volume>93</volume>
<fpage>179</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="doi">10.1093/bmb/ldp046</pub-id>
<?supplied-pmid 20007668?><pub-id pub-id-type="pmid">20007668</pub-id></element-citation></ref><ref id="B3-molecules-22-00058"><label>3.</label><element-citation publication-type="book">
<person-group person-group-type="author"><collab>World Health Organization</collab></person-group>
<source>World Health Report 2004: Changing History</source>
<publisher-name>World Health Organization</publisher-name>
<publisher-loc>Geneva, Switzerland</publisher-loc>
<year>2004</year>
</element-citation></ref><ref id="B4-molecules-22-00058"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bern</surname><given-names>C.</given-names></name><name><surname>Maguire</surname><given-names>J.H.</given-names></name><name><surname>Alvar</surname><given-names>J.</given-names></name></person-group>
<article-title>Complexities of assessing the disease burden attributable to leishmaniasis</article-title>
<source>PLoS Negl. Trop. Dis.</source>
<year>2008</year>
<volume>2</volume>
<elocation-id>e313</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0000313</pub-id>
<?supplied-pmid 18958165?><pub-id pub-id-type="pmid">18958165</pub-id></element-citation></ref><ref id="B5-molecules-22-00058"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bethony</surname><given-names>J.</given-names></name><name><surname>Brooker</surname><given-names>S.</given-names></name><name><surname>Albonico</surname><given-names>M.</given-names></name><name><surname>Geiger</surname><given-names>S.M.</given-names></name><name><surname>Loukas</surname><given-names>A.</given-names></name><name><surname>Diemert</surname><given-names>D.</given-names></name><name><surname>Hotez</surname><given-names>P.J.</given-names></name></person-group>
<article-title>Soil-transmitted helminth infections: Ascariasis, trichuriasis, and hookworm</article-title>
<source>Lancet</source>
<year>2006</year>
<volume>367</volume>
<fpage>1521</fpage>
<lpage>1532</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(06)68653-4</pub-id>
<pub-id pub-id-type="pmid">16679166</pub-id></element-citation></ref><ref id="B6-molecules-22-00058"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crompton</surname><given-names>D.W.T.</given-names></name><name><surname>Nesheim</surname><given-names>M.C.</given-names></name></person-group>
<article-title>Nutritional impact of intestinal helminthiasis during the human life cycle</article-title>
<source>Annu. Rev. Nutr.</source>
<year>2002</year>
<volume>22</volume>
<fpage>35</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.nutr.22.120501.134539</pub-id>
<?supplied-pmid 12055337?><pub-id pub-id-type="pmid">12055337</pub-id></element-citation></ref><ref id="B7-molecules-22-00058"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hotez</surname><given-names>P.J.</given-names></name><name><surname>Ferris</surname><given-names>M.T.</given-names></name></person-group>
<article-title>The antipoverty vaccines</article-title>
<source>Vaccine</source>
<year>2006</year>
<volume>24</volume>
<fpage>5787</fpage>
<lpage>5799</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.05.008</pub-id>
<?supplied-pmid 16759763?><pub-id pub-id-type="pmid">16759763</pub-id></element-citation></ref><ref id="B8-molecules-22-00058"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Colley</surname><given-names>D.G.</given-names></name><name><surname>Bustinduy</surname><given-names>A.L.</given-names></name><name><surname>Secor</surname><given-names>W.E.</given-names></name><name><surname>King</surname><given-names>C.H.</given-names></name></person-group>
<article-title>Human schistosomiasis</article-title>
<source>Lancet</source>
<year>2014</year>
<volume>383</volume>
<fpage>2253</fpage>
<lpage>2264</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(13)61949-2</pub-id>
<pub-id pub-id-type="pmid">24698483</pub-id></element-citation></ref><ref id="B9-molecules-22-00058"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perera</surname><given-names>M.</given-names></name><name><surname>Whitehead</surname><given-names>M.</given-names></name><name><surname>Molyneux</surname><given-names>D.</given-names></name><name><surname>Weerasooriya</surname><given-names>M.</given-names></name><name><surname>Gunatilleke</surname><given-names>G.</given-names></name></person-group>
<article-title>Neglected Patients with a Neglected Disease? A Qualitative Study of Lymphatic Filariasis</article-title>
<source>PLoS Negl. Trop. Dis.</source>
<year>2007</year>
<volume>1</volume>
<elocation-id>e128</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0000128</pub-id>
<?supplied-pmid 18060080?><pub-id pub-id-type="pmid">18060080</pub-id></element-citation></ref><ref id="B10-molecules-22-00058"><label>10.</label><element-citation publication-type="webpage">
<article-title>Trachoma: Situation and Trends</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.webcitation.org/6kfb0UvfZ">http://www.webcitation.org/6kfb0UvfZ</ext-link></comment>
<date-in-citation>(accessed on 20 September 2016)</date-in-citation>
</element-citation></ref><ref id="B11-molecules-22-00058"><label>11.</label><element-citation publication-type="webpage">
<article-title>NTD Overview: What are Neglected Tropical Diseases</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.webcitation.org/6kc3jm5cS">http://www.webcitation.org/6kc3jm5cS</ext-link></comment>
<date-in-citation>(accessed on 18 September 2016)</date-in-citation>
</element-citation></ref><ref id="B12-molecules-22-00058"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hotez</surname><given-names>P.J.</given-names></name><name><surname>Kamath</surname><given-names>A.</given-names></name></person-group>
<article-title>Neglected tropical diseases in sub-Saharan Africa: Review of their prevalence, distribution, and disease burden</article-title>
<source>PLoS Negl. Trop. Dis.</source>
<year>2009</year>
<volume>3</volume>
<elocation-id>e412</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0000412</pub-id>
<?supplied-pmid 19707588?><pub-id pub-id-type="pmid">19707588</pub-id></element-citation></ref><ref id="B13-molecules-22-00058"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fenwick</surname><given-names>A.</given-names></name></person-group>
<article-title>The global burden of neglected tropical diseases</article-title>
<source>Public Health</source>
<year>2012</year>
<volume>126</volume>
<fpage>233</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.1016/j.puhe.2011.11.015</pub-id>
<?supplied-pmid 22325616?><pub-id pub-id-type="pmid">22325616</pub-id></element-citation></ref><ref id="B14-molecules-22-00058"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pink</surname><given-names>R.</given-names></name><name><surname>Hudson</surname><given-names>A.</given-names></name><name><surname>Mouri&#x000e8;s</surname><given-names>M.-A.</given-names></name><name><surname>Bendig</surname><given-names>M.</given-names></name></person-group>
<article-title>Opportunities and Challenges in Antiparasitic Drug Discovery</article-title>
<source>Nat. Rev. Drug Discov.</source>
<year>2005</year>
<volume>4</volume>
<fpage>727</fpage>
<lpage>740</lpage>
<pub-id pub-id-type="doi">10.1038/nrd1824</pub-id>
<?supplied-pmid 16138106?><pub-id pub-id-type="pmid">16138106</pub-id></element-citation></ref><ref id="B15-molecules-22-00058"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clark</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Natural Products as a Resource for New Drugs</article-title>
<source>Pharm. Res.</source>
<year>1996</year>
<volume>13</volume>
<fpage>1133</fpage>
<lpage>1141</lpage>
<pub-id pub-id-type="doi">10.1023/A:1016091631721</pub-id>
<?supplied-pmid 8865302?><pub-id pub-id-type="pmid">8865302</pub-id></element-citation></ref><ref id="B16-molecules-22-00058"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soejarto</surname><given-names>D.D.</given-names></name><name><surname>Farnsworth</surname><given-names>N.R.</given-names></name></person-group>
<article-title>Tropical Rain Forests: Potential Source of New Drugs?</article-title>
<source>Perspect. Biol. Med.</source>
<year>1989</year>
<volume>32</volume>
<fpage>244</fpage>
<lpage>256</lpage>
<pub-id pub-id-type="doi">10.1353/pbm.1989.0003</pub-id>
<?supplied-pmid 2648321?><pub-id pub-id-type="pmid">2648321</pub-id></element-citation></ref><ref id="B17-molecules-22-00058"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Newman</surname><given-names>D.J.</given-names></name><name><surname>Cragg</surname><given-names>G.M.</given-names></name></person-group>
<article-title>Natural Products as Sources of New Drugs over the Last 25 Years</article-title>
<source>J. Nat. Prod.</source>
<year>2007</year>
<volume>70</volume>
<fpage>461</fpage>
<lpage>477</lpage>
<pub-id pub-id-type="doi">10.1021/np068054v</pub-id>
<?supplied-pmid 17309302?><pub-id pub-id-type="pmid">17309302</pub-id></element-citation></ref><ref id="B18-molecules-22-00058"><label>18.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Tyler</surname><given-names>V.E.</given-names></name><name><surname>Brady</surname><given-names>L.R.</given-names></name><name><surname>Robbers</surname><given-names>J.E.</given-names></name></person-group>
<source>Pharmacognosy</source>
<edition>9th ed.</edition>
<publisher-name>Lea &#x00026; Febiger</publisher-name>
<publisher-loc>Philadephia, PA, USA</publisher-loc>
<year>1998</year>
</element-citation></ref><ref id="B19-molecules-22-00058"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butler</surname><given-names>M.S.</given-names></name></person-group>
<article-title>Natural products to drugs: Natural product-derived compounds in clinical trials</article-title>
<source>Nat. Prod. Rep.</source>
<year>2008</year>
<volume>25</volume>
<fpage>475</fpage>
<lpage>516</lpage>
<pub-id pub-id-type="doi">10.1039/b514294f</pub-id>
<?supplied-pmid 18497896?><pub-id pub-id-type="pmid">18497896</pub-id></element-citation></ref><ref id="B20-molecules-22-00058"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chin</surname><given-names>Y.-W.</given-names></name><name><surname>Balunas</surname><given-names>M.J.</given-names></name><name><surname>Chai</surname><given-names>H.B.</given-names></name><name><surname>Kinghorn</surname><given-names>A.D.</given-names></name></person-group>
<article-title>Drug discovery from natural sources</article-title>
<source>AAPS J.</source>
<year>2006</year>
<volume>8</volume>
<fpage>E239</fpage>
<lpage>E253</lpage>
<pub-id pub-id-type="doi">10.1007/BF02854894</pub-id>
<?supplied-pmid 16796374?><pub-id pub-id-type="pmid">16796374</pub-id></element-citation></ref><ref id="B21-molecules-22-00058"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lam</surname><given-names>K.S.</given-names></name></person-group>
<article-title>New aspects of natural products in drug discovery</article-title>
<source>Trends Microbiol.</source>
<year>2007</year>
<volume>15</volume>
<fpage>279</fpage>
<lpage>289</lpage>
<pub-id pub-id-type="doi">10.1016/j.tim.2007.04.001</pub-id>
<?supplied-pmid 17433686?><pub-id pub-id-type="pmid">17433686</pub-id></element-citation></ref><ref id="B22-molecules-22-00058"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ganesan</surname><given-names>A.</given-names></name></person-group>
<article-title>The impact of natural products upon modern drug discovery</article-title>
<source>Curr. Opin. Chem. Biol.</source>
<year>2008</year>
<volume>12</volume>
<fpage>306</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1016/j.cbpa.2008.03.016</pub-id>
<?supplied-pmid 18423384?><pub-id pub-id-type="pmid">18423384</pub-id></element-citation></ref><ref id="B23-molecules-22-00058"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baker</surname><given-names>D.D.</given-names></name><name><surname>Chu</surname><given-names>M.</given-names></name><name><surname>Oza</surname><given-names>U.</given-names></name><name><surname>Rajgarhia</surname><given-names>V.</given-names></name></person-group>
<article-title>The value of natural products to future pharmaceutical discovery</article-title>
<source>Nat. Prod. Rep.</source>
<year>2007</year>
<volume>24</volume>
<fpage>1225</fpage>
<lpage>1244</lpage>
<pub-id pub-id-type="doi">10.1039/b602241n</pub-id>
<?supplied-pmid 18033577?><pub-id pub-id-type="pmid">18033577</pub-id></element-citation></ref><ref id="B24-molecules-22-00058"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McChesney</surname><given-names>J.D.</given-names></name><name><surname>Venkataraman</surname><given-names>S.K.</given-names></name><name><surname>Henri</surname><given-names>J.T.</given-names></name></person-group>
<article-title>Plant natural products: Back to the future or into extinction?</article-title>
<source>Phytochemistry</source>
<year>2007</year>
<volume>68</volume>
<fpage>2015</fpage>
<lpage>2022</lpage>
<pub-id pub-id-type="doi">10.1016/j.phytochem.2007.04.032</pub-id>
<?supplied-pmid 17574638?><pub-id pub-id-type="pmid">17574638</pub-id></element-citation></ref><ref id="B25-molecules-22-00058"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rishton</surname><given-names>G.M.</given-names></name></person-group>
<article-title>Natural Products as a Robust Source of New Drugs and Drug Leads: Past Successes and Present Day Issues</article-title>
<source>Am. J. Cardiol.</source>
<year>2008</year>
<volume>101</volume>
<fpage>S43</fpage>
<lpage>S49</lpage>
<pub-id pub-id-type="doi">10.1016/j.amjcard.2008.02.007</pub-id>
<?supplied-pmid 18474274?><pub-id pub-id-type="pmid">18474274</pub-id></element-citation></ref><ref id="B26-molecules-22-00058"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zofou</surname><given-names>D.</given-names></name><name><surname>Ntie-Kang</surname><given-names>F.</given-names></name><name><surname>Sippl</surname><given-names>W.</given-names></name><name><surname>Efange</surname><given-names>S.M.N.</given-names></name></person-group>
<article-title>Bioactive natural products derived from the Central African flora against neglected tropical diseases and HIV</article-title>
<source>Nat. Prod. Rep.</source>
<year>2013</year>
<volume>30</volume>
<fpage>1098</fpage>
<lpage>1120</lpage>
<pub-id pub-id-type="doi">10.1039/c3np70030e</pub-id>
<?supplied-pmid 23817666?><pub-id pub-id-type="pmid">23817666</pub-id></element-citation></ref><ref id="B27-molecules-22-00058"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ioset</surname><given-names>J.-R.</given-names></name></person-group>
<article-title>Natural Products for Neglected Diseases: A Review</article-title>
<source>Curr. Org. Chem.</source>
<year>2008</year>
<volume>12</volume>
<fpage>643</fpage>
<lpage>666</lpage>
<pub-id pub-id-type="doi">10.2174/138527208784577394</pub-id>
</element-citation></ref><ref id="B28-molecules-22-00058"><label>28.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Haridas</surname><given-names>D.</given-names></name><name><surname>Setzer</surname><given-names>W.N.</given-names></name></person-group>
<article-title>Phytomedicinal agents for treatment of schistosomiasis</article-title>
<source>Drug Plants III</source>
<person-group person-group-type="editor"><name><surname>Govil</surname><given-names>J.N.</given-names></name><name><surname>Singh</surname><given-names>V.K.</given-names></name></person-group>
<publisher-name>Studium Press LLC</publisher-name>
<publisher-loc>Houston, TX, USA</publisher-loc>
<year>2010</year>
<fpage>79</fpage>
<lpage>91</lpage>
</element-citation></ref><ref id="B29-molecules-22-00058"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ndjonka</surname><given-names>D.</given-names></name><name><surname>Rapado</surname><given-names>L.</given-names></name><name><surname>Silber</surname><given-names>A.</given-names></name><name><surname>Liebau</surname><given-names>E.</given-names></name><name><surname>Wrenger</surname><given-names>C.</given-names></name></person-group>
<article-title>Natural Products as a Source for Treating Neglected Parasitic Diseases</article-title>
<source>Int. J. Mol. Sci.</source>
<year>2013</year>
<volume>14</volume>
<fpage>3395</fpage>
<lpage>3439</lpage>
<pub-id pub-id-type="doi">10.3390/ijms14023395</pub-id>
<?supplied-pmid 23389040?><pub-id pub-id-type="pmid">23389040</pub-id></element-citation></ref><ref id="B30-molecules-22-00058"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Neves</surname><given-names>B.</given-names></name><name><surname>Andrade</surname><given-names>C.</given-names></name><name><surname>Cravo</surname><given-names>P.</given-names></name></person-group>
<article-title>Natural Products as Leads in Schistosome Drug Discovery</article-title>
<source>Molecules</source>
<year>2015</year>
<volume>20</volume>
<fpage>1872</fpage>
<lpage>1903</lpage>
<pub-id pub-id-type="doi">10.3390/molecules20021872</pub-id>
<?supplied-pmid 25625682?><pub-id pub-id-type="pmid">25625682</pub-id></element-citation></ref><ref id="B31-molecules-22-00058"><label>31.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Ogungbe</surname><given-names>I.V.</given-names></name><name><surname>Singh</surname><given-names>M.</given-names></name><name><surname>Setzer</surname><given-names>W.N.</given-names></name></person-group>
<article-title>Antileishmanial natural products from plants</article-title>
<source>Studies in Natural Products Chemistry</source>
<person-group person-group-type="editor"><name><surname>Rahman</surname><given-names>A.</given-names></name></person-group>
<publisher-name>Elsevier</publisher-name>
<publisher-loc>Oxford, UK</publisher-loc>
<year>2012</year>
<fpage>331</fpage>
<lpage>382</lpage>
</element-citation></ref><ref id="B32-molecules-22-00058"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoet</surname><given-names>S.</given-names></name><name><surname>Opperdoes</surname><given-names>F.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name><name><surname>Quetin-Leclercq</surname><given-names>J.</given-names></name></person-group>
<article-title>Natural products active against African trypanosomes: A step towards new drugs</article-title>
<source>Nat. Prod. Rep.</source>
<year>2004</year>
<volume>21</volume>
<fpage>353</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="doi">10.1039/b311021b</pub-id>
<?supplied-pmid 15162223?><pub-id pub-id-type="pmid">15162223</pub-id></element-citation></ref><ref id="B33-molecules-22-00058"><label>33.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Setzer</surname><given-names>W.N.</given-names></name><name><surname>Setzer</surname><given-names>M.C.</given-names></name></person-group>
<article-title>Antitrypanosomal agents from higher plants</article-title>
<source>Biologically Active Natural Products for the 21st Century</source>
<person-group person-group-type="editor"><name><surname>Williams</surname><given-names>L.A.D.</given-names></name><name><surname>Reese</surname><given-names>P.B.</given-names></name></person-group>
<publisher-name>Research Signpost</publisher-name>
<publisher-loc>Trivandrum, India</publisher-loc>
<year>2006</year>
<fpage>47</fpage>
<lpage>95</lpage>
</element-citation></ref><ref id="B34-molecules-22-00058"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>T.J.</given-names></name><name><surname>Khalid</surname><given-names>S.A.</given-names></name><name><surname>Romanha</surname><given-names>A.J.</given-names></name><name><surname>Alves</surname><given-names>T.M.</given-names></name><name><surname>Biavatti</surname><given-names>M.W.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name><name><surname>Da Costa</surname><given-names>F.B.</given-names></name><name><surname>de Castro</surname><given-names>S.L.</given-names></name><name><surname>Ferreira</surname><given-names>V.F.</given-names></name><name><surname>de Lacerda</surname><given-names>M.V.G.</given-names></name><etal/></person-group>
<article-title>The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases&#x02014;Part I</article-title>
<source>Curr. Med. Chem.</source>
<year>2012</year>
<volume>19</volume>
<fpage>2128</fpage>
<lpage>2175</lpage>
<?supplied-pmid 22414103?><pub-id pub-id-type="pmid">22414103</pub-id></element-citation></ref><ref id="B35-molecules-22-00058"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>T.J.</given-names></name><name><surname>Khalid</surname><given-names>S.A.</given-names></name><name><surname>Romanha</surname><given-names>A.J.</given-names></name><name><surname>Alves</surname><given-names>T.M.</given-names></name><name><surname>Biavatti</surname><given-names>M.W.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name><name><surname>Da Costa</surname><given-names>F.B.</given-names></name><name><surname>de Castro</surname><given-names>S.L.</given-names></name><name><surname>Ferreira</surname><given-names>V.F.</given-names></name><name><surname>de Lacerda</surname><given-names>M.V.G.</given-names></name><etal/></person-group>
<article-title>The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases&#x02014;Part II</article-title>
<source>Curr. Med. Chem.</source>
<year>2012</year>
<volume>19</volume>
<fpage>2176</fpage>
<lpage>2228</lpage>
<pub-id pub-id-type="doi">10.2174/092986712800229087</pub-id>
<?supplied-pmid 22414104?><pub-id pub-id-type="pmid">22414104</pub-id></element-citation></ref><ref id="B36-molecules-22-00058"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rocha</surname><given-names>L.G.</given-names></name><name><surname>Almeida</surname><given-names>J.R.G.S.</given-names></name><name><surname>Mac&#x000ea;do</surname><given-names>R.O.</given-names></name><name><surname>Barbosa-Filho</surname><given-names>J.M.</given-names></name></person-group>
<article-title>A review of natural products with antileishmanial activity</article-title>
<source>Phytomedicine</source>
<year>2005</year>
<volume>12</volume>
<fpage>514</fpage>
<lpage>535</lpage>
<pub-id pub-id-type="doi">10.1016/j.phymed.2003.10.006</pub-id>
<?supplied-pmid 16008131?><pub-id pub-id-type="pmid">16008131</pub-id></element-citation></ref><ref id="B37-molecules-22-00058"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kolodziej</surname><given-names>H.</given-names></name><name><surname>Kiderlen</surname><given-names>A.F.</given-names></name></person-group>
<article-title>Antileishmanial activity and immune modulatory effects of tannins and related compounds on Leishmania parasitised RAW 264.7 cells</article-title>
<source>Phytochemistry</source>
<year>2005</year>
<volume>66</volume>
<fpage>2056</fpage>
<lpage>2071</lpage>
<pub-id pub-id-type="doi">10.1016/j.phytochem.2005.01.011</pub-id>
<?supplied-pmid 16153409?><pub-id pub-id-type="pmid">16153409</pub-id></element-citation></ref><ref id="B38-molecules-22-00058"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mishra</surname><given-names>B.B.</given-names></name><name><surname>Singh</surname><given-names>R.K.</given-names></name><name><surname>Srivastava</surname><given-names>A.</given-names></name><name><surname>Tripathi</surname><given-names>V.J.</given-names></name><name><surname>Tiwari</surname><given-names>V.K.</given-names></name></person-group>
<article-title>Fighting against Leishmaniasis: Search of alkaloids as future true potential anti-Leishmanial agents</article-title>
<source>Mini Rev. Med. Chem.</source>
<year>2009</year>
<volume>9</volume>
<fpage>107</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.2174/138955709787001758</pub-id>
<?supplied-pmid 19149664?><pub-id pub-id-type="pmid">19149664</pub-id></element-citation></ref><ref id="B39-molecules-22-00058"><label>39.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Carvalho</surname><given-names>P.B.</given-names></name><name><surname>Ferreira</surname><given-names>E.I.</given-names></name></person-group>
<article-title>Leishmaniasis phytotherapy. Nature&#x02019;s leadership against an ancient disease</article-title>
<source>Fitoterapia</source>
<year>2001</year>
<volume>72</volume>
<fpage>599</fpage>
<lpage>618</lpage>
<pub-id pub-id-type="doi">10.1016/S0367-326X(01)00301-X</pub-id>
<pub-id pub-id-type="pmid">11543959</pub-id></element-citation></ref><ref id="B40-molecules-22-00058"><label>40.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Polonio</surname><given-names>T.</given-names></name><name><surname>Efferth</surname><given-names>T.</given-names></name></person-group>
<article-title>Leishmaniasis: Drug resistance and natural products (review)</article-title>
<source>Int. J. Mol. Med.</source>
<year>2008</year>
<volume>22</volume>
<fpage>277</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.3892/ijmm_00000020</pub-id>
<?supplied-pmid 18698485?><pub-id pub-id-type="pmid">18698485</pub-id></element-citation></ref><ref id="B41-molecules-22-00058"><label>41.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Mishra</surname><given-names>B.B.</given-names></name><name><surname>Bajpai</surname><given-names>S.</given-names></name><name><surname>Singh</surname><given-names>R.K.</given-names></name><name><surname>Tiwari</surname><given-names>V.K.</given-names></name></person-group>
<article-title>Natural product based leads to fight against leishmaniasis</article-title>
<source>Bioorg. Med. Chem.</source>
<year>2014</year>
<volume>22</volume>
<fpage>18</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmc.2013.11.048</pub-id>
<?supplied-pmid 24355247?><pub-id pub-id-type="pmid">24355247</pub-id></element-citation></ref><ref id="B42-molecules-22-00058"><label>42.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kayser</surname><given-names>O.</given-names></name><name><surname>Kiderlen</surname><given-names>A.F.</given-names></name><name><surname>Croft</surname><given-names>S.L.</given-names></name></person-group>
<article-title>Natural products as antiparasitic drugs</article-title>
<source>Parasitol. Res.</source>
<year>2003</year>
<volume>90</volume>
<fpage>S55</fpage>
<lpage>S62</lpage>
<pub-id pub-id-type="doi">10.1007/s00436-002-0768-3</pub-id>
<?supplied-pmid 12937967?><pub-id pub-id-type="pmid">12937967</pub-id></element-citation></ref><ref id="B43-molecules-22-00058"><label>43.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fournet</surname><given-names>A.</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>V.</given-names></name></person-group>
<article-title>Natural products as trypanocidal, antileishmanial and antimalarial drugs</article-title>
<source>Curr. Top. Med. Chem.</source>
<year>2002</year>
<volume>2</volume>
<fpage>1215</fpage>
<lpage>1237</lpage>
<pub-id pub-id-type="doi">10.2174/1568026023393011</pub-id>
<?supplied-pmid 12171582?><pub-id pub-id-type="pmid">12171582</pub-id></element-citation></ref><ref id="B44-molecules-22-00058"><label>44.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salem</surname><given-names>M.M.</given-names></name><name><surname>Werbovetz</surname><given-names>K.A.</given-names></name></person-group>
<article-title>Natural products from plants as drug candidates and lead compounds against leishmaniasis and trypanosomiasis</article-title>
<source>Curr. Med. Chem.</source>
<year>2006</year>
<volume>13</volume>
<fpage>2571</fpage>
<lpage>2598</lpage>
<pub-id pub-id-type="doi">10.2174/092986706778201611</pub-id>
<?supplied-pmid 17017912?><pub-id pub-id-type="pmid">17017912</pub-id></element-citation></ref><ref id="B45-molecules-22-00058"><label>45.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akendengue</surname><given-names>B.</given-names></name><name><surname>Ngou-Milama</surname><given-names>E.</given-names></name><name><surname>Laurens</surname><given-names>A.</given-names></name><name><surname>Hocquemiller</surname><given-names>R.</given-names></name></person-group>
<article-title>Recent advances in the fight against leishmaniasis with natural products</article-title>
<source>Parasite</source>
<year>1999</year>
<volume>6</volume>
<fpage>3</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1051/parasite/1999061003</pub-id>
<?supplied-pmid 10229931?><pub-id pub-id-type="pmid">10229931</pub-id></element-citation></ref><ref id="B46-molecules-22-00058"><label>46.</label><element-citation publication-type="webpage">
<article-title>Human African Trypanosomiasis</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.webcitation.org/6ki7VaGnQ">http://www.webcitation.org/6ki7VaGnQ</ext-link></comment>
<date-in-citation>(accessed on 22 September 2016)</date-in-citation>
</element-citation></ref><ref id="B47-molecules-22-00058"><label>47.</label><element-citation publication-type="webpage">
<article-title>Trypanosomiasis, Human African (Sleeping Sickness)</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.webcitation.org/6kidfPDjR">http://www.webcitation.org/6kidfPDjR</ext-link></comment>
<date-in-citation>(accessed on 22 September 2016)</date-in-citation>
</element-citation></ref><ref id="B48-molecules-22-00058"><label>48.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Docampo</surname><given-names>R.</given-names></name><name><surname>Moreno</surname><given-names>S.N.J.</given-names></name></person-group>
<article-title>Current chemotherapy of human African trypanosomiasis</article-title>
<source>Parasitol. Res.</source>
<year>2003</year>
<volume>90</volume>
<fpage>S10</fpage>
<lpage>S13</lpage>
<?supplied-pmid 12811544?><pub-id pub-id-type="pmid">12811544</pub-id></element-citation></ref><ref id="B49-molecules-22-00058"><label>49.</label><element-citation publication-type="webpage">
<person-group person-group-type="author"><collab>International Federation of Pharmaceutical Manufacturers &#x00026; Associations Health Partnerships for the Developing World</collab></person-group>
<article-title>Sanofi-Aventis Sleeping Sickness Program</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://ifpma.org/index.php?id=287">http://ifpma.org/index.php?id=287</ext-link></comment>
<date-in-citation>(accessed on 9 July 2009)</date-in-citation>
</element-citation></ref><ref id="B50-molecules-22-00058"><label>50.</label><element-citation publication-type="webpage">
<article-title>AG Bayer Bayer Sustainable Development Report 2004, Bayer AG, Leverkusen (2004)</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.bayer.co.id/materials/File_Eng/publication_file_eng_229_8RXhl.pdf">http://www.bayer.co.id/materials/File_Eng/publication_file_eng_229_8RXhl.pdf</ext-link></comment>
<date-in-citation>(accessed on 9 July 2009)</date-in-citation>
</element-citation></ref><ref id="B51-molecules-22-00058"><label>51.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brun</surname><given-names>R.</given-names></name><name><surname>Blum</surname><given-names>J.</given-names></name><name><surname>Chappuis</surname><given-names>F.</given-names></name><name><surname>Burri</surname><given-names>C.</given-names></name></person-group>
<article-title>Human African trypanosomiasis</article-title>
<source>Lancet</source>
<year>2010</year>
<volume>375</volume>
<fpage>148</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(09)60829-1</pub-id>
<pub-id pub-id-type="pmid">19833383</pub-id></element-citation></ref><ref id="B52-molecules-22-00058"><label>52.</label><element-citation publication-type="book">
<person-group person-group-type="author"><collab>World Health Organ (WHO)</collab></person-group>
<source>Epidemiology and Control of African Trypanosomiasis</source>
<series>World Health Organ Technical Report Series</series>
<publisher-name>World Health Organ</publisher-name>
<publisher-loc>Geneva, Switzerland</publisher-loc>
<year>1986</year>
<fpage>739</fpage>
</element-citation></ref><ref id="B53-molecules-22-00058"><label>53.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Gustafsson</surname><given-names>L.L.</given-names></name><name><surname>Beerman</surname><given-names>B.</given-names></name><name><surname>Aden Abdi</surname><given-names>Y.</given-names></name></person-group>
<article-title>Suramin</article-title>
<source>Handbook of Drugs for Tropical Parasitic Infections</source>
<edition>1st ed.</edition>
<person-group person-group-type="editor"><name><surname>Gustafsson</surname><given-names>L.L.</given-names></name><name><surname>Beerman</surname><given-names>B.</given-names></name><name><surname>Aden Abdi</surname><given-names>Y.</given-names></name></person-group>
<publisher-name>Taylor &#x00026; Francis</publisher-name>
<publisher-loc>Basingstoke, UK</publisher-loc>
<year>1987</year>
<fpage>160</fpage>
<lpage>163</lpage>
</element-citation></ref><ref id="B54-molecules-22-00058"><label>54.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Jordan</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Tsetse-flies (Glossinidae)</article-title>
<source>Medical Insects and Arachnids</source>
<person-group person-group-type="editor"><name><surname>Lane</surname><given-names>R.P.</given-names></name><name><surname>Crosskey</surname><given-names>R.W.</given-names></name></person-group>
<publisher-name>Chapman and Hall</publisher-name>
<publisher-loc>London, UK</publisher-loc>
<year>1993</year>
<fpage>333</fpage>
<lpage>388</lpage>
</element-citation></ref><ref id="B55-molecules-22-00058"><label>55.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chappuis</surname><given-names>F.</given-names></name><name><surname>Udayraj</surname><given-names>N.</given-names></name><name><surname>Stietenroth</surname><given-names>K.</given-names></name><name><surname>Meussen</surname><given-names>A.</given-names></name><name><surname>Bovier</surname><given-names>P.A.</given-names></name></person-group>
<article-title>Eflornithine Is Safer than Melarsoprol for the Treatment of Second-Stage Trypanosoma brucei gambiense Human African Trypanosomiasis</article-title>
<source>Clin. Infect. Dis.</source>
<year>2005</year>
<volume>41</volume>
<fpage>748</fpage>
<lpage>751</lpage>
<pub-id pub-id-type="doi">10.1086/432576</pub-id>
<?supplied-pmid 16080099?><pub-id pub-id-type="pmid">16080099</pub-id></element-citation></ref><ref id="B56-molecules-22-00058"><label>56.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burri</surname><given-names>C.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name></person-group>
<article-title>Eflornithine for the treatment of human African trypanosomiasis</article-title>
<source>Parasitol. Res.</source>
<year>2003</year>
<volume>90</volume>
<fpage>S49</fpage>
<lpage>S52</lpage>
<?supplied-pmid 12811548?><pub-id pub-id-type="pmid">12811548</pub-id></element-citation></ref><ref id="B57-molecules-22-00058"><label>57.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Simarro</surname><given-names>P.P.</given-names></name><name><surname>Jannin</surname><given-names>J.</given-names></name><name><surname>Cattand</surname><given-names>P.</given-names></name></person-group>
<article-title>Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next?</article-title>
<source>PLoS Med.</source>
<year>2008</year>
<volume>5</volume>
<elocation-id>e55</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pmed.0050055</pub-id>
<?supplied-pmid 18303943?><pub-id pub-id-type="pmid">18303943</pub-id></element-citation></ref><ref id="B58-molecules-22-00058"><label>58.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tagboto</surname><given-names>S.</given-names></name><name><surname>Townson</surname><given-names>S.</given-names></name></person-group>
<article-title>Antiparasitic properties of medicinal plants and other naturally occurring products</article-title>
<source>Adv. Parasitol.</source>
<year>2001</year>
<volume>50</volume>
<fpage>199</fpage>
<lpage>295</lpage>
<?supplied-pmid 11757332?><pub-id pub-id-type="pmid">11757332</pub-id></element-citation></ref><ref id="B59-molecules-22-00058"><label>59.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wright</surname><given-names>A.D.</given-names></name><name><surname>Goclik</surname><given-names>E.</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>G.M.</given-names></name><name><surname>Kaminsky</surname><given-names>R.</given-names></name></person-group>
<article-title>Lepadins D&#x02212;F: Antiplasmodial and Antitrypanosomal Decahydroquinoline Derivatives from the Tropical Marine Tunicate Didemnum sp.</article-title>
<source>J. Med. Chem.</source>
<year>2002</year>
<volume>45</volume>
<fpage>3067</fpage>
<lpage>3072</lpage>
<pub-id pub-id-type="doi">10.1021/jm0110892</pub-id>
<?supplied-pmid 12086492?><pub-id pub-id-type="pmid">12086492</pub-id></element-citation></ref><ref id="B60-molecules-22-00058"><label>60.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirsch</surname><given-names>G.</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>G.M.</given-names></name><name><surname>Wright</surname><given-names>A.D.</given-names></name><name><surname>Kaminsky</surname><given-names>R.</given-names></name></person-group>
<article-title>A New Bioactive Sesterterpene and Antiplasmodial Alkaloids from the Marine Sponge Hyrtios cf. erecta</article-title>
<source>J. Nat. Prod.</source>
<year>2000</year>
<volume>63</volume>
<fpage>825</fpage>
<lpage>829</lpage>
<pub-id pub-id-type="doi">10.1021/np990555b</pub-id>
<?supplied-pmid 10869210?><pub-id pub-id-type="pmid">10869210</pub-id></element-citation></ref><ref id="B61-molecules-22-00058"><label>61.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Copp</surname><given-names>B.R.</given-names></name><name><surname>Kayser</surname><given-names>O.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name><name><surname>Kiderlen</surname><given-names>A.F.</given-names></name></person-group>
<article-title>Antiparasitic activity of marine pyridoacridone alkaloids related to the ascididemins</article-title>
<source>Planta Med.</source>
<year>2003</year>
<volume>69</volume>
<fpage>527</fpage>
<lpage>531</lpage>
<?supplied-pmid 12865971?><pub-id pub-id-type="pmid">12865971</pub-id></element-citation></ref><ref id="B62-molecules-22-00058"><label>62.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chianese</surname><given-names>G.</given-names></name><name><surname>Fattorusso</surname><given-names>E.</given-names></name><name><surname>Scala</surname><given-names>F.</given-names></name><name><surname>Teta</surname><given-names>R.</given-names></name><name><surname>Calcinai</surname><given-names>B.</given-names></name><name><surname>Bavestrello</surname><given-names>G.</given-names></name><name><surname>Dien</surname><given-names>H.A.</given-names></name><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Tasdemir</surname><given-names>D.</given-names></name><name><surname>Taglialatela-Scafati</surname><given-names>O.</given-names></name></person-group>
<article-title>Manadoperoxides, a new class of potent antitrypanosomal agents of marine origin</article-title>
<source>Org. Biomol. Chem.</source>
<year>2012</year>
<volume>10</volume>
<fpage>7197</fpage>
<lpage>7207</lpage>
<pub-id pub-id-type="doi">10.1039/c2ob26124c</pub-id>
<?supplied-pmid 22859016?><pub-id pub-id-type="pmid">22859016</pub-id></element-citation></ref><ref id="B63-molecules-22-00058"><label>63.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Regalado</surname><given-names>E.L.</given-names></name><name><surname>Tasdemir</surname><given-names>D.</given-names></name><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Cachet</surname><given-names>N.</given-names></name><name><surname>Amade</surname><given-names>P.</given-names></name><name><surname>Thomas</surname><given-names>O.P.</given-names></name></person-group>
<article-title>Antiprotozoal Steroidal Saponins from the Marine Sponge Pandaros acanthifolium</article-title>
<source>J. Nat. Prod.</source>
<year>2010</year>
<volume>73</volume>
<fpage>1404</fpage>
<lpage>1410</lpage>
<pub-id pub-id-type="doi">10.1021/np100348x</pub-id>
<?supplied-pmid 20614907?><pub-id pub-id-type="pmid">20614907</pub-id></element-citation></ref><ref id="B64-molecules-22-00058"><label>64.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scala</surname><given-names>F.</given-names></name><name><surname>Fattorusso</surname><given-names>E.</given-names></name><name><surname>Menna</surname><given-names>M.</given-names></name><name><surname>Taglialatela-Scafati</surname><given-names>O.</given-names></name><name><surname>Tierney</surname><given-names>M.</given-names></name><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Tasdemir</surname><given-names>D.</given-names></name></person-group>
<article-title>Bromopyrrole Alkaloids as Lead Compounds against Protozoan Parasites</article-title>
<source>Mar. Drugs</source>
<year>2010</year>
<volume>8</volume>
<fpage>2162</fpage>
<lpage>2174</lpage>
<pub-id pub-id-type="doi">10.3390/md8072162</pub-id>
<?supplied-pmid 20714430?><pub-id pub-id-type="pmid">20714430</pub-id></element-citation></ref><ref id="B65-molecules-22-00058"><label>65.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aiello</surname><given-names>A.</given-names></name><name><surname>D&#x02019;Esposito</surname><given-names>M.</given-names></name><name><surname>Fattorusso</surname><given-names>E.</given-names></name><name><surname>Menna</surname><given-names>M.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>W.E.G.</given-names></name><name><surname>Perovi&#x00107;-Ottstadt</surname><given-names>S.</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>H.C.</given-names></name></person-group>
<article-title>Novel bioactive bromopyrrole alkaloids from the Mediterranean sponge Axinella verrucosa</article-title>
<source>Bioorg. Med. Chem.</source>
<year>2006</year>
<volume>14</volume>
<fpage>17</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmc.2005.07.057</pub-id>
<?supplied-pmid 16169235?><pub-id pub-id-type="pmid">16169235</pub-id></element-citation></ref><ref id="B66-molecules-22-00058"><label>66.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>R&#x000e4;z</surname><given-names>B.</given-names></name></person-group>
<article-title>Isolation and Evaluation of Antiparasitic Lead Compounds from African Medicinal Plants</article-title>
<source>Ph.D. Thesis</source>
<publisher-name>Universit&#x000e4;t Basel</publisher-name>
<publisher-loc>Basel, Switzerland</publisher-loc>
<year>1998</year>
</element-citation></ref><ref id="B67-molecules-22-00058"><label>67.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tarus</surname><given-names>P.K.</given-names></name><name><surname>Machocho</surname><given-names>A.K.</given-names></name><name><surname>Lang&#x02019;at-Thoruwa</surname><given-names>C.C.</given-names></name><name><surname>Chhabra</surname><given-names>S.C.</given-names></name></person-group>
<article-title>Flavonoids from Tephrosia aequilata</article-title>
<source>Phytochemistry</source>
<year>2002</year>
<volume>60</volume>
<fpage>375</fpage>
<lpage>379</lpage>
<pub-id pub-id-type="doi">10.1016/S0031-9422(02)00078-X</pub-id>
<pub-id pub-id-type="pmid">12031428</pub-id></element-citation></ref><ref id="B68-molecules-22-00058"><label>68.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gertsch</surname><given-names>J.</given-names></name><name><surname>Th&#x000f6;ni Tobler</surname><given-names>R.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name><name><surname>Sticher</surname><given-names>O.</given-names></name><name><surname>Heilmann</surname><given-names>J.</given-names></name></person-group>
<article-title>Antifungal, antiprotozoal, cytotoxic and piscicidal properties of justicidin B and a new arylnaphthalide lignan from Phyllanthus piscatorum</article-title>
<source>Planta Med.</source>
<year>2003</year>
<volume>69</volume>
<fpage>420</fpage>
<lpage>424</lpage>
<?supplied-pmid 12802722?><pub-id pub-id-type="pmid">12802722</pub-id></element-citation></ref><ref id="B69-molecules-22-00058"><label>69.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ram&#x000ed;rez</surname><given-names>I.</given-names></name><name><surname>Carabot</surname><given-names>A.</given-names></name><name><surname>Mel&#x000e9;ndez</surname><given-names>P.</given-names></name><name><surname>Carmona</surname><given-names>J.</given-names></name><name><surname>Jimenez</surname><given-names>M.</given-names></name><name><surname>Patel</surname><given-names>A.V.</given-names></name><name><surname>Crabb</surname><given-names>T.A.</given-names></name><name><surname>Blunden</surname><given-names>G.</given-names></name><name><surname>Cary</surname><given-names>P.D.</given-names></name><name><surname>Croft</surname><given-names>S.L.</given-names></name><etal/></person-group>
<article-title>Cissampeloflavone, a chalcone-flavone dimer from Cissampelos pareira</article-title>
<source>Phytochemistry</source>
<year>2003</year>
<volume>64</volume>
<fpage>645</fpage>
<lpage>647</lpage>
<pub-id pub-id-type="pmid">12943789</pub-id></element-citation></ref><ref id="B70-molecules-22-00058"><label>70.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moideen</surname><given-names>S.V.K.</given-names></name><name><surname>Houghton</surname><given-names>P.J.</given-names></name><name><surname>Rock</surname><given-names>P.</given-names></name><name><surname>Croft</surname><given-names>S.L.</given-names></name><name><surname>Aboagye-Nyame</surname><given-names>F.</given-names></name></person-group>
<article-title>Activity of Extracts and Naphthoquinones from Kigelia pinnata Against Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense</article-title>
<source>Planta Med.</source>
<year>1999</year>
<volume>65</volume>
<fpage>536</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="doi">10.1055/s-1999-14011</pub-id>
<?supplied-pmid 10483374?><pub-id pub-id-type="pmid">10483374</pub-id></element-citation></ref><ref id="B71-molecules-22-00058"><label>71.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gunatilaka</surname><given-names>A.A.L.</given-names></name><name><surname>Berger</surname><given-names>J.M.</given-names></name><name><surname>Evans</surname><given-names>R.</given-names></name><name><surname>Miller</surname><given-names>J.S.</given-names></name><name><surname>Wisse</surname><given-names>J.H.</given-names></name><name><surname>Neddermann</surname><given-names>K.M.</given-names></name><name><surname>Bursuker</surname><given-names>I.</given-names></name><name><surname>Kingston</surname><given-names>D.G.I.</given-names></name></person-group>
<article-title>Isolation, Synthesis, and Structure&#x02212;Activity Relationships of Bioactive Benzoquinones from Miconia lepidota from the Suriname Rainforest 1</article-title>
<source>J. Nat. Prod.</source>
<year>2001</year>
<volume>64</volume>
<fpage>2</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1021/np000219r</pub-id>
<?supplied-pmid 11170656?><pub-id pub-id-type="pmid">11170656</pub-id></element-citation></ref><ref id="B72-molecules-22-00058"><label>72.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tasdemir</surname><given-names>D.</given-names></name><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name><name><surname>Yardley</surname><given-names>V.</given-names></name><name><surname>Schmidt</surname><given-names>T.J.</given-names></name><name><surname>Tosun</surname><given-names>F.</given-names></name><name><surname>Ruedi</surname><given-names>P.</given-names></name></person-group>
<article-title>Antitrypanosomal and Antileishmanial Activities of Flavonoids and Their Analogues: In Vitro, In Vivo, Structure-Activity Relationship, and Quantitative Structure-Activity Relationship Studies</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2006</year>
<volume>50</volume>
<fpage>1352</fpage>
<lpage>1364</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.50.4.1352-1364.2006</pub-id>
<?supplied-pmid 16569852?><pub-id pub-id-type="pmid">16569852</pub-id></element-citation></ref><ref id="B73-molecules-22-00058"><label>73.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>T.J.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name><name><surname>Willuhn</surname><given-names>G.</given-names></name><name><surname>Khalid</surname><given-names>S.A.</given-names></name></person-group>
<article-title>Anti-trypanosomal activity of helenalin and some structurally related sesquiterpene lactones</article-title>
<source>Planta Med.</source>
<year>2002</year>
<volume>68</volume>
<fpage>750</fpage>
<lpage>751</lpage>
<pub-id pub-id-type="doi">10.1055/s-2002-33799</pub-id>
<?supplied-pmid 12221603?><pub-id pub-id-type="pmid">12221603</pub-id></element-citation></ref><ref id="B74-molecules-22-00058"><label>74.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Julianti</surname><given-names>T.</given-names></name><name><surname>Hata</surname><given-names>Y.</given-names></name><name><surname>Zimmermann</surname><given-names>S.</given-names></name><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Hamburger</surname><given-names>M.</given-names></name><name><surname>Adams</surname><given-names>M.</given-names></name></person-group>
<article-title>Antitrypanosomal sesquiterpene lactones from Saussurea costus</article-title>
<source>Fitoterapia</source>
<year>2011</year>
<volume>82</volume>
<fpage>955</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="doi">10.1016/j.fitote.2011.05.010</pub-id>
<?supplied-pmid 21624443?><pub-id pub-id-type="pmid">21624443</pub-id></element-citation></ref><ref id="B75-molecules-22-00058"><label>75.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>T.J.</given-names></name><name><surname>Da Costa</surname><given-names>F.B.</given-names></name><name><surname>Lopes</surname><given-names>N.P.</given-names></name><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name></person-group>
<article-title>In Silico prediction and experimental evaluation of furanoheliangolide sesquiterpene lactones as potent agents against Trypanosoma brucei rhodesiense</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2014</year>
<volume>58</volume>
<fpage>325</fpage>
<lpage>332</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.01263-13</pub-id>
<?supplied-pmid 24165182?><pub-id pub-id-type="pmid">24165182</pub-id></element-citation></ref><ref id="B76-molecules-22-00058"><label>76.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schomburg</surname><given-names>C.</given-names></name><name><surname>Schuehly</surname><given-names>W.</given-names></name><name><surname>Da Costa</surname><given-names>F.B.</given-names></name><name><surname>Klempnauer</surname><given-names>K.-H.</given-names></name><name><surname>Schmidt</surname><given-names>T.J.</given-names></name></person-group>
<article-title>Natural sesquiterpene lactones as inhibitors of Myb-dependent gene expression: Structure&#x02013;activity relationships</article-title>
<source>Eur. J. Med. Chem.</source>
<year>2013</year>
<volume>63</volume>
<fpage>313</fpage>
<lpage>320</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejmech.2013.02.018</pub-id>
<?supplied-pmid 23501116?><pub-id pub-id-type="pmid">23501116</pub-id></element-citation></ref><ref id="B77-molecules-22-00058"><label>77.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Da Costa</surname><given-names>F.B.</given-names></name><name><surname>Dias</surname><given-names>D.A.</given-names></name><name><surname>Callegari Lopes</surname><given-names>J.L.</given-names></name><name><surname>Vichnewski</surname><given-names>W.</given-names></name></person-group>
<article-title>Flavonoids and heliangolides from Lychnophora diamantinana</article-title>
<source>Phytochemistry</source>
<year>1993</year>
<volume>34</volume>
<fpage>261</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.1016/S0031-9422(00)90815-X</pub-id>
</element-citation></ref><ref id="B78-molecules-22-00058"><label>78.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arakawa</surname><given-names>N.S.</given-names></name><name><surname>Schorr</surname><given-names>K.</given-names></name><name><surname>Ambr&#x000f3;sio</surname><given-names>S.R.</given-names></name><name><surname>Merfort</surname><given-names>I.</given-names></name><name><surname>Da Costa</surname><given-names>F.B.</given-names></name></person-group>
<article-title>Further Sesquiterpene Lactones from Viguiera robusta and the Potential Anti-Inflammatory Activity of a Heliangolide: Inhibition of Human Neutrophil Elastase Release</article-title>
<source>Z. Naturforschung C</source>
<year>2008</year>
<volume>63</volume>
<fpage>533</fpage>
<lpage>538</lpage>
<pub-id pub-id-type="doi">10.1515/znc-2008-7-811</pub-id>
</element-citation></ref><ref id="B79-molecules-22-00058"><label>79.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vichnewski</surname><given-names>W.</given-names></name><name><surname>Sarti</surname><given-names>S.J.</given-names></name><name><surname>Gilbert</surname><given-names>B.</given-names></name><name><surname>Herz</surname><given-names>W.</given-names></name></person-group>
<article-title>Goyazensolide, a schistosomicidal heliangolide from Eremanthus goyazensis</article-title>
<source>Phytochemistry</source>
<year>1976</year>
<volume>15</volume>
<fpage>191</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="doi">10.1016/S0031-9422(00)89082-2</pub-id>
</element-citation></ref><ref id="B80-molecules-22-00058"><label>80.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Freiburghaus</surname><given-names>F.</given-names></name><name><surname>Steck</surname><given-names>A.</given-names></name><name><surname>Pfander</surname><given-names>H.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name></person-group>
<article-title>Bioassay-guided isolation of a diastereoisomer of kolavenol from Entada abyssinica active on Trypanosoma brucei rhodesiense</article-title>
<source>J. Ethnopharmacol.</source>
<year>1998</year>
<volume>61</volume>
<fpage>179</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1016/S0378-8741(98)00035-X</pub-id>
<pub-id pub-id-type="pmid">9705008</pub-id></element-citation></ref><ref id="B81-molecules-22-00058"><label>81.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tchinda</surname><given-names>A.T.</given-names></name><name><surname>Tsopmo</surname><given-names>A.</given-names></name><name><surname>Tane</surname><given-names>P.</given-names></name><name><surname>Ayafor</surname><given-names>J.F.</given-names></name><name><surname>Connolly</surname><given-names>J.D.</given-names></name><name><surname>Sterner</surname><given-names>O.</given-names></name></person-group>
<article-title>Vernoguinosterol and vernoguinoside, trypanocidal stigmastane derivatives from Vernonia guineensis (Asteraceae)</article-title>
<source>Phytochemistry</source>
<year>2002</year>
<volume>59</volume>
<fpage>371</fpage>
<lpage>374</lpage>
<pub-id pub-id-type="doi">10.1016/S0031-9422(01)00448-4</pub-id>
<pub-id pub-id-type="pmid">11830150</pub-id></element-citation></ref><ref id="B82-molecules-22-00058"><label>82.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Del Rayo Camacho</surname><given-names>M.</given-names></name><name><surname>Phillipson</surname><given-names>J.D.</given-names></name><name><surname>Croft</surname><given-names>S.L.</given-names></name><name><surname>Marley</surname><given-names>D.</given-names></name><name><surname>Kirby</surname><given-names>G.C.</given-names></name><name><surname>Warhurst</surname><given-names>D.C.</given-names></name></person-group>
<article-title>Assessment of the Antiprotozoal Activity of Galphimia g lauca and the Isolation of New Nor-secofriedelanes and Nor-friedelanes</article-title>
<source>J. Nat. Prod.</source>
<year>2002</year>
<volume>65</volume>
<fpage>1457</fpage>
<lpage>1461</lpage>
<pub-id pub-id-type="doi">10.1021/np010419i</pub-id>
<?supplied-pmid 12398543?><pub-id pub-id-type="pmid">12398543</pub-id></element-citation></ref><ref id="B83-molecules-22-00058"><label>83.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Del Rayo Camacho</surname><given-names>M.</given-names></name><name><surname>Phillipson</surname><given-names>J.D.</given-names></name><name><surname>Croft</surname><given-names>S.L.</given-names></name><name><surname>Kirby</surname><given-names>G.C.</given-names></name><name><surname>Warhurst</surname><given-names>D.C.</given-names></name><name><surname>Solis</surname><given-names>P.N.</given-names></name></person-group>
<article-title>Terpenoids from Guarea rhophalocarpa</article-title>
<source>Phytochemistry</source>
<year>2001</year>
<volume>56</volume>
<fpage>203</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="doi">10.1016/S0031-9422(00)00310-1</pub-id>
<pub-id pub-id-type="pmid">11219815</pub-id></element-citation></ref><ref id="B84-molecules-22-00058"><label>84.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nour</surname><given-names>A.M.M.</given-names></name><name><surname>Khalid</surname><given-names>S.A.</given-names></name><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name><name><surname>Abdallah</surname><given-names>W.E.</given-names></name><name><surname>Schmidt</surname><given-names>T.J.</given-names></name></person-group>
<article-title>The antiprotozoal activity of sixteen asteraceae species native to Sudan and bioactivity-guided isolation of xanthanolides from Xanthium brasilicum</article-title>
<source>Planta Med.</source>
<year>2009</year>
<volume>75</volume>
<fpage>1363</fpage>
<lpage>1368</lpage>
<pub-id pub-id-type="doi">10.1055/s-0029-1185676</pub-id>
<?supplied-pmid 19431098?><pub-id pub-id-type="pmid">19431098</pub-id></element-citation></ref><ref id="B85-molecules-22-00058"><label>85.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaminsky</surname><given-names>R.</given-names></name><name><surname>Schmid</surname><given-names>C.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name></person-group>
<article-title>An in vitro selectivity index for evaluation of cytotoxicity of antitrypanosomal compounds</article-title>
<source>In Vitro Toxicol.</source>
<year>1996</year>
<volume>9</volume>
<fpage>315</fpage>
<lpage>324</lpage>
</element-citation></ref><ref id="B86-molecules-22-00058"><label>86.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dube</surname><given-names>D.K.</given-names></name><name><surname>Mpimbaza</surname><given-names>G.</given-names></name><name><surname>Allison</surname><given-names>A.C.</given-names></name><name><surname>Lederer</surname><given-names>E.</given-names></name><name><surname>Rovis</surname><given-names>L.</given-names></name></person-group>
<article-title>Antitrypanosomal activity of sinefungin</article-title>
<source>Am. J. Trop. Med. Hyg.</source>
<year>1983</year>
<volume>32</volume>
<fpage>31</fpage>
<lpage>33</lpage>
<?supplied-pmid 6130709?><pub-id pub-id-type="pmid">6130709</pub-id></element-citation></ref><ref id="B87-molecules-22-00058"><label>87.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zweygarth</surname><given-names>E.</given-names></name><name><surname>R&#x000f6;ttcher</surname><given-names>D.</given-names></name></person-group>
<article-title>Efficacy of experimental trypanocidal compounds against a multiple drug-resistantTrypanosoma brucei brucei stock in mice</article-title>
<source>Parasitol. Res.</source>
<year>1989</year>
<volume>75</volume>
<fpage>178</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="doi">10.1007/BF00931271</pub-id>
<?supplied-pmid 2710771?><pub-id pub-id-type="pmid">2710771</pub-id></element-citation></ref><ref id="B88-molecules-22-00058"><label>88.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zweygarth</surname><given-names>E.</given-names></name><name><surname>Schillinger</surname><given-names>D.</given-names></name><name><surname>Kaufmann</surname><given-names>W.</given-names></name><name><surname>Rottcher</surname><given-names>D.</given-names></name></person-group>
<article-title>Evaluation of sinefungin for the treatment of Trypanosoma (Nannomonas) congolense infections in goats</article-title>
<source>Trop. Med. Parasitol.</source>
<year>1986</year>
<volume>37</volume>
<fpage>255</fpage>
<lpage>257</lpage>
<?supplied-pmid 2878488?><pub-id pub-id-type="pmid">2878488</pub-id></element-citation></ref><ref id="B89-molecules-22-00058"><label>89.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heilmann</surname><given-names>J.</given-names></name><name><surname>Mayr</surname><given-names>S.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name><name><surname>Rali</surname><given-names>T.</given-names></name><name><surname>Sticher</surname><given-names>O.</given-names></name></person-group>
<article-title>Antiprotozoal Activity and Cytotoxicity of Novel 1,7-Dioxadispiro[5.1.5.2]pentadeca-9,12-dien-11-one Derivatives from <italic>Amomum</italic> aculeatum</article-title>
<source>Helv. Chim. Acta</source>
<year>2000</year>
<volume>83</volume>
<fpage>2939</fpage>
<lpage>2945</lpage>
<pub-id pub-id-type="doi">10.1002/1522-2675(20001108)83:11&#x0003c;2939::AID-HLCA2939&#x0003e;3.0.CO;2-N</pub-id>
</element-citation></ref><ref id="B90-molecules-22-00058"><label>90.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heilmann</surname><given-names>J.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name><name><surname>Mayr</surname><given-names>S.</given-names></name><name><surname>Rali</surname><given-names>T.</given-names></name><name><surname>Sticher</surname><given-names>O.</given-names></name></person-group>
<article-title>Minor cytotoxic and antibacterial compounds from the rhizomes of Amomum aculeatum</article-title>
<source>Phytochemistry</source>
<year>2001</year>
<volume>57</volume>
<fpage>1281</fpage>
<lpage>1285</lpage>
<pub-id pub-id-type="doi">10.1016/S0031-9422(01)00174-1</pub-id>
<pub-id pub-id-type="pmid">11454360</pub-id></element-citation></ref><ref id="B91-molecules-22-00058"><label>91.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chianese</surname><given-names>G.</given-names></name><name><surname>Scala</surname><given-names>F.</given-names></name><name><surname>Calcinai</surname><given-names>B.</given-names></name><name><surname>Cerrano</surname><given-names>C.</given-names></name><name><surname>Dien</surname><given-names>H.</given-names></name><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Tasdemir</surname><given-names>D.</given-names></name><name><surname>Taglialatela-Scafati</surname><given-names>O.</given-names></name></person-group>
<article-title>Natural and Semisynthetic Analogues of Manadoperoxide B Reveal New Structural Requirements for Trypanocidal Activity</article-title>
<source>Mar. Drugs</source>
<year>2013</year>
<volume>11</volume>
<fpage>3297</fpage>
<lpage>3308</lpage>
<pub-id pub-id-type="doi">10.3390/md11093297</pub-id>
<?supplied-pmid 23989650?><pub-id pub-id-type="pmid">23989650</pub-id></element-citation></ref><ref id="B92-molecules-22-00058"><label>92.</label><element-citation publication-type="webpage">
<article-title>Leishmaniasis</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs375/en">http://www.who.int/mediacentre/factsheets/fs375/en</ext-link></comment>
<date-in-citation>(accessed on 18 October 2016)</date-in-citation>
</element-citation></ref><ref id="B93-molecules-22-00058"><label>93.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chappuis</surname><given-names>F.</given-names></name><name><surname>Sundar</surname><given-names>S.</given-names></name><name><surname>Hailu</surname><given-names>A.</given-names></name><name><surname>Ghalib</surname><given-names>H.</given-names></name><name><surname>Rijal</surname><given-names>S.</given-names></name><name><surname>Peeling</surname><given-names>R.W.</given-names></name><name><surname>Alvar</surname><given-names>J.</given-names></name><name><surname>Boelaert</surname><given-names>M.</given-names></name></person-group>
<article-title>Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?</article-title>
<source>Nat. Rev. Microbiol.</source>
<year>2007</year>
<volume>5</volume>
<fpage>S7</fpage>
<lpage>S16</lpage>
<pub-id pub-id-type="doi">10.1038/nrmicro1748</pub-id>
<?supplied-pmid 17938629?><pub-id pub-id-type="pmid">17938629</pub-id></element-citation></ref><ref id="B94-molecules-22-00058"><label>94.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murray</surname><given-names>H.W.</given-names></name><name><surname>Berman</surname><given-names>J.D.</given-names></name><name><surname>Davies</surname><given-names>C.R.</given-names></name><name><surname>Saravia</surname><given-names>N.G.</given-names></name></person-group>
<article-title>Advances in leishmaniasis</article-title>
<source>Lancet</source>
<year>2005</year>
<volume>366</volume>
<fpage>1561</fpage>
<lpage>1577</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(05)67629-5</pub-id>
<pub-id pub-id-type="pmid">16257344</pub-id></element-citation></ref><ref id="B95-molecules-22-00058"><label>95.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amato</surname><given-names>V.S.</given-names></name><name><surname>Tuon</surname><given-names>F.F.</given-names></name><name><surname>Bacha</surname><given-names>H.A.</given-names></name><name><surname>Neto</surname><given-names>V.A.</given-names></name><name><surname>Nicodemo</surname><given-names>A.C.</given-names></name></person-group>
<article-title>Mucosal leishmaniasis</article-title>
<source>Acta Trop.</source>
<year>2008</year>
<volume>105</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.actatropica.2007.08.003</pub-id>
<?supplied-pmid 17884002?><pub-id pub-id-type="pmid">17884002</pub-id></element-citation></ref><ref id="B96-molecules-22-00058"><label>96.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sacks</surname><given-names>D.</given-names></name><name><surname>Noben-Trauth</surname><given-names>N.</given-names></name></person-group>
<article-title>The immunology of susceptibility and resistance to leishmania major in mice</article-title>
<source>Nat. Rev. Immunol.</source>
<year>2002</year>
<volume>2</volume>
<fpage>845</fpage>
<lpage>858</lpage>
<pub-id pub-id-type="doi">10.1038/nri933</pub-id>
<?supplied-pmid 12415308?><pub-id pub-id-type="pmid">12415308</pub-id></element-citation></ref><ref id="B97-molecules-22-00058"><label>97.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Von Stebut</surname><given-names>E.</given-names></name><name><surname>Udey</surname><given-names>M.C.</given-names></name></person-group>
<article-title>Requirements for Th1-dependent immunity against infection with Leishmania major</article-title>
<source>Microbes Infect.</source>
<year>2004</year>
<volume>6</volume>
<fpage>1102</fpage>
<lpage>1109</lpage>
<pub-id pub-id-type="doi">10.1016/j.micinf.2004.05.024</pub-id>
<?supplied-pmid 15380780?><pub-id pub-id-type="pmid">15380780</pub-id></element-citation></ref><ref id="B98-molecules-22-00058"><label>98.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>R.K.</given-names></name><name><surname>Pandey</surname><given-names>H.P.</given-names></name><name><surname>Sundar</surname><given-names>S.</given-names></name></person-group>
<article-title>Visceral leishmaniasis (kala-azar): challenges ahead</article-title>
<source>Indian J. Med. Res.</source>
<year>2006</year>
<volume>123</volume>
<fpage>331</fpage>
<lpage>344</lpage>
<?supplied-pmid 16778314?><pub-id pub-id-type="pmid">16778314</pub-id></element-citation></ref><ref id="B99-molecules-22-00058"><label>99.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maltezou</surname><given-names>H.C.</given-names></name></person-group>
<article-title>Drug Resistance in Visceral Leishmaniasis</article-title>
<source>J. Biomed. Biotechnol.</source>
<year>2010</year>
<volume>2010</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1155/2010/617521</pub-id>
<?supplied-pmid 19888437?><pub-id pub-id-type="pmid">19888437</pub-id></element-citation></ref><ref id="B100-molecules-22-00058"><label>100.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bern</surname><given-names>C.</given-names></name><name><surname>Adler-Moore</surname><given-names>J.</given-names></name><name><surname>Berenguer</surname><given-names>J.</given-names></name><name><surname>Boelaert</surname><given-names>M.</given-names></name><name><surname>den Boer</surname><given-names>M.</given-names></name><name><surname>Davidson</surname><given-names>R.N.</given-names></name><name><surname>Figueras</surname><given-names>C.</given-names></name><name><surname>Gradoni</surname><given-names>L.</given-names></name><name><surname>Kafetzis</surname><given-names>D.A.</given-names></name><name><surname>Ritmeijer</surname><given-names>K.</given-names></name><etal/></person-group>
<article-title>Reviews Of Anti-infective Agents: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis</article-title>
<source>Clin. Infect. Dis.</source>
<year>2006</year>
<volume>43</volume>
<fpage>917</fpage>
<lpage>924</lpage>
<pub-id pub-id-type="doi">10.1086/507530</pub-id>
<?supplied-pmid 16941377?><pub-id pub-id-type="pmid">16941377</pub-id></element-citation></ref><ref id="B101-molecules-22-00058"><label>101.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Izzedine</surname><given-names>H.</given-names></name><name><surname>Launay-Vacher</surname><given-names>V.</given-names></name><name><surname>Legrand</surname><given-names>M.</given-names></name><name><surname>Lieberherr</surname><given-names>D.</given-names></name><name><surname>Caumes</surname><given-names>E.</given-names></name><name><surname>Deray</surname><given-names>G.</given-names></name></person-group>
<article-title>ABT 378/r: A novel inhibitor of HIV-1 protease in haemodialysis</article-title>
<source>AIDS</source>
<year>2001</year>
<volume>15</volume>
<fpage>662</fpage>
<lpage>664</lpage>
<pub-id pub-id-type="doi">10.1097/00002030-200103300-00024</pub-id>
<?supplied-pmid 11317012?><pub-id pub-id-type="pmid">11317012</pub-id></element-citation></ref><ref id="B102-molecules-22-00058"><label>102.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Laniado-Labor&#x000ed;n</surname><given-names>R.</given-names></name><name><surname>Cabrales-Vargas</surname><given-names>M.N.</given-names></name></person-group>
<article-title>Amphotericin B: Side effects and toxicity</article-title>
<source>Rev. Iberoam. Micol.</source>
<year>2009</year>
<volume>26</volume>
<fpage>223</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1016/j.riam.2009.06.003</pub-id>
<?supplied-pmid 19836985?><pub-id pub-id-type="pmid">19836985</pub-id></element-citation></ref><ref id="B103-molecules-22-00058"><label>103.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Kumar</surname><given-names>M.</given-names></name><name><surname>Singh</surname><given-names>R.K.</given-names></name></person-group>
<article-title>Leishmaniasis: Current status of available drugs and new potential drug targets</article-title>
<source>Asian Pac. J. Trop. Med.</source>
<year>2012</year>
<volume>5</volume>
<fpage>485</fpage>
<lpage>497</lpage>
<pub-id pub-id-type="doi">10.1016/S1995-7645(12)60084-4</pub-id>
<pub-id pub-id-type="pmid">22575984</pub-id></element-citation></ref><ref id="B104-molecules-22-00058"><label>104.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sundar</surname><given-names>S.</given-names></name><name><surname>Chatterjee</surname><given-names>M.</given-names></name></person-group>
<article-title>Visceral leishmaniasis&#x02014;Current therapeutic modalities</article-title>
<source>Indian J. Med. Res.</source>
<year>2006</year>
<volume>123</volume>
<fpage>345</fpage>
<lpage>352</lpage>
<?supplied-pmid 16778315?><pub-id pub-id-type="pmid">16778315</pub-id></element-citation></ref><ref id="B105-molecules-22-00058"><label>105.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>S.K.</given-names></name><name><surname>Sinha</surname><given-names>P.K.</given-names></name><name><surname>Sundar</surname><given-names>S.</given-names></name><name><surname>Thakur</surname><given-names>C.P.</given-names></name><name><surname>Jha</surname><given-names>T.K.</given-names></name><name><surname>Pandey</surname><given-names>K.</given-names></name><name><surname>Das</surname><given-names>V.R.</given-names></name><name><surname>Kumar</surname><given-names>N.</given-names></name><name><surname>Lal</surname><given-names>C.</given-names></name><name><surname>Verma</surname><given-names>N.</given-names></name><etal/></person-group>
<article-title>Phase 4 Trial of Miltefosine for the Treatment of Indian Visceral Leishmaniasis</article-title>
<source>J. Infect. Dis.</source>
<year>2007</year>
<volume>196</volume>
<fpage>591</fpage>
<lpage>598</lpage>
<pub-id pub-id-type="doi">10.1086/519690</pub-id>
<?supplied-pmid 17624846?><pub-id pub-id-type="pmid">17624846</pub-id></element-citation></ref><ref id="B106-molecules-22-00058"><label>106.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jha</surname><given-names>T.K.</given-names></name><name><surname>Sundar</surname><given-names>S.</given-names></name><name><surname>Thakur</surname><given-names>C.P.</given-names></name><name><surname>Bachmann</surname><given-names>P.</given-names></name><name><surname>Karbwang</surname><given-names>J.</given-names></name><name><surname>Fischer</surname><given-names>C.</given-names></name><name><surname>Voss</surname><given-names>A.</given-names></name><name><surname>Berman</surname><given-names>J.</given-names></name></person-group>
<article-title>Miltefosine, an Oral Agent, for the Treatment of Indian Visceral Leishmaniasis</article-title>
<source>N. Engl. J. Med.</source>
<year>1999</year>
<volume>341</volume>
<fpage>1795</fpage>
<lpage>1800</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM199912093412403</pub-id>
<?supplied-pmid 10588964?><pub-id pub-id-type="pmid">10588964</pub-id></element-citation></ref><ref id="B107-molecules-22-00058"><label>107.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sundar</surname><given-names>S.</given-names></name><name><surname>Jha</surname><given-names>T.K.</given-names></name><name><surname>Thakur</surname><given-names>C.P.</given-names></name><name><surname>Bhattacharya</surname><given-names>S.K.</given-names></name><name><surname>Rai</surname><given-names>M.</given-names></name></person-group>
<article-title>Oral miltefosine for the treatment of Indian visceral leishmaniasis</article-title>
<source>Trans. R. Soc. Trop. Med. Hyg.</source>
<year>2006</year>
<volume>100</volume>
<fpage>S26</fpage>
<lpage>S33</lpage>
<pub-id pub-id-type="doi">10.1016/j.trstmh.2006.02.011</pub-id>
<?supplied-pmid 16730038?><pub-id pub-id-type="pmid">16730038</pub-id></element-citation></ref><ref id="B108-molecules-22-00058"><label>108.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sundar</surname><given-names>S.</given-names></name><name><surname>Sinha</surname><given-names>P.K.</given-names></name><name><surname>Rai</surname><given-names>M.</given-names></name><name><surname>Verma</surname><given-names>D.K.</given-names></name><name><surname>Nawin</surname><given-names>K.</given-names></name><name><surname>Alam</surname><given-names>S.</given-names></name><name><surname>Chakravarty</surname><given-names>J.</given-names></name><name><surname>Vaillant</surname><given-names>M.</given-names></name><name><surname>Verma</surname><given-names>N.</given-names></name><name><surname>Pandey</surname><given-names>K.</given-names></name><etal/></person-group>
<article-title>Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: An open-label, non-inferiority, randomised controlled trial</article-title>
<source>Lancet</source>
<year>2011</year>
<volume>377</volume>
<fpage>477</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(10)62050-8</pub-id>
<pub-id pub-id-type="pmid">21255828</pub-id></element-citation></ref><ref id="B109-molecules-22-00058"><label>109.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thakur</surname><given-names>C.P.</given-names></name><name><surname>Kanyok</surname><given-names>T.P.</given-names></name><name><surname>Pandey</surname><given-names>A.K.</given-names></name><name><surname>Sinha</surname><given-names>G.P.</given-names></name><name><surname>Messick</surname><given-names>C.</given-names></name><name><surname>Olliaro</surname><given-names>P.</given-names></name></person-group>
<article-title>Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study</article-title>
<source>Trans. R. Soc. Trop. Med. Hyg.</source>
<year>2000</year>
<volume>94</volume>
<fpage>432</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="doi">10.1016/S0035-9203(00)90131-7</pub-id>
<pub-id pub-id-type="pmid">11127251</pub-id></element-citation></ref><ref id="B110-molecules-22-00058"><label>110.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thakur</surname><given-names>B.B.</given-names></name></person-group>
<article-title>Breakthrough in the management of visceral leishmaniasis</article-title>
<source>J. Assoc. Phys. India</source>
<year>2003</year>
<volume>51</volume>
<fpage>649</fpage>
<lpage>651</lpage>
</element-citation></ref><ref id="B111-molecules-22-00058"><label>111.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jha</surname><given-names>T.K.</given-names></name><name><surname>Sundar</surname><given-names>S.</given-names></name><name><surname>Thakur</surname><given-names>C.P.</given-names></name><name><surname>Felton</surname><given-names>J.M.</given-names></name><name><surname>Sabin</surname><given-names>A.J.</given-names></name><name><surname>Horton</surname><given-names>J.</given-names></name></person-group>
<article-title>A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India</article-title>
<source>Am. J. Trop. Med. Hyg.</source>
<year>2005</year>
<volume>73</volume>
<fpage>1005</fpage>
<lpage>1011</lpage>
<?supplied-pmid 16354802?><pub-id pub-id-type="pmid">16354802</pub-id></element-citation></ref><ref id="B112-molecules-22-00058"><label>112.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wasunna</surname><given-names>M.K.</given-names></name><name><surname>Rashid</surname><given-names>J.R.</given-names></name><name><surname>Mbui</surname><given-names>J.</given-names></name><name><surname>Kirigi</surname><given-names>G.</given-names></name><name><surname>Kinoti</surname><given-names>D.</given-names></name><name><surname>Lodenyo</surname><given-names>H.</given-names></name><name><surname>Felton</surname><given-names>J.M.</given-names></name><name><surname>Sabin</surname><given-names>A.J.</given-names></name><name><surname>Albert</surname><given-names>M.J.</given-names></name><name><surname>Horton</surname><given-names>J.</given-names></name></person-group>
<article-title>A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya</article-title>
<source>Am. J. Trop. Med. Hyg.</source>
<year>2005</year>
<volume>73</volume>
<fpage>871</fpage>
<lpage>876</lpage>
<?supplied-pmid 16282296?><pub-id pub-id-type="pmid">16282296</pub-id></element-citation></ref><ref id="B113-molecules-22-00058"><label>113.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Das</surname><given-names>V.N.</given-names></name><name><surname>Ranjan</surname><given-names>A.</given-names></name><name><surname>Sinha</surname><given-names>A.N.</given-names></name><name><surname>Verma</surname><given-names>N.</given-names></name><name><surname>Lal</surname><given-names>C.S.</given-names></name><name><surname>Gupta</surname><given-names>A.K.</given-names></name><name><surname>Siddiqui</surname><given-names>N.A.</given-names></name><name><surname>Kar</surname><given-names>S.K.</given-names></name></person-group>
<article-title>A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis</article-title>
<source>J. Assoc. Phys. India</source>
<year>2001</year>
<volume>49</volume>
<fpage>609</fpage>
<lpage>613</lpage>
</element-citation></ref><ref id="B114-molecules-22-00058"><label>114.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mittra</surname><given-names>B.</given-names></name><name><surname>Saha</surname><given-names>A.</given-names></name><name><surname>Chowdhury</surname><given-names>A.R.</given-names></name><name><surname>Pal</surname><given-names>C.</given-names></name><name><surname>Mandal</surname><given-names>S.</given-names></name><name><surname>Mukhopadhyay</surname><given-names>S.</given-names></name><name><surname>Bandyopadhyay</surname><given-names>S.</given-names></name><name><surname>Majumder</surname><given-names>H.K.</given-names></name></person-group>
<article-title>Luteolin, an abundant dietary component is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis</article-title>
<source>Mol. Med.</source>
<year>2000</year>
<volume>6</volume>
<fpage>527</fpage>
<lpage>541</lpage>
<?supplied-pmid 10972088?><pub-id pub-id-type="pmid">10972088</pub-id></element-citation></ref><ref id="B115-molecules-22-00058"><label>115.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pan</surname><given-names>L.</given-names></name><name><surname>Lezama-Davila</surname><given-names>C.M.</given-names></name><name><surname>Isaac-Marquez</surname><given-names>A.P.</given-names></name><name><surname>Calomeni</surname><given-names>E.P.</given-names></name><name><surname>Fuchs</surname><given-names>J.R.</given-names></name><name><surname>Satoskar</surname><given-names>A.R.</given-names></name><name><surname>Kinghorn</surname><given-names>A.D.</given-names></name></person-group>
<article-title>Sterols with antileishmanial activity isolated from the roots of Pentalinon andrieuxii</article-title>
<source>Phytochemistry</source>
<year>2012</year>
<volume>82</volume>
<fpage>128</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="doi">10.1016/j.phytochem.2012.06.012</pub-id>
<?supplied-pmid 22840389?><pub-id pub-id-type="pmid">22840389</pub-id></element-citation></ref><ref id="B116-molecules-22-00058"><label>116.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Christensen</surname><given-names>S.B.</given-names></name><name><surname>Blom</surname><given-names>J.</given-names></name><name><surname>Lemmich</surname><given-names>E.</given-names></name><name><surname>Nadelmann</surname><given-names>L.</given-names></name><name><surname>Fich</surname><given-names>K.</given-names></name><name><surname>Theander</surname><given-names>T.G.</given-names></name><name><surname>Kharazmi</surname><given-names>A.</given-names></name></person-group>
<article-title>Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>1993</year>
<volume>37</volume>
<fpage>2550</fpage>
<lpage>2556</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.37.12.2550</pub-id>
<?supplied-pmid 8109916?><pub-id pub-id-type="pmid">8109916</pub-id></element-citation></ref><ref id="B117-molecules-22-00058"><label>117.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhai</surname><given-names>L.</given-names></name></person-group>
<article-title>The antileishmanial activity of novel oxygenated chalcones and their mechanism of action</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>1999</year>
<volume>43</volume>
<fpage>793</fpage>
<lpage>803</lpage>
<pub-id pub-id-type="doi">10.1093/jac/43.6.793</pub-id>
<?supplied-pmid 10404318?><pub-id pub-id-type="pmid">10404318</pub-id></element-citation></ref><ref id="B118-molecules-22-00058"><label>118.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Christensen</surname><given-names>S.B.</given-names></name><name><surname>Theander</surname><given-names>T.G.</given-names></name><name><surname>Kharazmi</surname><given-names>A.</given-names></name></person-group>
<article-title>Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>1994</year>
<volume>38</volume>
<fpage>1339</fpage>
<lpage>1344</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.38.6.1339</pub-id>
<?supplied-pmid 8092835?><pub-id pub-id-type="pmid">8092835</pub-id></element-citation></ref><ref id="B119-molecules-22-00058"><label>119.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Zhai</surname><given-names>L.</given-names></name><name><surname>Christensen</surname><given-names>S.B.</given-names></name><name><surname>Theander</surname><given-names>T.G.</given-names></name><name><surname>Kharazmi</surname><given-names>A.</given-names></name></person-group>
<article-title>Inhibition of Fumarate Reductase in Leishmania major and L. donovani by Chalcones</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2001</year>
<volume>45</volume>
<fpage>2023</fpage>
<lpage>2029</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.45.7.2023-2029.2001</pub-id>
<?supplied-pmid 11408218?><pub-id pub-id-type="pmid">11408218</pub-id></element-citation></ref><ref id="B120-molecules-22-00058"><label>120.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Torres-Santos</surname><given-names>E.C.</given-names></name><name><surname>Rodrigues</surname><given-names>J.M.</given-names></name><name><surname>Moreira</surname><given-names>D.L.</given-names></name><name><surname>Kaplan</surname><given-names>M.A.</given-names></name><name><surname>Rossi-Bergmann</surname><given-names>B.</given-names></name></person-group>
<article-title>Improvement of in vitro and in vivo antileishmanial activities of 2&#x02032;,6&#x02032;-dihydroxy-4&#x02032;-methoxychalcone by entrapment in poly(<sc>d</sc>,<sc>l</sc>-lactide) nanoparticles</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>1999</year>
<volume>43</volume>
<fpage>1776</fpage>
<lpage>1778</lpage>
<?supplied-pmid 10390243?><pub-id pub-id-type="pmid">10390243</pub-id></element-citation></ref><ref id="B121-molecules-22-00058"><label>121.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boeck</surname><given-names>P.</given-names></name><name><surname>Bandeira Falc&#x000e3;o</surname><given-names>C.A.</given-names></name><name><surname>Leal</surname><given-names>P.C.</given-names></name><name><surname>Yunes</surname><given-names>R.A.</given-names></name><name><surname>Filho</surname><given-names>V.C.</given-names></name><name><surname>Torres-Santos</surname><given-names>E.C.</given-names></name><name><surname>Rossi-Bergmann</surname><given-names>B.</given-names></name></person-group>
<article-title>Synthesis of chalcone analogues with increased antileishmanial activity</article-title>
<source>Bioorg. Med. Chem.</source>
<year>2006</year>
<volume>14</volume>
<fpage>1538</fpage>
<lpage>1545</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmc.2005.10.005</pub-id>
<?supplied-pmid 16386424?><pub-id pub-id-type="pmid">16386424</pub-id></element-citation></ref><ref id="B122-molecules-22-00058"><label>122.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haudecoeur</surname><given-names>R.</given-names></name><name><surname>Boumendjel</surname><given-names>A.</given-names></name></person-group>
<article-title>Recent Advances in the Medicinal Chemistry of Aurones</article-title>
<source>Curr. Med. Chem.</source>
<year>2012</year>
<volume>19</volume>
<fpage>2861</fpage>
<lpage>2875</lpage>
<pub-id pub-id-type="doi">10.2174/092986712800672085</pub-id>
<?supplied-pmid 22519399?><pub-id pub-id-type="pmid">22519399</pub-id></element-citation></ref><ref id="B123-molecules-22-00058"><label>123.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Napolitano</surname><given-names>H.B.</given-names></name><name><surname>Silva</surname><given-names>M.</given-names></name><name><surname>Ellena</surname><given-names>J.</given-names></name><name><surname>Rodrigues</surname><given-names>B.D.G.</given-names></name><name><surname>Almeida</surname><given-names>A.L.C.</given-names></name><name><surname>Vieira</surname><given-names>P.C.</given-names></name><name><surname>Oliva</surname><given-names>G.</given-names></name><name><surname>Thiemann</surname><given-names>O.H.</given-names></name></person-group>
<article-title>Aurapten, a coumarin with growth inhibition against Leishmania major promastigotes</article-title>
<source>Braz. J. Med. Biol. Res.</source>
<year>2004</year>
<volume>37</volume>
<fpage>1847</fpage>
<lpage>1852</lpage>
<pub-id pub-id-type="doi">10.1590/S0100-879X2004001200010</pub-id>
<?supplied-pmid 15558191?><pub-id pub-id-type="pmid">15558191</pub-id></element-citation></ref><ref id="B124-molecules-22-00058"><label>124.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oketch-Rabah</surname><given-names>H.A.</given-names></name><name><surname>Lemmich</surname><given-names>E.</given-names></name><name><surname>Dossaji</surname><given-names>S.F.</given-names></name><name><surname>Theander</surname><given-names>T.G.</given-names></name><name><surname>Olsen</surname><given-names>C.E.</given-names></name><name><surname>Cornett</surname><given-names>C.</given-names></name><name><surname>Kharazmi</surname><given-names>A.</given-names></name><name><surname>Christensen</surname><given-names>S.B.</given-names></name></person-group>
<article-title>Two New Antiprotozoal 5-Methylcoumarins from Vernonia brachycalyx</article-title>
<source>J. Nat. Prod.</source>
<year>1997</year>
<volume>60</volume>
<fpage>458</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="doi">10.1021/np970030o</pub-id>
<?supplied-pmid 9170288?><pub-id pub-id-type="pmid">9170288</pub-id></element-citation></ref><ref id="B125-molecules-22-00058"><label>125.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iranshahi</surname><given-names>M.</given-names></name><name><surname>Arfa</surname><given-names>P.</given-names></name><name><surname>Ramezani</surname><given-names>M.</given-names></name><name><surname>Jaafari</surname><given-names>M.R.</given-names></name><name><surname>Sadeghian</surname><given-names>H.</given-names></name><name><surname>Bassarello</surname><given-names>C.</given-names></name><name><surname>Piacente</surname><given-names>S.</given-names></name><name><surname>Pizza</surname><given-names>C.</given-names></name></person-group>
<article-title>Sesquiterpene coumarins from Ferula szowitsiana and in vitro antileishmanial activity of 7-prenyloxycoumarins against promastigotes</article-title>
<source>Phytochemistry</source>
<year>2007</year>
<volume>68</volume>
<fpage>554</fpage>
<lpage>561</lpage>
<pub-id pub-id-type="doi">10.1016/j.phytochem.2006.11.002</pub-id>
<?supplied-pmid 17196626?><pub-id pub-id-type="pmid">17196626</pub-id></element-citation></ref><ref id="B126-molecules-22-00058"><label>126.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brenzan</surname><given-names>M.A.</given-names></name><name><surname>Santos</surname><given-names>A.O.</given-names></name><name><surname>Nakamura</surname><given-names>C.V.</given-names></name><name><surname>Filho</surname><given-names>B.P.D.</given-names></name><name><surname>Ueda-Nakamura</surname><given-names>T.</given-names></name><name><surname>Young</surname><given-names>M.C.M.</given-names></name><name><surname>C&#x000f4;rrea</surname><given-names>A.G.</given-names></name><name><surname>J&#x000fa;nior</surname><given-names>J.A.</given-names></name><name><surname>Morgado-D&#x000ed;az</surname><given-names>J.A.</given-names></name><name><surname>Cortez</surname><given-names>D.A.G.</given-names></name></person-group>
<article-title>Effects of (&#x02212;) mammea A/BB isolated from Calophyllum brasiliense leaves and derivatives on mitochondrial membrane of Leishmania amazonensis</article-title>
<source>Phytomedicine</source>
<year>2012</year>
<volume>19</volume>
<fpage>223</fpage>
<lpage>230</lpage>
<pub-id pub-id-type="doi">10.1016/j.phymed.2011.10.008</pub-id>
<?supplied-pmid 22285848?><pub-id pub-id-type="pmid">22285848</pub-id></element-citation></ref><ref id="B127-molecules-22-00058"><label>127.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haslam</surname><given-names>E.</given-names></name></person-group>
<article-title>Natural polyphenols (vegetable tannins) as drugs: Possible modes of action</article-title>
<source>J. Nat. Prod.</source>
<year>1996</year>
<volume>59</volume>
<fpage>205</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="doi">10.1021/np960040+</pub-id>
<?supplied-pmid 8991956?><pub-id pub-id-type="pmid">8991956</pub-id></element-citation></ref><ref id="B128-molecules-22-00058"><label>128.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haslam</surname><given-names>E.</given-names></name><name><surname>Lilley</surname><given-names>T.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Martin</surname><given-names>R.</given-names></name><name><surname>Mangnolato</surname><given-names>D.</given-names></name></person-group>
<article-title>Traditional Herbal Medicines&#x02014;The Role of Polyphenols</article-title>
<source>Planta Med.</source>
<year>1989</year>
<volume>55</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1055/s-2006-961764</pub-id>
<?supplied-pmid 2654977?><pub-id pub-id-type="pmid">2654977</pub-id></element-citation></ref><ref id="B129-molecules-22-00058"><label>129.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kolodziej</surname><given-names>H.</given-names></name><name><surname>Kayser</surname><given-names>O.</given-names></name><name><surname>Kiderlen</surname><given-names>A.F.</given-names></name><name><surname>Ito</surname><given-names>H.</given-names></name><name><surname>Hatano</surname><given-names>T.</given-names></name><name><surname>Yoshida</surname><given-names>T.</given-names></name><name><surname>Foo</surname><given-names>L.Y.</given-names></name></person-group>
<article-title>Antileishmanial activity of hydrolyzable tannins and their modulatory effects on nitric oxide and tumour necrosis factor-alpha release in macrophages in vitro</article-title>
<source>Planta Med.</source>
<year>2001</year>
<volume>67</volume>
<fpage>825</fpage>
<lpage>832</lpage>
<pub-id pub-id-type="doi">10.1055/s-2001-18850</pub-id>
<?supplied-pmid 11745019?><pub-id pub-id-type="pmid">11745019</pub-id></element-citation></ref><ref id="B130-molecules-22-00058"><label>130.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gour</surname><given-names>J.K.</given-names></name><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Bajpai</surname><given-names>S.</given-names></name><name><surname>Pandey</surname><given-names>H.P.</given-names></name><name><surname>Singh</surname><given-names>R.K.</given-names></name></person-group>
<article-title>Identification of Th1-responsive leishmanial excretory&#x02014;Secretory antigens (LESAs)</article-title>
<source>Exp. Parasitol.</source>
<year>2012</year>
<volume>132</volume>
<fpage>355</fpage>
<lpage>361</lpage>
<pub-id pub-id-type="doi">10.1016/j.exppara.2012.04.022</pub-id>
<?supplied-pmid 22955114?><pub-id pub-id-type="pmid">22955114</pub-id></element-citation></ref><ref id="B131-molecules-22-00058"><label>131.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ray</surname><given-names>S.</given-names></name><name><surname>Majumder</surname><given-names>H.K.</given-names></name><name><surname>Chakravarty</surname><given-names>A.K.</given-names></name><name><surname>Mukhopadhyay</surname><given-names>S.</given-names></name><name><surname>Gil</surname><given-names>R.R.</given-names></name><name><surname>Cordell</surname><given-names>G.A.</given-names></name></person-group>
<article-title>Amarogentin, a Naturally Occurring Secoiridoid Glycoside and a Newly Recognized Inhibitor of Topoisomerase I from Leishmania donovani</article-title>
<source>J. Nat. Prod.</source>
<year>1996</year>
<volume>59</volume>
<fpage>27</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1021/np960018g</pub-id>
<?supplied-pmid 8984149?><pub-id pub-id-type="pmid">8984149</pub-id></element-citation></ref><ref id="B132-molecules-22-00058"><label>132.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Medda</surname><given-names>S.</given-names></name></person-group>
<article-title>Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>1999</year>
<volume>44</volume>
<fpage>791</fpage>
<lpage>794</lpage>
<pub-id pub-id-type="doi">10.1093/jac/44.6.791</pub-id>
<?supplied-pmid 10590280?><pub-id pub-id-type="pmid">10590280</pub-id></element-citation></ref><ref id="B133-molecules-22-00058"><label>133.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fournet</surname><given-names>A.</given-names></name><name><surname>Angelo</surname><given-names>A.</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>V.</given-names></name><name><surname>Roblot</surname><given-names>F.</given-names></name><name><surname>Hocquemiller</surname><given-names>R.</given-names></name><name><surname>Cav&#x000e9;</surname><given-names>A.</given-names></name></person-group>
<article-title>Biological and chemical studies of Pera benensis, a Bolivian plant used in folk medicine as a treatment of cutaneous leishmaniasis</article-title>
<source>J. Ethnopharmacol.</source>
<year>1992</year>
<volume>37</volume>
<fpage>159</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="doi">10.1016/0378-8741(92)90074-2</pub-id>
<pub-id pub-id-type="pmid">1434690</pub-id></element-citation></ref><ref id="B134-molecules-22-00058"><label>134.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hazra</surname><given-names>B.</given-names></name><name><surname>Sarkar</surname><given-names>R.</given-names></name><name><surname>Bhattacharyya</surname><given-names>S.</given-names></name><name><surname>Ghosh</surname><given-names>P.K.</given-names></name><name><surname>Chel</surname><given-names>G.</given-names></name><name><surname>Dinda</surname><given-names>B.</given-names></name></person-group>
<article-title>Synthesis of plumbagin derivatives and their inhibitory activities against Ehrlich ascites carcinomain vivo andLeishmania donovani Promastigotes in vitro</article-title>
<source>Phyther. Res.</source>
<year>2002</year>
<volume>16</volume>
<fpage>133</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1002/ptr.867</pub-id>
<?supplied-pmid 11933114?><pub-id pub-id-type="pmid">11933114</pub-id></element-citation></ref><ref id="B135-molecules-22-00058"><label>135.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fournet</surname><given-names>A.</given-names></name><name><surname>Barrios</surname><given-names>A.A.</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>V.</given-names></name><name><surname>Hocquemiller</surname><given-names>R.</given-names></name><name><surname>Cav&#x000e9;</surname><given-names>A.</given-names></name></person-group>
<article-title>Effect of natural naphthoquinones in BALB/c mice infected with Leishmania amazonensis and L. venezuelensis</article-title>
<source>Trop. Med. Parasitol.</source>
<year>1992</year>
<volume>43</volume>
<fpage>219</fpage>
<lpage>222</lpage>
<?supplied-pmid 1293723?><pub-id pub-id-type="pmid">1293723</pub-id></element-citation></ref><ref id="B136-molecules-22-00058"><label>136.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fujii</surname><given-names>N.</given-names></name><name><surname>Yamashita</surname><given-names>Y.</given-names></name><name><surname>Arima</surname><given-names>Y.</given-names></name><name><surname>Nagashima</surname><given-names>M.</given-names></name><name><surname>Nakano</surname><given-names>H.</given-names></name></person-group>
<article-title>Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>1992</year>
<volume>36</volume>
<fpage>2589</fpage>
<lpage>2594</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.36.12.2589</pub-id>
<pub-id pub-id-type="pmid">1336338</pub-id></element-citation></ref><ref id="B137-molecules-22-00058"><label>137.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mori-Yasumoto</surname><given-names>K.</given-names></name><name><surname>Izumoto</surname><given-names>R.</given-names></name><name><surname>Fuchino</surname><given-names>H.</given-names></name><name><surname>Ooi</surname><given-names>T.</given-names></name><name><surname>Agatsuma</surname><given-names>Y.</given-names></name><name><surname>Kusumi</surname><given-names>T.</given-names></name><name><surname>Satake</surname><given-names>M.</given-names></name><name><surname>Sekita</surname><given-names>S.</given-names></name></person-group>
<article-title>Leishmanicidal activities and cytotoxicities of bisnaphthoquinone analogues and naphthol derivatives from Burman Diospyros burmanica</article-title>
<source>Bioorg. Med. Chem.</source>
<year>2012</year>
<volume>20</volume>
<fpage>5215</fpage>
<lpage>5219</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmc.2012.06.055</pub-id>
<?supplied-pmid 22858297?><pub-id pub-id-type="pmid">22858297</pub-id></element-citation></ref><ref id="B138-molecules-22-00058"><label>138.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Fuchino</surname><given-names>H.</given-names></name><name><surname>Satake</surname><given-names>M.</given-names></name><name><surname>Agatsuma</surname><given-names>Y.</given-names></name><name><surname>Sekita</surname><given-names>S.</given-names></name></person-group>
<article-title>In Vitro Screening of Leishmanicidal Activity in Myanmar Timber Extracts</article-title>
<source>Biol. Pharm. Bull.</source>
<year>2004</year>
<volume>27</volume>
<fpage>921</fpage>
<lpage>925</lpage>
<pub-id pub-id-type="doi">10.1248/bpb.27.921</pub-id>
<?supplied-pmid 15187448?><pub-id pub-id-type="pmid">15187448</pub-id></element-citation></ref><ref id="B139-molecules-22-00058"><label>139.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fournet</surname><given-names>A.</given-names></name><name><surname>Ferreira</surname><given-names>M.E.</given-names></name><name><surname>de Arias</surname><given-names>A.R.</given-names></name><name><surname>Ortiz</surname><given-names>S.T.</given-names></name><name><surname>Fuentes</surname><given-names>S.</given-names></name><name><surname>Nakayama</surname><given-names>H.</given-names></name><name><surname>Schinini</surname><given-names>A.</given-names></name><name><surname>Hocquemiller</surname><given-names>R.</given-names></name></person-group>
<article-title>In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>1996</year>
<volume>40</volume>
<fpage>2447</fpage>
<lpage>2451</lpage>
<?supplied-pmid 8913444?><pub-id pub-id-type="pmid">8913444</pub-id></element-citation></ref><ref id="B140-molecules-22-00058"><label>140.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fournet</surname><given-names>A.</given-names></name><name><surname>Gantier</surname><given-names>J.C.</given-names></name><name><surname>Gautheret</surname><given-names>A.</given-names></name><name><surname>Leysalles</surname><given-names>L.</given-names></name><name><surname>Munos</surname><given-names>M.H.</given-names></name><name><surname>Mayrargue</surname><given-names>J.</given-names></name><name><surname>Moskowitz</surname><given-names>H.</given-names></name><name><surname>Cav&#x000e9;</surname><given-names>A.</given-names></name><name><surname>Hocquemiller</surname><given-names>R.</given-names></name></person-group>
<article-title>The activity of 2-substituted quinoline alkaloids in BALB/c mice infected with Leishmania donovani</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>1994</year>
<volume>33</volume>
<fpage>537</fpage>
<lpage>544</lpage>
<pub-id pub-id-type="doi">10.1093/jac/33.3.537</pub-id>
<?supplied-pmid 8040117?><pub-id pub-id-type="pmid">8040117</pub-id></element-citation></ref><ref id="B141-molecules-22-00058"><label>141.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muhammad</surname><given-names>I.</given-names></name><name><surname>Dunbar</surname><given-names>D.C.</given-names></name><name><surname>Khan</surname><given-names>S.I.</given-names></name><name><surname>Tekwani</surname><given-names>B.L.</given-names></name><name><surname>Bedir</surname><given-names>E.</given-names></name><name><surname>Takamatsu</surname><given-names>S.</given-names></name><name><surname>Ferreira</surname><given-names>D.</given-names></name><name><surname>Walker</surname><given-names>L.A.</given-names></name></person-group>
<article-title>Antiparasitic Alkaloids from Psychotria klugii</article-title>
<source>J. Nat. Prod.</source>
<year>2003</year>
<volume>66</volume>
<fpage>962</fpage>
<lpage>967</lpage>
<pub-id pub-id-type="doi">10.1021/np030086k</pub-id>
<?supplied-pmid 12880315?><pub-id pub-id-type="pmid">12880315</pub-id></element-citation></ref><ref id="B142-molecules-22-00058"><label>142.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lala</surname><given-names>S.</given-names></name><name><surname>Pramanick</surname><given-names>S.</given-names></name><name><surname>Mukhopadhyay</surname><given-names>S.</given-names></name><name><surname>Bandyopadhyay</surname><given-names>S.</given-names></name><name><surname>Basu</surname><given-names>M.K.</given-names></name></person-group>
<article-title>Harmine: Evaluation of its Antileishmanial Properties in Various Vesicular Delivery Systems</article-title>
<source>J. Drug Target.</source>
<year>2004</year>
<volume>12</volume>
<fpage>165</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.1080/10611860410001712696</pub-id>
<?supplied-pmid 15203896?><pub-id pub-id-type="pmid">15203896</pub-id></element-citation></ref><ref id="B143-molecules-22-00058"><label>143.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Peng</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Hou</surname><given-names>X.</given-names></name><name><surname>Guan</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>A.</given-names></name></person-group>
<article-title>DNA binding properties of 9-substituted harmine derivatives</article-title>
<source>Biochem. Biophys. Res. Commun.</source>
<year>2005</year>
<volume>338</volume>
<fpage>1557</fpage>
<lpage>1563</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2005.10.121</pub-id>
<?supplied-pmid 16288723?><pub-id pub-id-type="pmid">16288723</pub-id></element-citation></ref><ref id="B144-molecules-22-00058"><label>144.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Germonprez</surname><given-names>N.</given-names></name><name><surname>Maes</surname><given-names>L.</given-names></name><name><surname>Van Puyvelde</surname><given-names>L.</given-names></name><name><surname>Van Tri</surname><given-names>M.</given-names></name><name><surname>Tuan</surname><given-names>D.A.</given-names></name><name><surname>de Kimpe</surname><given-names>N.</given-names></name></person-group>
<article-title>In Vitro and in Vivo Anti-Leishmanial Activity of Triterpenoid Saponins Isolated from Maesa b alansae and Some Chemical Derivatives</article-title>
<source>J. Med. Chem.</source>
<year>2005</year>
<volume>48</volume>
<fpage>32</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1021/jm031150y</pub-id>
<?supplied-pmid 15633999?><pub-id pub-id-type="pmid">15633999</pub-id></element-citation></ref><ref id="B145-molecules-22-00058"><label>145.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dutta</surname><given-names>A.</given-names></name><name><surname>Ghoshal</surname><given-names>A.</given-names></name><name><surname>Mandal</surname><given-names>D.</given-names></name><name><surname>Mondal</surname><given-names>N.B.</given-names></name><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Sahu</surname><given-names>N.P.</given-names></name><name><surname>Mandal</surname><given-names>C.</given-names></name></person-group>
<article-title>Racemoside A, an anti-leishmanial, water-soluble, natural steroidal saponin, induces programmed cell death in Leishmania donovani</article-title>
<source>J. Med. Microbiol.</source>
<year>2007</year>
<volume>56</volume>
<fpage>1196</fpage>
<lpage>1204</lpage>
<pub-id pub-id-type="doi">10.1099/jmm.0.47114-0</pub-id>
<?supplied-pmid 17761483?><pub-id pub-id-type="pmid">17761483</pub-id></element-citation></ref><ref id="B146-molecules-22-00058"><label>146.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Delmas</surname><given-names>F.</given-names></name><name><surname>di Giorgio</surname><given-names>C.</given-names></name><name><surname>Elias</surname><given-names>R.</given-names></name><name><surname>Gasquet</surname><given-names>M.</given-names></name><name><surname>Azas</surname><given-names>N.</given-names></name><name><surname>Mshvildadze</surname><given-names>V.</given-names></name><name><surname>Dekanosidze</surname><given-names>G.</given-names></name><name><surname>Kemertelidze</surname><given-names>E.</given-names></name><name><surname>Timon-David</surname><given-names>P.</given-names></name></person-group>
<article-title>Antileishmanial activity of three saponins isolated from ivy, alpha-hederin, beta-hederin and hederacolchiside A1, as compared to their action on mammalian cells cultured in vitro</article-title>
<source>Planta Med.</source>
<year>2000</year>
<volume>66</volume>
<fpage>343</fpage>
<lpage>347</lpage>
<pub-id pub-id-type="doi">10.1055/s-2000-8541</pub-id>
<?supplied-pmid 10865451?><pub-id pub-id-type="pmid">10865451</pub-id></element-citation></ref><ref id="B147-molecules-22-00058"><label>147.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Giorgio</surname><given-names>C.</given-names></name><name><surname>Delmas</surname><given-names>F.</given-names></name><name><surname>Akhmedjanova</surname><given-names>V.</given-names></name><name><surname>Ollivier</surname><given-names>E.</given-names></name><name><surname>Bessonova</surname><given-names>I.</given-names></name><name><surname>Riad</surname><given-names>E.</given-names></name><name><surname>Timon-David</surname><given-names>P.</given-names></name></person-group>
<article-title>In vitro antileishmanial activity of diphyllin isolated from Haplophyllum bucharicum</article-title>
<source>Planta Med.</source>
<year>2005</year>
<volume>71</volume>
<fpage>366</fpage>
<lpage>369</lpage>
<pub-id pub-id-type="doi">10.1055/s-2005-864106</pub-id>
<?supplied-pmid 15856417?><pub-id pub-id-type="pmid">15856417</pub-id></element-citation></ref><ref id="B148-molecules-22-00058"><label>148.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Georgopoulou</surname><given-names>K.</given-names></name><name><surname>Smirlis</surname><given-names>D.</given-names></name><name><surname>Bisti</surname><given-names>S.</given-names></name><name><surname>Xingi</surname><given-names>E.</given-names></name><name><surname>Skaltsounis</surname><given-names>L.</given-names></name><name><surname>Soteriadou</surname><given-names>K.</given-names></name></person-group>
<article-title>In vitro activity of 10-deacetylbaccatin III against Leishmania donovani promastigotes and intracellular amastigotes</article-title>
<source>Planta Med.</source>
<year>2007</year>
<volume>73</volume>
<fpage>1081</fpage>
<lpage>1088</lpage>
<pub-id pub-id-type="doi">10.1055/s-2007-981579</pub-id>
<?supplied-pmid 17691059?><pub-id pub-id-type="pmid">17691059</pub-id></element-citation></ref><ref id="B149-molecules-22-00058"><label>149.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosa</surname><given-names>M.d.S.S.</given-names></name><name><surname>Mendonca-Filho</surname><given-names>R.R.</given-names></name><name><surname>Bizzo</surname><given-names>H.R.</given-names></name><name><surname>Rodrigues</surname><given-names>I.d.A.</given-names></name><name><surname>Soares</surname><given-names>R.M.A.</given-names></name><name><surname>Souto-Padron</surname><given-names>T.</given-names></name><name><surname>Alviano</surname><given-names>C.S.</given-names></name><name><surname>Lopes</surname><given-names>A.H.C.S.</given-names></name></person-group>
<article-title>Antileishmanial Activity of a Linalool-Rich Essential Oil from Croton cajucara</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2003</year>
<volume>47</volume>
<fpage>1895</fpage>
<lpage>1901</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.47.6.1895-1901.2003</pub-id>
<pub-id pub-id-type="pmid">12760864</pub-id></element-citation></ref><ref id="B150-molecules-22-00058"><label>150.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tan</surname><given-names>N.</given-names></name><name><surname>Kaloga</surname><given-names>M.</given-names></name><name><surname>Radtke</surname><given-names>O.A.</given-names></name><name><surname>Kiderlen</surname><given-names>A.F.</given-names></name><name><surname>&#x000d6;ks&#x000fc;z</surname><given-names>S.</given-names></name><name><surname>Ulubelen</surname><given-names>A.</given-names></name><name><surname>Kolodziej</surname><given-names>H.</given-names></name></person-group>
<article-title>Abietane diterpenoids and triterpenoic acids from Salvia cilicica and their antileishmanial activities</article-title>
<source>Phytochemistry</source>
<year>2002</year>
<volume>61</volume>
<fpage>881</fpage>
<lpage>884</lpage>
<pub-id pub-id-type="doi">10.1016/S0031-9422(02)00361-8</pub-id>
<pub-id pub-id-type="pmid">12453510</pub-id></element-citation></ref><ref id="B151-molecules-22-00058"><label>151.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Danelli</surname><given-names>M.G.M.</given-names></name><name><surname>Soares</surname><given-names>D.C.</given-names></name><name><surname>Abreu</surname><given-names>H.S.</given-names></name><name><surname>Pe&#x000e7;anha</surname><given-names>L.M.T.</given-names></name><name><surname>Saraiva</surname><given-names>E.M.</given-names></name></person-group>
<article-title>Leishmanicidal effect of LLD-3 (1), a nor-triterpene isolated from Lophanthera lactescens</article-title>
<source>Phytochemistry</source>
<year>2009</year>
<volume>70</volume>
<fpage>608</fpage>
<lpage>614</lpage>
<pub-id pub-id-type="doi">10.1016/j.phytochem.2009.03.009</pub-id>
<?supplied-pmid 19359020?><pub-id pub-id-type="pmid">19359020</pub-id></element-citation></ref><ref id="B152-molecules-22-00058"><label>152.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thiem</surname><given-names>D.A.</given-names></name><name><surname>Sneden</surname><given-names>A.T.</given-names></name><name><surname>Khan</surname><given-names>S.I.</given-names></name><name><surname>Tekwani</surname><given-names>B.L.</given-names></name></person-group>
<article-title>Bisnortriterpenes from Salacia m adagascariensis</article-title>
<source>J. Nat. Prod.</source>
<year>2005</year>
<volume>68</volume>
<fpage>251</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1021/np0497088</pub-id>
<?supplied-pmid 15730255?><pub-id pub-id-type="pmid">15730255</pub-id></element-citation></ref><ref id="B153-molecules-22-00058"><label>153.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fuchino</surname><given-names>H.</given-names></name><name><surname>Koide</surname><given-names>T.</given-names></name><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Sekita</surname><given-names>S.</given-names></name><name><surname>Satake</surname><given-names>M.</given-names></name></person-group>
<article-title>New sesquiterpene lactones from Elephantopus mollis and their leishmanicidal activities</article-title>
<source>Planta Med.</source>
<year>2001</year>
<volume>67</volume>
<fpage>647</fpage>
<lpage>653</lpage>
<pub-id pub-id-type="doi">10.1055/s-2001-17349</pub-id>
<?supplied-pmid 11582544?><pub-id pub-id-type="pmid">11582544</pub-id></element-citation></ref><ref id="B154-molecules-22-00058"><label>154.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sulsen</surname><given-names>V.P.</given-names></name><name><surname>Frank</surname><given-names>F.M.</given-names></name><name><surname>Cazorla</surname><given-names>S.I.</given-names></name><name><surname>Anesini</surname><given-names>C.A.</given-names></name><name><surname>Malchiodi</surname><given-names>E.L.</given-names></name><name><surname>Freixa</surname><given-names>B.</given-names></name><name><surname>Vila</surname><given-names>R.</given-names></name><name><surname>Muschietti</surname><given-names>L.V.</given-names></name><name><surname>Martino</surname><given-names>V.S.</given-names></name></person-group>
<article-title>Trypanocidal and Leishmanicidal Activities of Sesquiterpene Lactones from Ambrosia tenuifolia Sprengel (Asteraceae)</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2008</year>
<volume>52</volume>
<fpage>2415</fpage>
<lpage>2419</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.01630-07</pub-id>
<?supplied-pmid 18443111?><pub-id pub-id-type="pmid">18443111</pub-id></element-citation></ref><ref id="B155-molecules-22-00058"><label>155.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muhammad</surname><given-names>I.</given-names></name><name><surname>Bedir</surname><given-names>E.</given-names></name><name><surname>Khan</surname><given-names>S.I.</given-names></name><name><surname>Tekwani</surname><given-names>B.L.</given-names></name><name><surname>Khan</surname><given-names>I.A.</given-names></name><name><surname>Takamatsu</surname><given-names>S.</given-names></name><name><surname>Pelletier</surname><given-names>J.</given-names></name><name><surname>Walker</surname><given-names>L.A.</given-names></name></person-group>
<article-title>A New Antimalarial Quassinoid from Simaba o rinocensis</article-title>
<source>J. Nat. Prod.</source>
<year>2004</year>
<volume>67</volume>
<fpage>772</fpage>
<lpage>777</lpage>
<pub-id pub-id-type="doi">10.1021/np030524n</pub-id>
<?supplied-pmid 15165136?><pub-id pub-id-type="pmid">15165136</pub-id></element-citation></ref><ref id="B156-molecules-22-00058"><label>156.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lenta</surname><given-names>B.</given-names></name><name><surname>Weniger</surname><given-names>B.</given-names></name><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Vonthron-S&#x000e9;n&#x000e9;cheau</surname><given-names>C.</given-names></name></person-group>
<article-title>Antileishmanial natural prenylated anthranoids</article-title>
<source>Planta Med.</source>
<year>2012</year>
<volume>78</volume>
<fpage>PI290</fpage>
<pub-id pub-id-type="doi">10.1055/s-0032-1320977</pub-id>
</element-citation></ref><ref id="B157-molecules-22-00058"><label>157.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Da Silva</surname><given-names>D.B.</given-names></name><name><surname>Tulli</surname><given-names>E.C.O.</given-names></name><name><surname>Milit&#x000e3;o</surname><given-names>G.C.G.</given-names></name><name><surname>Costa-Lotufo</surname><given-names>L.V.</given-names></name><name><surname>Pessoa</surname><given-names>C.</given-names></name><name><surname>de Moraes</surname><given-names>M.O.</given-names></name><name><surname>Albuquerque</surname><given-names>S.</given-names></name><name><surname>de Siqueira</surname><given-names>J.M.</given-names></name></person-group>
<article-title>The antitumoral, trypanocidal and antileishmanial activities of extract and alkaloids isolated from Duguetia furfuracea</article-title>
<source>Phytomedicine</source>
<year>2009</year>
<volume>16</volume>
<fpage>1059</fpage>
<lpage>1063</lpage>
<pub-id pub-id-type="doi">10.1016/j.phymed.2009.03.019</pub-id>
<?supplied-pmid 19423311?><pub-id pub-id-type="pmid">19423311</pub-id></element-citation></ref><ref id="B158-molecules-22-00058"><label>158.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmeda-Hirschmann</surname><given-names>G.</given-names></name><name><surname>Razmilic</surname><given-names>I.</given-names></name><name><surname>Sauvain</surname><given-names>M.</given-names></name><name><surname>Moretti</surname><given-names>C.</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>V.</given-names></name><name><surname>Ruiz</surname><given-names>E.</given-names></name><name><surname>Balanza</surname><given-names>E.</given-names></name><name><surname>Fournet</surname><given-names>A.</given-names></name></person-group>
<article-title>Antiprotozoal activity of Jatrogrossidione from Jatropha grossidentata and Jatrophone from Jatropha isabellii</article-title>
<source>Phyther. Res.</source>
<year>1996</year>
<volume>10</volume>
<fpage>375</fpage>
<lpage>378</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1099-1573(199608)10:5&#x0003c;375::AID-PTR847&#x0003e;3.0.CO;2-#</pub-id>
</element-citation></ref><ref id="B159-molecules-22-00058"><label>159.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakao</surname><given-names>Y.</given-names></name><name><surname>Shiroiwa</surname><given-names>T.</given-names></name><name><surname>Murayama</surname><given-names>S.</given-names></name><name><surname>Matsunaga</surname><given-names>S.</given-names></name><name><surname>Goto</surname><given-names>Y.</given-names></name><name><surname>Matsumoto</surname><given-names>Y.</given-names></name><name><surname>Fusetani</surname><given-names>N.</given-names></name></person-group>
<article-title>Identification of Renieramycin A as an Antileishmanial Substance in a Marine Sponge Neopetrosia sp.</article-title>
<source>Mar. Drugs</source>
<year>2004</year>
<volume>2</volume>
<fpage>55</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.3390/md202055</pub-id>
</element-citation></ref><ref id="B160-molecules-22-00058"><label>160.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Compagnone</surname><given-names>R.S.</given-names></name><name><surname>Pi&#x000f1;a</surname><given-names>I.C.</given-names></name><name><surname>Rangel</surname><given-names>H.R.</given-names></name><name><surname>Dagger</surname><given-names>F.</given-names></name><name><surname>Su&#x000e1;rez</surname><given-names>A.I.</given-names></name><name><surname>Venkata Rami Reddy</surname><given-names>M.</given-names></name><name><surname>John Faulkner</surname><given-names>D.</given-names></name></person-group>
<article-title>Antileishmanial cyclic peroxides from the Palauan sponge Plakortis aff. angulospiculatus</article-title>
<source>Tetrahedron</source>
<year>1998</year>
<volume>54</volume>
<fpage>3057</fpage>
<lpage>3068</lpage>
<pub-id pub-id-type="doi">10.1016/S0040-4020(98)00055-6</pub-id>
</element-citation></ref><ref id="B161-molecules-22-00058"><label>161.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Linington</surname><given-names>R.G.</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>J.</given-names></name><name><surname>Ure&#x000f1;a</surname><given-names>L.-D.</given-names></name><name><surname>Romero</surname><given-names>L.I.</given-names></name><name><surname>Ortega-Barr&#x000ed;a</surname><given-names>E.</given-names></name><name><surname>Gerwick</surname><given-names>W.H.</given-names></name></person-group>
<article-title>Venturamides A and B: Antimalarial Constituents of the Panamanian Marine Cyanobacterium Oscillatoria sp.</article-title>
<source>J. Nat. Prod.</source>
<year>2007</year>
<volume>70</volume>
<fpage>397</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="doi">10.1021/np0605790</pub-id>
<?supplied-pmid 17328572?><pub-id pub-id-type="pmid">17328572</pub-id></element-citation></ref><ref id="B162-molecules-22-00058"><label>162.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pimentel-Elardo</surname><given-names>S.M.</given-names></name><name><surname>Kozytska</surname><given-names>S.</given-names></name><name><surname>Bugni</surname><given-names>T.S.</given-names></name><name><surname>Ireland</surname><given-names>C.M.</given-names></name><name><surname>Moll</surname><given-names>H.</given-names></name><name><surname>Hentschel</surname><given-names>U.</given-names></name></person-group>
<article-title>Anti-Parasitic Compounds from Streptomyces sp. Strains Isolated from Mediterranean Sponges</article-title>
<source>Mar. Drugs</source>
<year>2010</year>
<volume>8</volume>
<fpage>373</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="doi">10.3390/md8020373</pub-id>
<?supplied-pmid 20390111?><pub-id pub-id-type="pmid">20390111</pub-id></element-citation></ref><ref id="B163-molecules-22-00058"><label>163.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vik</surname><given-names>A.</given-names></name><name><surname>Proszeny&#x000e1;k</surname><given-names>&#x000c1;.</given-names></name><name><surname>Vermeersch</surname><given-names>M.</given-names></name><name><surname>Cos</surname><given-names>P.</given-names></name><name><surname>Maes</surname><given-names>L.</given-names></name><name><surname>Gundersen</surname><given-names>L.-L.</given-names></name></person-group>
<article-title>Screening of Agelasine D and Analogs for Inhibitory Activity against Pathogenic Protozoa; Identification of Hits for Visceral Leishmaniasis and Chagas Disease</article-title>
<source>Molecules</source>
<year>2009</year>
<volume>14</volume>
<fpage>279</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="doi">10.3390/molecules14010279</pub-id>
<?supplied-pmid 19136916?><pub-id pub-id-type="pmid">19136916</pub-id></element-citation></ref><ref id="B164-molecules-22-00058"><label>164.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Chauhan</surname><given-names>K.</given-names></name><name><surname>Shivahare</surname><given-names>R.</given-names></name><name><surname>Vishwakarma</surname><given-names>P.</given-names></name><name><surname>Suthar</surname><given-names>M.K.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Saxena</surname><given-names>J.K.</given-names></name><name><surname>Lal</surname><given-names>J.</given-names></name><name><surname>Chandra</surname><given-names>P.</given-names></name><etal/></person-group>
<article-title>Discovery of a New Class of Natural Product-Inspired Quinazolinone Hybrid as Potent Antileishmanial agents</article-title>
<source>J. Med. Chem.</source>
<year>2013</year>
<volume>56</volume>
<fpage>4374</fpage>
<lpage>4392</lpage>
<pub-id pub-id-type="doi">10.1021/jm400053v</pub-id>
<?supplied-pmid 23611626?><pub-id pub-id-type="pmid">23611626</pub-id></element-citation></ref><ref id="B165-molecules-22-00058"><label>165.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J.</given-names></name></person-group>
<article-title>Antimalarials in the Treatment of Schistosomiasis</article-title>
<source>Curr. Pharm. Des.</source>
<year>2012</year>
<volume>18</volume>
<fpage>3531</fpage>
<lpage>3538</lpage>
<pub-id pub-id-type="doi">10.2174/138161212801327293</pub-id>
<?supplied-pmid 22607145?><pub-id pub-id-type="pmid">22607145</pub-id></element-citation></ref><ref id="B166-molecules-22-00058"><label>166.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ingram-Sieber</surname><given-names>K.</given-names></name><name><surname>Cowan</surname><given-names>N.</given-names></name><name><surname>Panic</surname><given-names>G.</given-names></name><name><surname>Vargas</surname><given-names>M.</given-names></name><name><surname>Mansour</surname><given-names>N.R.</given-names></name><name><surname>Bickle</surname><given-names>Q.D.</given-names></name><name><surname>Wells</surname><given-names>T.N.C.</given-names></name><name><surname>Spangenberg</surname><given-names>T.</given-names></name><name><surname>Keiser</surname><given-names>J.</given-names></name></person-group>
<article-title>Orally Active Antischistosomal Early Leads Identified from the Open Access Malaria Box</article-title>
<source>PLoS Negl. Trop. Dis.</source>
<year>2014</year>
<volume>8</volume>
<elocation-id>30</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0002610</pub-id>
<?supplied-pmid 24416463?><pub-id pub-id-type="pmid">24416463</pub-id></element-citation></ref><ref id="B167-molecules-22-00058"><label>167.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lescano</surname><given-names>S.Z.</given-names></name><name><surname>Chieffi</surname><given-names>P.P.</given-names></name><name><surname>Canhassi</surname><given-names>R.R.</given-names></name><name><surname>Boulos</surname><given-names>M.</given-names></name><name><surname>Amato Neto</surname><given-names>V.</given-names></name></person-group>
<article-title>Antischistosomal activity of artemether in experimental Schistosomiasis mansoni</article-title>
<source>Rev. Saude Publica</source>
<year>2004</year>
<volume>38</volume>
<fpage>71</fpage>
<lpage>75</lpage>
<?supplied-pmid 14963544?><pub-id pub-id-type="pmid">14963544</pub-id></element-citation></ref><ref id="B168-molecules-22-00058"><label>168.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Njoroge</surname><given-names>M.</given-names></name><name><surname>Njuguna</surname><given-names>N.M.</given-names></name><name><surname>Mutai</surname><given-names>P.</given-names></name><name><surname>Ongarora</surname><given-names>D.S.B.</given-names></name><name><surname>Smith</surname><given-names>P.W.</given-names></name><name><surname>Chibale</surname><given-names>K.</given-names></name></person-group>
<article-title>Recent Approaches to Chemical Discovery and Development Against Malaria and the Neglected Tropical Diseases Human African Trypanosomiasis and Schistosomiasis</article-title>
<source>Chem. Rev.</source>
<year>2014</year>
<volume>114</volume>
<fpage>11138</fpage>
<lpage>11163</lpage>
<pub-id pub-id-type="doi">10.1021/cr500098f</pub-id>
<?supplied-pmid 25014712?><pub-id pub-id-type="pmid">25014712</pub-id></element-citation></ref><ref id="B169-molecules-22-00058"><label>169.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Neves</surname><given-names>B.J.</given-names></name><name><surname>Andrade</surname><given-names>C.H.</given-names></name><name><surname>Cravo</surname><given-names>P.V.L.</given-names></name></person-group>
<article-title>Natural products as leads in schistosome drug discovery</article-title>
<source>Molecules</source>
<year>2015</year>
<volume>20</volume>
<fpage>1872</fpage>
<lpage>1903</lpage>
<pub-id pub-id-type="doi">10.3390/molecules20021872</pub-id>
<?supplied-pmid 25625682?><pub-id pub-id-type="pmid">25625682</pub-id></element-citation></ref><ref id="B170-molecules-22-00058"><label>170.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Utzinger</surname><given-names>J.</given-names></name><name><surname>Raso</surname><given-names>G.</given-names></name><name><surname>Brooker</surname><given-names>S.</given-names></name><name><surname>De Savigny</surname><given-names>D.</given-names></name><name><surname>Tanner</surname><given-names>M.</given-names></name><name><surname>Ornbjerg</surname><given-names>N.</given-names></name><name><surname>Singer</surname><given-names>B.H.</given-names></name><name><surname>N&#x02019;goran</surname><given-names>E.K.</given-names></name></person-group>
<article-title>Schistosomiasis and neglected tropical diseases: Towards integrated and sustainable control and a word of caution</article-title>
<source>Parasitology</source>
<year>2009</year>
<volume>136</volume>
<fpage>1859</fpage>
<lpage>1874</lpage>
<pub-id pub-id-type="doi">10.1017/S0031182009991600</pub-id>
<?supplied-pmid 19906318?><pub-id pub-id-type="pmid">19906318</pub-id></element-citation></ref><ref id="B171-molecules-22-00058"><label>171.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schafer</surname><given-names>T.</given-names></name><name><surname>Hale</surname><given-names>B.</given-names></name></person-group>
<article-title>Gastrointestinal complications of schistosomiasis</article-title>
<source>Curr. Gastroenterol. Rep.</source>
<year>2001</year>
<volume>3</volume>
<fpage>293</fpage>
<pub-id pub-id-type="doi">10.1007/s11894-001-0052-1</pub-id>
<?supplied-pmid 11469998?><pub-id pub-id-type="pmid">11469998</pub-id></element-citation></ref><ref id="B172-molecules-22-00058"><label>172.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mbabazi</surname><given-names>P.S.</given-names></name><name><surname>Andan</surname><given-names>O.</given-names></name><name><surname>Fitzgerald</surname><given-names>D.W.</given-names></name><name><surname>Chitsulo</surname><given-names>L.</given-names></name><name><surname>Engels</surname><given-names>D.</given-names></name><name><surname>Downs</surname><given-names>J.A.</given-names></name></person-group>
<article-title>Examining the relationship between urogenital schistosomiasis and HIV infection</article-title>
<source>PLoS Negl. Trop. Dis.</source>
<year>2011</year>
<volume>5</volume>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0001396</pub-id>
<?supplied-pmid 22163056?><pub-id pub-id-type="pmid">22163056</pub-id></element-citation></ref><ref id="B173-molecules-22-00058"><label>173.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feldmeier</surname><given-names>H.</given-names></name><name><surname>Krantz</surname><given-names>I.</given-names></name><name><surname>Poggensee</surname><given-names>G.</given-names></name></person-group>
<article-title>Female Genital Schistosomiasis as a Risk-Factor for the Transmission of HIV</article-title>
<source>Int. J. STD AIDS</source>
<year>1994</year>
<volume>5</volume>
<fpage>368</fpage>
<lpage>372</lpage>
<pub-id pub-id-type="doi">10.1016/0035-9203(95)90512-X</pub-id>
<pub-id pub-id-type="pmid">7819359</pub-id></element-citation></ref><ref id="B174-molecules-22-00058"><label>174.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kallestrup</surname><given-names>P.</given-names></name><name><surname>Zinyama</surname><given-names>R.</given-names></name><name><surname>Gomo</surname><given-names>E.</given-names></name><name><surname>Butterworth</surname><given-names>A.E.</given-names></name><name><surname>Mudenge</surname><given-names>B.</given-names></name><name><surname>van Dam</surname><given-names>G.J.</given-names></name><name><surname>Gerstoft</surname><given-names>J.</given-names></name><name><surname>Erikstrup</surname><given-names>C.</given-names></name><name><surname>Ullum</surname><given-names>H.</given-names></name></person-group>
<article-title>Schistosomiasis and HIV-1 infection in rural Zimbabwe: Effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load</article-title>
<source>J. Infect. Dis.</source>
<year>2005</year>
<volume>192</volume>
<fpage>1956</fpage>
<lpage>1961</lpage>
<pub-id pub-id-type="doi">10.1086/497696</pub-id>
<?supplied-pmid 16267767?><pub-id pub-id-type="pmid">16267767</pub-id></element-citation></ref><ref id="B175-molecules-22-00058"><label>175.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cioli</surname><given-names>D.</given-names></name><name><surname>Pica-Mattoccia</surname><given-names>L.</given-names></name><name><surname>Archer</surname><given-names>S.</given-names></name></person-group>
<article-title>Antischistosomal drugs: Past, present &#x02026; and future?</article-title>
<source>Pharmacol. Ther.</source>
<year>1995</year>
<volume>68</volume>
<fpage>35</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1016/0163-7258(95)00026-7</pub-id>
<pub-id pub-id-type="pmid">8604437</pub-id></element-citation></ref><ref id="B176-molecules-22-00058"><label>176.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Utzinger</surname><given-names>J.</given-names></name><name><surname>Shuhua</surname><given-names>X.</given-names></name><name><surname>N&#x02019;Goran</surname><given-names>E.K.</given-names></name><name><surname>Bergquist</surname><given-names>R.</given-names></name><name><surname>Tanner</surname><given-names>M.</given-names></name></person-group>
<article-title>The potential of artemether for the control of schistosomiasis</article-title>
<source>Int. J. Parasitol.</source>
<year>2001</year>
<volume>31</volume>
<fpage>1549</fpage>
<lpage>1562</lpage>
<pub-id pub-id-type="doi">10.1016/S0020-7519(01)00297-1</pub-id>
<pub-id pub-id-type="pmid">11730781</pub-id></element-citation></ref><ref id="B177-molecules-22-00058"><label>177.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiao</surname><given-names>S.H.</given-names></name><name><surname>Catto</surname><given-names>B.A.</given-names></name><name><surname>Webster</surname><given-names>L.T.</given-names></name></person-group>
<article-title>Effects of praziquantel on different developmental stages of <italic>Schistosoma</italic> mansoni in vitro and in vivo</article-title>
<source>J. Infect. Dis.</source>
<year>1985</year>
<volume>151</volume>
<fpage>1130</fpage>
<lpage>1137</lpage>
<pub-id pub-id-type="doi">10.1093/infdis/151.6.1130</pub-id>
<?supplied-pmid 3998507?><pub-id pub-id-type="pmid">3998507</pub-id></element-citation></ref><ref id="B178-molecules-22-00058"><label>178.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mostafa</surname><given-names>O.M.S.</given-names></name><name><surname>Eid</surname><given-names>R.A.</given-names></name><name><surname>Adly</surname><given-names>M.A.</given-names></name></person-group>
<article-title>Antischistosomal activity of ginger (Zingiber <italic>Officinale</italic>) against Schistosoma mansoni harbored in C57 mice</article-title>
<source>Parasitol. Res.</source>
<year>2011</year>
<volume>109</volume>
<fpage>395</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="doi">10.1007/s00436-011-2267-x</pub-id>
<?supplied-pmid 21327992?><pub-id pub-id-type="pmid">21327992</pub-id></element-citation></ref><ref id="B179-molecules-22-00058"><label>179.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Coles</surname><given-names>G.C.</given-names></name><name><surname>Bruce</surname><given-names>J.I.</given-names></name><name><surname>Kinoti</surname><given-names>G.K.</given-names></name><name><surname>Mutahi</surname><given-names>W.T.</given-names></name><name><surname>Dias</surname><given-names>L.C.S.</given-names></name><name><surname>Rocha</surname><given-names>R.S.</given-names></name><name><surname>Katz</surname><given-names>N.</given-names></name></person-group>
<article-title>The potential for drug resistance in schistosomiasis</article-title>
<source>Parasitol. Today</source>
<year>1987</year>
<volume>3</volume>
<fpage>349</fpage>
<lpage>350</lpage>
<pub-id pub-id-type="doi">10.1016/0169-4758(87)90121-9</pub-id>
<pub-id pub-id-type="pmid">15462884</pub-id></element-citation></ref><ref id="B180-molecules-22-00058"><label>180.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Danso-Appiah</surname><given-names>A.</given-names></name><name><surname>De Vlas</surname><given-names>S.J.</given-names></name></person-group>
<article-title>Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal</article-title>
<source>Trends Parasitol.</source>
<year>2002</year>
<volume>18</volume>
<fpage>125</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="doi">10.1016/S1471-4922(01)02209-7</pub-id>
<pub-id pub-id-type="pmid">11854090</pub-id></element-citation></ref><ref id="B181-molecules-22-00058"><label>181.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Faghiri</surname><given-names>Z.</given-names></name><name><surname>Camargo</surname><given-names>S.M.R.</given-names></name><name><surname>Huggel</surname><given-names>K.</given-names></name><name><surname>Forster</surname><given-names>I.C.</given-names></name><name><surname>Ndegwa</surname><given-names>D.</given-names></name><name><surname>Verrey</surname><given-names>F.</given-names></name><name><surname>Skelly</surname><given-names>P.J.</given-names></name></person-group>
<article-title>The tegument of the human parasitic worm Schistosoma mansoni as an excretory organ: The surface aquaporin SmAQP is a lactate transporter</article-title>
<source>PLoS ONE</source>
<year>2010</year>
<volume>5</volume>
<pub-id pub-id-type="doi">10.1371/journal.pone.0010451</pub-id>
<?supplied-pmid 20454673?><pub-id pub-id-type="pmid">20454673</pub-id></element-citation></ref><ref id="B182-molecules-22-00058"><label>182.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Hellemond</surname><given-names>J.J.</given-names></name><name><surname>Retra</surname><given-names>K.</given-names></name><name><surname>Brouwers</surname><given-names>J.F.H.M.</given-names></name><name><surname>van Balkom</surname><given-names>B.W.M.</given-names></name><name><surname>Yazdanbakhsh</surname><given-names>M.</given-names></name><name><surname>Shoemaker</surname><given-names>C.B.</given-names></name><name><surname>Tielens</surname><given-names>A.G.M.</given-names></name></person-group>
<article-title>Functions of the tegument of schistosomes: Clues from the proteome and lipidome</article-title>
<source>Int. J. Parasitol.</source>
<year>2006</year>
<volume>36</volume>
<fpage>691</fpage>
<lpage>699</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijpara.2006.01.007</pub-id>
<?supplied-pmid 16545817?><pub-id pub-id-type="pmid">16545817</pub-id></element-citation></ref><ref id="B183-molecules-22-00058"><label>183.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guimar&#x000e3;es</surname><given-names>M.A.</given-names></name><name><surname>de Oliveira</surname><given-names>R.N.</given-names></name><name><surname>V&#x000e9;ras</surname><given-names>L.M.C.</given-names></name><name><surname>Lima</surname><given-names>D.F.</given-names></name><name><surname>Campelo</surname><given-names>Y.D.M.</given-names></name><name><surname>Campos</surname><given-names>S.A.</given-names></name><name><surname>Kuckelhaus</surname><given-names>S.A.S.</given-names></name><name><surname>Pinto</surname><given-names>P.L.S.</given-names></name><name><surname>Eaton</surname><given-names>P.</given-names></name><name><surname>Mafud</surname><given-names>A.C.</given-names></name><etal/></person-group>
<article-title>Anthelmintic Activity In Vivo of Epiisopiloturine against Juvenile and Adult Worms of Schistosoma mansoni</article-title>
<source>PLoS Negl. Trop. Dis.</source>
<year>2015</year>
<volume>9</volume>
<elocation-id>e0003656</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0003656</pub-id>
<?supplied-pmid 25816129?><pub-id pub-id-type="pmid">25816129</pub-id></element-citation></ref><ref id="B184-molecules-22-00058"><label>184.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>A.</given-names></name><name><surname>Dutta</surname><given-names>C.P.</given-names></name></person-group>
<article-title>Alkaloids of Piper longum Linn. I. Structure and synthesis of piperlongumine and piperlonguminine</article-title>
<source>Tetrahedron</source>
<year>1967</year>
<volume>23</volume>
<fpage>1769</fpage>
<lpage>1781</lpage>
<pub-id pub-id-type="doi">10.1016/S0040-4020(01)82575-8</pub-id>
<pub-id pub-id-type="pmid">6047519</pub-id></element-citation></ref><ref id="B185-molecules-22-00058"><label>185.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bezerra</surname><given-names>D.P.</given-names></name><name><surname>Pessoa</surname><given-names>C.</given-names></name><name><surname>De Moraes</surname><given-names>M.O.</given-names></name><name><surname>Saker-Neto</surname><given-names>N.</given-names></name><name><surname>Silveira</surname><given-names>E.R.</given-names></name><name><surname>Costa-Lotufo</surname><given-names>L.V.</given-names></name></person-group>
<article-title>Overview of the therapeutic potential of piplartine (piperlongumine)</article-title>
<source>Eur. J. Pharm. Sci.</source>
<year>2013</year>
<volume>48</volume>
<fpage>453</fpage>
<lpage>463</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejps.2012.12.003</pub-id>
<?supplied-pmid 23238172?><pub-id pub-id-type="pmid">23238172</pub-id></element-citation></ref><ref id="B186-molecules-22-00058"><label>186.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Moraes</surname><given-names>J.</given-names></name><name><surname>Nascimento</surname><given-names>C.</given-names></name><name><surname>Yamaguchi</surname><given-names>L.F.</given-names></name><name><surname>Kato</surname><given-names>M.J.</given-names></name><name><surname>Nakano</surname><given-names>E.</given-names></name></person-group>
<article-title>Schistosoma mansoni: In vitro schistosomicidal activity and tegumental alterations induced by piplartine on schistosomula</article-title>
<source>Exp. Parasitol.</source>
<year>2012</year>
<volume>132</volume>
<fpage>222</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1016/j.exppara.2012.07.004</pub-id>
<?supplied-pmid 22796749?><pub-id pub-id-type="pmid">22796749</pub-id></element-citation></ref><ref id="B187-molecules-22-00058"><label>187.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Moraes</surname><given-names>J.</given-names></name><name><surname>Nascimento</surname><given-names>C.</given-names></name><name><surname>Lopes</surname><given-names>P.O.M.V.</given-names></name><name><surname>Nakano</surname><given-names>E.</given-names></name><name><surname>Yamaguchi</surname><given-names>L.F.</given-names></name><name><surname>Kato</surname><given-names>M.J.</given-names></name><name><surname>Kawano</surname><given-names>T.</given-names></name></person-group>
<article-title>Schistosoma mansoni: In vitro schistosomicidal activity of piplartine</article-title>
<source>Exp. Parasitol.</source>
<year>2011</year>
<volume>127</volume>
<fpage>357</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="doi">10.1016/j.exppara.2010.08.021</pub-id>
<?supplied-pmid 20832410?><pub-id pub-id-type="pmid">20832410</pub-id></element-citation></ref><ref id="B188-molecules-22-00058"><label>188.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Moraes</surname><given-names>J.</given-names></name><name><surname>Keiser</surname><given-names>J.</given-names></name><name><surname>Ingram</surname><given-names>K.</given-names></name><name><surname>Nascimento</surname><given-names>C.</given-names></name><name><surname>Yamaguchi</surname><given-names>L.F.</given-names></name><name><surname>Bittencourt</surname><given-names>C.R.</given-names></name><name><surname>Bemquerer</surname><given-names>M.P.</given-names></name><name><surname>Leite</surname><given-names>J.R.</given-names></name><name><surname>Kato</surname><given-names>M.J.</given-names></name><name><surname>Nakano</surname><given-names>E.</given-names></name></person-group>
<article-title>In vitro synergistic interaction between amide piplartine and antimicrobial peptide dermaseptin against Schistosoma mansoni schistosomula and adult worms</article-title>
<source>Curr. Med. Chem.</source>
<year>2013</year>
<volume>20</volume>
<fpage>301</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="doi">10.2174/092986713804806694</pub-id>
<?supplied-pmid 23061657?><pub-id pub-id-type="pmid">23061657</pub-id></element-citation></ref><ref id="B189-molecules-22-00058"><label>189.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bezerra</surname><given-names>D.P.</given-names></name><name><surname>Moura</surname><given-names>D.J.</given-names></name><name><surname>Rosa</surname><given-names>R.M.</given-names></name><name><surname>de Vasconcellos</surname><given-names>M.C.</given-names></name><name><surname>Silva</surname><given-names>A.C.R.</given-names></name><name><surname>de Moraes</surname><given-names>M.O.</given-names></name><name><surname>Silveira</surname><given-names>E.R.</given-names></name><name><surname>Lima</surname><given-names>M.A.S.</given-names></name><name><surname>Henriques</surname><given-names>J.A.P.</given-names></name><name><surname>Costa-Lotufo</surname><given-names>L.V.</given-names></name><etal/></person-group>
<article-title>Evaluation of the genotoxicity of piplartine, an alkamide of Piper tuberculatum, in yeast and mammalian V79 cells</article-title>
<source>Mutat. Res. Genet. Toxicol. Environ. Mutagen.</source>
<year>2008</year>
<volume>652</volume>
<fpage>164</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1016/j.mrgentox.2008.02.001</pub-id>
<?supplied-pmid 18372210?><pub-id pub-id-type="pmid">18372210</pub-id></element-citation></ref><ref id="B190-molecules-22-00058"><label>190.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bezerra</surname><given-names>D.P.</given-names></name><name><surname>Milit&#x000e3;o</surname><given-names>G.C.G.</given-names></name><name><surname>de Castro</surname><given-names>F.O.</given-names></name><name><surname>Pessoa</surname><given-names>C.</given-names></name><name><surname>de Moraes</surname><given-names>M.O.</given-names></name><name><surname>Silveira</surname><given-names>E.R.</given-names></name><name><surname>Lima</surname><given-names>M.A.S.</given-names></name><name><surname>Elmiro</surname><given-names>F.J.M.</given-names></name><name><surname>Costa-Lotufo</surname><given-names>L.V.</given-names></name></person-group>
<article-title>Piplartine induces inhibition of leukemia cell proliferation triggering both apoptosis and necrosis pathways</article-title>
<source>Toxicol. In Vitro</source>
<year>2007</year>
<volume>21</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.tiv.2006.07.007</pub-id>
<?supplied-pmid 16971088?><pub-id pub-id-type="pmid">16971088</pub-id></element-citation></ref><ref id="B191-molecules-22-00058"><label>191.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raj</surname><given-names>L.</given-names></name><name><surname>Ide</surname><given-names>T.</given-names></name><name><surname>Gurkar</surname><given-names>A.U.</given-names></name><name><surname>Foley</surname><given-names>M.</given-names></name><name><surname>Schenone</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Tolliday</surname><given-names>N.J.</given-names></name><name><surname>Golub</surname><given-names>T.R.</given-names></name><name><surname>Carr</surname><given-names>S.A.</given-names></name><name><surname>Shamji</surname><given-names>A.F.</given-names></name><etal/></person-group>
<article-title>Selective killing of cancer cells by a small molecule targeting the stress response to ROS</article-title>
<source>Nature</source>
<year>2011</year>
<volume>475</volume>
<fpage>231</fpage>
<lpage>234</lpage>
<pub-id pub-id-type="doi">10.1038/nature10167</pub-id>
<?supplied-pmid 21753854?><pub-id pub-id-type="pmid">21753854</pub-id></element-citation></ref><ref id="B192-molecules-22-00058"><label>192.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schaab</surname><given-names>E.H.</given-names></name><name><surname>Crotti</surname><given-names>A.E.M.</given-names></name><name><surname>Iamamoto</surname><given-names>Y.</given-names></name><name><surname>Kato</surname><given-names>M.J.</given-names></name><name><surname>Lotufo</surname><given-names>L.V.C.</given-names></name><name><surname>Lopes</surname><given-names>N.P.</given-names></name></person-group>
<article-title>Biomimetic oxidation of piperine and piplartine catalyzed by iron(III) and manganese(III) porphyrins</article-title>
<source>Biol. Pharm. Bull.</source>
<year>2010</year>
<volume>33</volume>
<fpage>912</fpage>
<lpage>916</lpage>
<pub-id pub-id-type="doi">10.1248/bpb.33.912</pub-id>
<?supplied-pmid 20460777?><pub-id pub-id-type="pmid">20460777</pub-id></element-citation></ref><ref id="B193-molecules-22-00058"><label>193.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanderson</surname><given-names>L.</given-names></name><name><surname>Bartlett</surname><given-names>A.</given-names></name><name><surname>Whitfield</surname><given-names>P.J.</given-names></name></person-group>
<article-title>In vitro and in vivo studies on the bioactivity of a ginger (Zingiber <italic>Officinale</italic>) extract towards adult schistosomes and their egg production</article-title>
<source>J. Helminthol.</source>
<year>2002</year>
<volume>76</volume>
<fpage>241</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="doi">10.1079/JOH2002116</pub-id>
<?supplied-pmid 12363378?><pub-id pub-id-type="pmid">12363378</pub-id></element-citation></ref><ref id="B194-molecules-22-00058"><label>194.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adewunmi</surname><given-names>C.O.</given-names></name><name><surname>Oguntimein</surname><given-names>B.O.</given-names></name><name><surname>Furu</surname><given-names>P.</given-names></name></person-group>
<article-title>Molluscicidal and antischistosomal activities of Zingiber <italic>Officinale</italic></article-title>
<source>Planta Med.</source>
<year>1990</year>
<volume>56</volume>
<fpage>374</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="doi">10.1055/s-2006-960986</pub-id>
<?supplied-pmid 2236291?><pub-id pub-id-type="pmid">2236291</pub-id></element-citation></ref><ref id="B195-molecules-22-00058"><label>195.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Moraes</surname><given-names>J.</given-names></name><name><surname>de Oliveira</surname><given-names>R.N.</given-names></name><name><surname>Costa</surname><given-names>J.P.</given-names></name><name><surname>Junior</surname><given-names>A.L.G.</given-names></name><name><surname>de Sousa</surname><given-names>D.P.</given-names></name><name><surname>Freitas</surname><given-names>R.M.</given-names></name><name><surname>Allegretti</surname><given-names>S.M.</given-names></name><name><surname>Pinto</surname><given-names>P.L.S.</given-names></name></person-group>
<article-title>Phytol, a Diterpene Alcohol from Chlorophyll, as a Drug against Neglected Tropical Disease Schistosomiasis Mansoni</article-title>
<source>PLoS Negl. Trop. Dis.</source>
<year>2014</year>
<volume>8</volume>
<elocation-id>51</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0002617</pub-id>
<?supplied-pmid 24392173?><pub-id pub-id-type="pmid">24392173</pub-id></element-citation></ref><ref id="B196-molecules-22-00058"><label>196.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Newman</surname><given-names>D.J.</given-names></name><name><surname>Cragg</surname><given-names>G.M.</given-names></name></person-group>
<article-title>Natural products as sources of new drugs over the 30 years from 1981 to 2010</article-title>
<source>J. Nat. Prod.</source>
<year>2012</year>
<volume>75</volume>
<fpage>311</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="doi">10.1021/np200906s</pub-id>
<?supplied-pmid 22316239?><pub-id pub-id-type="pmid">22316239</pub-id></element-citation></ref><ref id="B197-molecules-22-00058"><label>197.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>R.R.</given-names></name><name><surname>Ghosh</surname><given-names>S.K.</given-names></name></person-group>
<article-title>Phytol-derived novel isoprenoid immunostimulants</article-title>
<source>Front. Immunol.</source>
<year>2012</year>
<volume>3</volume>
<fpage>49</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2012.00049</pub-id>
<?supplied-pmid 22566931?><pub-id pub-id-type="pmid">22566931</pub-id></element-citation></ref><ref id="B198-molecules-22-00058"><label>198.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vetter</surname><given-names>W.</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>M.</given-names></name><name><surname>Lehnert</surname><given-names>K.</given-names></name></person-group>
<article-title>Differentiation of refined and virgin edible oils by means of the trans&#x02014;And cis-phytol isomer distribution</article-title>
<source>J. Agric. Food Chem.</source>
<year>2012</year>
<volume>60</volume>
<fpage>6103</fpage>
<lpage>6107</lpage>
<pub-id pub-id-type="doi">10.1021/jf301373k</pub-id>
<?supplied-pmid 22642869?><pub-id pub-id-type="pmid">22642869</pub-id></element-citation></ref><ref id="B199-molecules-22-00058"><label>199.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hatcher</surname><given-names>H.</given-names></name><name><surname>Planalp</surname><given-names>R.</given-names></name><name><surname>Cho</surname><given-names>J.</given-names></name><name><surname>Torti</surname><given-names>F.M.</given-names></name><name><surname>Torti</surname><given-names>S.V.</given-names></name></person-group>
<article-title>Curcumin: From ancient medicine to current clinical trials</article-title>
<source>Cell. Mol. Life Sci.</source>
<year>2008</year>
<volume>65</volume>
<fpage>1631</fpage>
<lpage>1652</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-008-7452-4</pub-id>
<?supplied-pmid 18324353?><pub-id pub-id-type="pmid">18324353</pub-id></element-citation></ref><ref id="B200-molecules-22-00058"><label>200.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>S.-S.</given-names></name><name><surname>Keum</surname><given-names>Y.-S.</given-names></name><name><surname>Seo</surname><given-names>H.-J.</given-names></name><name><surname>Surh</surname><given-names>Y.-J.</given-names></name></person-group>
<article-title>Curcumin suppresses activation of NF-&#x003ba;B and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells</article-title>
<source>J. Biochem. Mol. Biol.</source>
<year>2002</year>
<volume>35</volume>
<fpage>337</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="doi">10.5483/BMBRep.2002.35.3.337</pub-id>
<?supplied-pmid 12297018?><pub-id pub-id-type="pmid">12297018</pub-id></element-citation></ref><ref id="B201-molecules-22-00058"><label>201.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Magalh&#x000e3;es</surname><given-names>L.G.</given-names></name><name><surname>Machado</surname><given-names>C.B.</given-names></name><name><surname>Morais</surname><given-names>E.R.</given-names></name><name><surname>Bueno De Carvalho Moreira</surname><given-names>&#x000c9;.</given-names></name><name><surname>Soares</surname><given-names>C.S.</given-names></name><name><surname>da Silva</surname><given-names>S.H.</given-names></name><name><surname>da Silva Filho</surname><given-names>A.A.</given-names></name><name><surname>Rodrigues</surname><given-names>V.</given-names></name></person-group>
<article-title>In vitro schistosomicidal activity of curcumin against Schistosoma mansoni adult worms</article-title>
<source>Parasitol. Res.</source>
<year>2009</year>
<volume>104</volume>
<fpage>1197</fpage>
<lpage>1201</lpage>
<pub-id pub-id-type="doi">10.1007/s00436-008-1311-y</pub-id>
<?supplied-pmid 19096877?><pub-id pub-id-type="pmid">19096877</pub-id></element-citation></ref><ref id="B202-molecules-22-00058"><label>202.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Na</surname><given-names>M.</given-names></name><name><surname>Jang</surname><given-names>J.</given-names></name><name><surname>Min</surname><given-names>B.S.</given-names></name><name><surname>Lee</surname><given-names>S.J.</given-names></name><name><surname>Lee</surname><given-names>M.S.</given-names></name><name><surname>Kim</surname><given-names>B.Y.</given-names></name><name><surname>Oh</surname><given-names>W.K.</given-names></name><name><surname>Ahn</surname><given-names>J.S.</given-names></name></person-group>
<article-title>Fatty acid synthase inhibitory activity of acylphloroglucinols isolated from Dryopteris crassirhizoma</article-title>
<source>Bioorg. Med. Chem. Lett.</source>
<year>2006</year>
<volume>16</volume>
<fpage>4738</fpage>
<lpage>4742</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmcl.2006.07.018</pub-id>
<?supplied-pmid 16870425?><pub-id pub-id-type="pmid">16870425</pub-id></element-citation></ref><ref id="B203-molecules-22-00058"><label>203.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.-M.</given-names></name><name><surname>Na</surname><given-names>M.-K.</given-names></name><name><surname>An</surname><given-names>R.-B.</given-names></name><name><surname>Min</surname><given-names>B.-S.</given-names></name><name><surname>Lee</surname><given-names>H.-K.</given-names></name></person-group>
<article-title>Antioxidant activity of two phloroglucinol derivatives from Dryopteris crassirhizoma</article-title>
<source>Biol. Pharm. Bull.</source>
<year>2003</year>
<volume>26</volume>
<fpage>1354</fpage>
<lpage>1356</lpage>
<pub-id pub-id-type="doi">10.1248/bpb.26.1354</pub-id>
<?supplied-pmid 12951487?><pub-id pub-id-type="pmid">12951487</pub-id></element-citation></ref><ref id="B204-molecules-22-00058"><label>204.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kapadia</surname><given-names>G.J.</given-names></name><name><surname>Tokuda</surname><given-names>H.</given-names></name><name><surname>Konoshima</surname><given-names>T.</given-names></name><name><surname>Takasaki</surname><given-names>M.</given-names></name><name><surname>Takayasu</surname><given-names>J.</given-names></name><name><surname>Nishino</surname><given-names>H.</given-names></name></person-group>
<article-title>Anti-tumor promoting activity of Dryopteris phlorophenone derivatives</article-title>
<source>Cancer Lett.</source>
<year>1996</year>
<volume>105</volume>
<fpage>161</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1016/0304-3835(96)04275-9</pub-id>
<pub-id pub-id-type="pmid">8697439</pub-id></element-citation></ref><ref id="B205-molecules-22-00058"><label>205.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Magalh&#x000e3;es</surname><given-names>L.G.</given-names></name><name><surname>Kapadia</surname><given-names>G.J.</given-names></name><name><surname>da Silva Tonuci</surname><given-names>L.R.</given-names></name><name><surname>Caixeta</surname><given-names>S.C.</given-names></name><name><surname>Parreira</surname><given-names>N.A.</given-names></name><name><surname>Rodrigues</surname><given-names>V.</given-names></name><name><surname>da Silva Filho</surname><given-names>A.A.</given-names></name></person-group>
<article-title>In vitro schistosomicidal effects of some phloroglucinol derivatives from Dryopteris species against Schistosoma mansoni adult worms</article-title>
<source>Parasitol. Res.</source>
<year>2010</year>
<volume>106</volume>
<fpage>395</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="doi">10.1007/s00436-009-1674-8</pub-id>
<?supplied-pmid 19898869?><pub-id pub-id-type="pmid">19898869</pub-id></element-citation></ref><ref id="B206-molecules-22-00058"><label>206.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaur</surname><given-names>K.</given-names></name><name><surname>Jain</surname><given-names>M.</given-names></name><name><surname>Reddy</surname><given-names>R.P.</given-names></name><name><surname>Jain</surname><given-names>R.</given-names></name></person-group>
<article-title>Quinolines and structurally related heterocycles as antimalarials</article-title>
<source>Eur. J. Med. Chem.</source>
<year>2010</year>
<volume>45</volume>
<fpage>3245</fpage>
<lpage>3264</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejmech.2010.04.011</pub-id>
<?supplied-pmid 20466465?><pub-id pub-id-type="pmid">20466465</pub-id></element-citation></ref><ref id="B207-molecules-22-00058"><label>207.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ridley</surname><given-names>R.G.</given-names></name></person-group>
<article-title>Medical need, scientific opportunity and the drive for antimalarial drugs</article-title>
<source>Nature</source>
<year>2002</year>
<volume>415</volume>
<fpage>686</fpage>
<lpage>693</lpage>
<pub-id pub-id-type="doi">10.1038/415686a</pub-id>
<?supplied-pmid 11832957?><pub-id pub-id-type="pmid">11832957</pub-id></element-citation></ref><ref id="B208-molecules-22-00058"><label>208.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J.</given-names></name><name><surname>Chollet</surname><given-names>J.</given-names></name><name><surname>Xiao</surname><given-names>S.H.</given-names></name><name><surname>Mei</surname><given-names>J.Y.</given-names></name><name><surname>Jiao</surname><given-names>P.Y.</given-names></name><name><surname>Utzinger</surname><given-names>J.</given-names></name><name><surname>Tanner</surname><given-names>M.</given-names></name></person-group>
<article-title>Mefloquine&#x02014;An aminoalcohol with promising antischistosomal properties in mice</article-title>
<source>PLoS Negl. Trop. Dis.</source>
<year>2009</year>
<volume>3</volume>
<elocation-id>e305</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0000350</pub-id>
<?supplied-pmid 19125172?><pub-id pub-id-type="pmid">19125172</pub-id></element-citation></ref><ref id="B209-molecules-22-00058"><label>209.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ingram</surname><given-names>K.</given-names></name><name><surname>Ellis</surname><given-names>W.</given-names></name><name><surname>Keiser</surname><given-names>J.</given-names></name></person-group>
<article-title>Antischistosomal activities of mefloquine-related arylmethanols</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2012</year>
<volume>56</volume>
<fpage>3207</fpage>
<lpage>3215</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.06177-11</pub-id>
<?supplied-pmid 22470113?><pub-id pub-id-type="pmid">22470113</pub-id></element-citation></ref><ref id="B210-molecules-22-00058"><label>210.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manneck</surname><given-names>T.</given-names></name><name><surname>Haggenm&#x000fc;ller</surname><given-names>Y.</given-names></name><name><surname>Keiser</surname><given-names>J.</given-names></name></person-group>
<article-title>Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni</article-title>
<source>Parasitology</source>
<year>2010</year>
<volume>137</volume>
<fpage>85</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="doi">10.1017/S0031182009990965</pub-id>
<?supplied-pmid 19814844?><pub-id pub-id-type="pmid">19814844</pub-id></element-citation></ref><ref id="B211-molecules-22-00058"><label>211.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holtfreter</surname><given-names>M.C.</given-names></name><name><surname>Loebermann</surname><given-names>M.</given-names></name><name><surname>Klammt</surname><given-names>S.</given-names></name><name><surname>Sombetzki</surname><given-names>M.</given-names></name><name><surname>Bodammer</surname><given-names>P.</given-names></name><name><surname>Riebold</surname><given-names>D.</given-names></name><name><surname>Kinzelbach</surname><given-names>R.</given-names></name><name><surname>Reisinger</surname><given-names>E.C.</given-names></name></person-group>
<article-title>Schistosoma mansoni: Schistosomicidal effect of mefloquine and primaquine in vitro</article-title>
<source>Exp. Parasitol.</source>
<year>2011</year>
<volume>127</volume>
<fpage>270</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="doi">10.1016/j.exppara.2010.08.008</pub-id>
<?supplied-pmid 20807530?><pub-id pub-id-type="pmid">20807530</pub-id></element-citation></ref><ref id="B212-molecules-22-00058"><label>212.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J.</given-names></name><name><surname>Manneck</surname><given-names>T.</given-names></name><name><surname>Vargas</surname><given-names>M.</given-names></name></person-group>
<article-title>Interactions of mefloquine with praziquantel in the <italic>Schistosoma</italic> mansoni mouse model and in vitro</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>2011</year>
<volume>66</volume>
<fpage>1791</fpage>
<lpage>1797</lpage>
<pub-id pub-id-type="doi">10.1093/jac/dkr178</pub-id>
<?supplied-pmid 21602552?><pub-id pub-id-type="pmid">21602552</pub-id></element-citation></ref><ref id="B213-molecules-22-00058"><label>213.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiao</surname><given-names>S.H.</given-names></name><name><surname>Mei</surname><given-names>J.Y.</given-names></name><name><surname>Jiao</surname><given-names>P.Y.</given-names></name></person-group>
<article-title>Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum</article-title>
<source>Parasitol. Res.</source>
<year>2011</year>
<volume>108</volume>
<fpage>399</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="doi">10.1007/s00436-010-2080-y</pub-id>
<?supplied-pmid 20922425?><pub-id pub-id-type="pmid">20922425</pub-id></element-citation></ref><ref id="B214-molecules-22-00058"><label>214.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kamchonwongpaisan</surname><given-names>S.</given-names></name><name><surname>Meshnick</surname><given-names>S.R.</given-names></name></person-group>
<article-title>The mode of action of the antimalarial artemisinin and its derivatives</article-title>
<source>Gen. Pharmacol.</source>
<year>1996</year>
<volume>27</volume>
<fpage>587</fpage>
<lpage>592</lpage>
<pub-id pub-id-type="doi">10.1016/0306-3623(95)02047-0</pub-id>
<pub-id pub-id-type="pmid">8853288</pub-id></element-citation></ref><ref id="B215-molecules-22-00058"><label>215.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meshnick</surname><given-names>S.R.</given-names></name></person-group>
<article-title>Artemisinin: Mechanisms of action, resistance and toxicity</article-title>
<source>Int. J. Parasitol.</source>
<year>2002</year>
<volume>32</volume>
<fpage>1655</fpage>
<lpage>1660</lpage>
<pub-id pub-id-type="doi">10.1016/S0020-7519(02)00194-7</pub-id>
<pub-id pub-id-type="pmid">12435450</pub-id></element-citation></ref><ref id="B216-molecules-22-00058"><label>216.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klayman</surname><given-names>D.L.</given-names></name></person-group>
<article-title>Qinghaosu (artemisinin): An antimalarial drug from China</article-title>
<source>Science</source>
<year>1985</year>
<volume>228</volume>
<fpage>1049</fpage>
<lpage>1055</lpage>
<pub-id pub-id-type="doi">10.1126/science.3887571</pub-id>
<?supplied-pmid 3887571?><pub-id pub-id-type="pmid">3887571</pub-id></element-citation></ref><ref id="B217-molecules-22-00058"><label>217.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Le</surname><given-names>W.J.</given-names></name><name><surname>You</surname><given-names>J.Q.</given-names></name><name><surname>Yang</surname><given-names>Y.Q.</given-names></name><name><surname>Mei</surname><given-names>J.Y.</given-names></name><name><surname>Guo</surname><given-names>H.F.</given-names></name><name><surname>Yang</surname><given-names>H.Z.</given-names></name><name><surname>Zhang</surname><given-names>C.W.</given-names></name></person-group>
<article-title>Studies on the efficacy of artemether in experimental schistosomiasis (author&#x02019;s transl)</article-title>
<source>Acta Pharm. Sin.</source>
<year>1982</year>
<volume>17</volume>
<fpage>187</fpage>
<lpage>193</lpage>
</element-citation></ref><ref id="B218-molecules-22-00058"><label>218.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yin</surname><given-names>J.W.</given-names></name><name><surname>Yang</surname><given-names>Y.Q.</given-names></name><name><surname>Xiao</surname><given-names>S.H.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>H.J.</given-names></name></person-group>
<article-title>[Comparative studies on histological and histochemical alterations of Schistosoma japonicum induced by arteether and artemether]</article-title>
<source>Zhongguo Yao Li Xue Bao</source>
<year>1991</year>
<volume>12</volume>
<fpage>478</fpage>
<lpage>480</lpage>
<?supplied-pmid 1819908?><pub-id pub-id-type="pmid">1819908</pub-id></element-citation></ref><ref id="B219-molecules-22-00058"><label>219.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yue</surname><given-names>W.J.</given-names></name><name><surname>You</surname><given-names>J.Q.</given-names></name><name><surname>Mei</surname><given-names>J.Y.</given-names></name></person-group>
<article-title>[Effect of artemether on the tegumental surface antigen of Schistosoma japonicum]</article-title>
<source>Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi</source>
<year>1984</year>
<volume>2</volume>
<fpage>167</fpage>
<lpage>169</lpage>
<?supplied-pmid 6509742?><pub-id pub-id-type="pmid">6509742</pub-id></element-citation></ref><ref id="B220-molecules-22-00058"><label>220.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>L.J.</given-names></name><name><surname>Yang</surname><given-names>H.Z.</given-names></name><name><surname>Yang</surname><given-names>Y.Q.</given-names></name></person-group>
<article-title>Histological and histochemical changes of Schistosoma japonicum and host liver caused by artemether</article-title>
<source>Acta Pharm. Sin.</source>
<year>1983</year>
<volume>18</volume>
<fpage>7</fpage>
<lpage>14</lpage>
</element-citation></ref><ref id="B221-molecules-22-00058"><label>221.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Le</surname><given-names>W.J.</given-names></name><name><surname>You</surname><given-names>J.Q.</given-names></name><name><surname>Mei</surname><given-names>J.Y.</given-names></name></person-group>
<article-title>Chemotherapeutic effect of artesunate in experimental schistosomiasis</article-title>
<source>Acta Pharm. Sin.</source>
<year>1983</year>
<volume>18</volume>
<fpage>619</fpage>
<lpage>621</lpage>
</element-citation></ref><ref id="B222-molecules-22-00058"><label>222.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiao</surname><given-names>S.H.</given-names></name><name><surname>Yin</surname><given-names>J.W.</given-names></name><name><surname>Mei</surname><given-names>J.Y.</given-names></name><name><surname>You</surname><given-names>J.Q.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>H.J.</given-names></name></person-group>
<article-title>Effect of arteether on Schistosoma japonicum</article-title>
<source>Acta Pharm. Sin.</source>
<year>1992</year>
<volume>27</volume>
<fpage>161</fpage>
<lpage>165</lpage>
</element-citation></ref><ref id="B223-molecules-22-00058"><label>223.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abdel Aziz</surname><given-names>S.S.</given-names></name><name><surname>El-Badawy</surname><given-names>N.M.</given-names></name></person-group>
<article-title>Experimental trials of an artemisinin derivative in treatment of Schistosoma mansoni infected mice</article-title>
<source>J. Egypt. Soc. Parasitol.</source>
<year>2000</year>
<volume>30</volume>
<fpage>295</fpage>
<lpage>303</lpage>
<?supplied-pmid 10786040?><pub-id pub-id-type="pmid">10786040</pub-id></element-citation></ref><ref id="B224-molecules-22-00058"><label>224.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shuhua</surname><given-names>X.</given-names></name><name><surname>Chollet</surname><given-names>J.</given-names></name><name><surname>Weiss</surname><given-names>N.A.</given-names></name><name><surname>Bergquist</surname><given-names>R.N.</given-names></name><name><surname>Tanner</surname><given-names>M.</given-names></name></person-group>
<article-title>Preventive effect of artemether in experimental animals infected with Schistosoma mansoni</article-title>
<source>Parasitol. Int.</source>
<year>2000</year>
<volume>49</volume>
<fpage>19</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1016/S1383-5769(00)00028-3</pub-id>
<pub-id pub-id-type="pmid">10729713</pub-id></element-citation></ref><ref id="B225-molecules-22-00058"><label>225.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiao</surname><given-names>S.H.</given-names></name><name><surname>You</surname><given-names>J.Q.</given-names></name><name><surname>Yang</surname><given-names>Y.Q.</given-names></name><name><surname>Wang</surname><given-names>C.Z.</given-names></name></person-group>
<article-title>Experimental studies on early treatment of schistosomal infection with artemether</article-title>
<source>Southeast Asian J. Trop. Med. Public Health</source>
<year>1995</year>
<volume>26</volume>
<fpage>306</fpage>
<lpage>318</lpage>
<?supplied-pmid 8629066?><pub-id pub-id-type="pmid">8629066</pub-id></element-citation></ref><ref id="B226-molecules-22-00058"><label>226.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiao</surname><given-names>S.H.</given-names></name><name><surname>You</surname><given-names>J.Q.</given-names></name><name><surname>Mei</surname><given-names>J.Y.</given-names></name><name><surname>Jiao</surname><given-names>P.Y.</given-names></name><name><surname>Guo</surname><given-names>H.F.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name></person-group>
<article-title>Preventive effect of artemether in rabbits infected with Schistosoma japonicum cercariae</article-title>
<source>Zhongguo Yao Li Xue Bao</source>
<year>1998</year>
<volume>19</volume>
<fpage>63</fpage>
<lpage>66</lpage>
<?supplied-pmid 10375762?><pub-id pub-id-type="pmid">10375762</pub-id></element-citation></ref><ref id="B227-molecules-22-00058"><label>227.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>D.</given-names></name><name><surname>Vercruysse</surname><given-names>J.</given-names></name><name><surname>Verl&#x000e9;</surname><given-names>P.</given-names></name><name><surname>Niasse</surname><given-names>F.</given-names></name><name><surname>Kongs</surname><given-names>A.</given-names></name><name><surname>Diop</surname><given-names>M.</given-names></name></person-group>
<article-title>Efficacy of artesunate against Schistosoma mansoni infections in Richard Toll, Senegal</article-title>
<source>Trans. R. Soc. Trop. Med. Hyg.</source>
<year>2000</year>
<volume>94</volume>
<fpage>90</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1016/S0035-9203(00)90453-X</pub-id>
<pub-id pub-id-type="pmid">10748910</pub-id></element-citation></ref><ref id="B228-molecules-22-00058"><label>228.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Utzinger</surname><given-names>J.</given-names></name><name><surname>N&#x02019;Goran</surname><given-names>E.K.</given-names></name><name><surname>N&#x02019;Dri</surname><given-names>A.</given-names></name><name><surname>Lengeler</surname><given-names>C.</given-names></name><name><surname>Xiao</surname><given-names>S.</given-names></name><name><surname>Tanner</surname><given-names>M.</given-names></name></person-group>
<article-title>Oral artemether for prevention of Schistosoma mansoni infection: Randomised controlled trial</article-title>
<source>Lancet</source>
<year>2000</year>
<volume>355</volume>
<fpage>1320</fpage>
<lpage>1325</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(00)02114-0</pub-id>
<pub-id pub-id-type="pmid">10776745</pub-id></element-citation></ref><ref id="B229-molecules-22-00058"><label>229.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiao</surname><given-names>S.H.</given-names></name><name><surname>Booth</surname><given-names>M.</given-names></name><name><surname>Tanner</surname><given-names>M.</given-names></name></person-group>
<article-title>The prophylactic effects of artemether against <italic>Schistosoma</italic> japonicum infections</article-title>
<source>Parasitol. Today</source>
<year>2000</year>
<volume>16</volume>
<fpage>122</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="doi">10.1016/S0169-4758(99)01601-4</pub-id>
<pub-id pub-id-type="pmid">10689333</pub-id></element-citation></ref><ref id="B230-molecules-22-00058"><label>230.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Utzinger</surname><given-names>J.</given-names></name><name><surname>Chollet</surname><given-names>J.</given-names></name><name><surname>Jiqing</surname><given-names>Y.</given-names></name><name><surname>Jinyan</surname><given-names>M.</given-names></name><name><surname>Tanner</surname><given-names>M.</given-names></name><name><surname>Shuhua</surname><given-names>X.</given-names></name></person-group>
<article-title>Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals</article-title>
<source>Acta Trop.</source>
<year>2001</year>
<volume>80</volume>
<fpage>9</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1016/S0001-706X(01)00138-3</pub-id>
<pub-id pub-id-type="pmid">11495639</pub-id></element-citation></ref><ref id="B231-molecules-22-00058"><label>231.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>D.</given-names></name><name><surname>Vercruysse</surname><given-names>J.</given-names></name><name><surname>Verl&#x000e9;</surname><given-names>P.</given-names></name><name><surname>Kongs</surname><given-names>A.</given-names></name><name><surname>Diop</surname><given-names>M.</given-names></name></person-group>
<article-title>Short communication: What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections?</article-title>
<source>Trop. Med. Int. Health</source>
<year>2000</year>
<volume>5</volume>
<fpage>744</fpage>
<lpage>746</lpage>
<pub-id pub-id-type="doi">10.1046/j.1365-3156.2000.00628.x</pub-id>
<pub-id pub-id-type="pmid">11044270</pub-id></element-citation></ref><ref id="B232-molecules-22-00058"><label>232.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>White</surname><given-names>N.J.</given-names></name><name><surname>Nosten</surname><given-names>F.</given-names></name><name><surname>Looareesuwan</surname><given-names>S.</given-names></name><name><surname>Watkins</surname><given-names>W.M.</given-names></name><name><surname>Marsh</surname><given-names>K.</given-names></name><name><surname>Snow</surname><given-names>R.W.</given-names></name><name><surname>Kokwaro</surname><given-names>G.</given-names></name><name><surname>Ouma</surname><given-names>J.</given-names></name><name><surname>Hien</surname><given-names>T.T.</given-names></name><name><surname>Molyneux</surname><given-names>M.E.</given-names></name><etal/></person-group>
<article-title>Averting a malaria disaster</article-title>
<source>Lancet</source>
<year>1999</year>
<volume>353</volume>
<fpage>1965</fpage>
<lpage>1967</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(98)07367-X</pub-id>
<pub-id pub-id-type="pmid">10371589</pub-id></element-citation></ref><ref id="B233-molecules-22-00058"><label>233.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meshnick</surname><given-names>S.R.</given-names></name><name><surname>Thomas</surname><given-names>A.</given-names></name><name><surname>Ranz</surname><given-names>A.</given-names></name><name><surname>Xu</surname><given-names>C.M.</given-names></name><name><surname>Pan</surname><given-names>H.Z.</given-names></name></person-group>
<article-title>Artemisinin (qinghaosu): The role of intracellular hemin in its mechanism of antimalarial action</article-title>
<source>Mol. Biochem. Parasitol.</source>
<year>1991</year>
<volume>49</volume>
<fpage>181</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="doi">10.1016/0166-6851(91)90062-B</pub-id>
<pub-id pub-id-type="pmid">1775162</pub-id></element-citation></ref><ref id="B234-molecules-22-00058"><label>234.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krungkrai</surname><given-names>S.R.</given-names></name><name><surname>Yuthavong</surname><given-names>Y.</given-names></name></person-group>
<article-title>The antimalarial action on Plasmodium falciparum of qinghaosu and artesunate in combination with agents which modulate oxidant stress</article-title>
<source>Trans. R. Soc. Trop. Med. Hyg.</source>
<year>1987</year>
<volume>81</volume>
<fpage>710</fpage>
<lpage>714</lpage>
<pub-id pub-id-type="doi">10.1016/0035-9203(87)90003-4</pub-id>
<pub-id pub-id-type="pmid">3329778</pub-id></element-citation></ref><ref id="B235-molecules-22-00058"><label>235.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ingram</surname><given-names>K.</given-names></name><name><surname>Yaremenko</surname><given-names>I.A.</given-names></name><name><surname>Krylov</surname><given-names>I.B.</given-names></name><name><surname>Hofer</surname><given-names>L.</given-names></name><name><surname>Terentev</surname><given-names>A.O.</given-names></name><name><surname>Keiser</surname><given-names>J.</given-names></name></person-group>
<article-title>Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides</article-title>
<source>J. Med. Chem.</source>
<year>2012</year>
<volume>55</volume>
<fpage>8700</fpage>
<lpage>8711</lpage>
<pub-id pub-id-type="doi">10.1021/jm3009184</pub-id>
<?supplied-pmid 23013253?><pub-id pub-id-type="pmid">23013253</pub-id></element-citation></ref><ref id="B236-molecules-22-00058"><label>236.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mantawy</surname><given-names>M.M.</given-names></name><name><surname>Ali</surname><given-names>H.F.</given-names></name><name><surname>Rizk</surname><given-names>M.Z.</given-names></name></person-group>
<article-title>Therapeutic Effects of Allium sativum and Allium cepa in Schistosoma mansoni experimental infection</article-title>
<source>Rev. Inst. Med. Trop. Sao Paulo</source>
<year>2011</year>
<volume>53</volume>
<fpage>155</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="doi">10.1590/S0036-46652011000300007</pub-id>
<?supplied-pmid 21755238?><pub-id pub-id-type="pmid">21755238</pub-id></element-citation></ref><ref id="B237-molecules-22-00058"><label>237.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lima</surname><given-names>C.M.B.L.</given-names></name><name><surname>Freitas</surname><given-names>F.I.D.S.</given-names></name><name><surname>de Morais</surname><given-names>L.C.S.L.</given-names></name><name><surname>Cavalcanti</surname><given-names>M.G.D.S.</given-names></name><name><surname>Da Silva</surname><given-names>L.F.</given-names></name><name><surname>Padilha</surname><given-names>R.J.R.</given-names></name><name><surname>Barbosa</surname><given-names>C.G.S.</given-names></name><name><surname>dos Santos</surname><given-names>F.A.B.</given-names></name><name><surname>Alves</surname><given-names>L.C.</given-names></name><name><surname>Diniz</surname><given-names>M.D.F.F.M.</given-names></name></person-group>
<article-title>Ultrastructural study on the morphological changes to male worms of Schistosoma mansoni after in vitro exposure to allicin</article-title>
<source>Rev. Soc. Bras. Med. Trop.</source>
<year>2011</year>
<volume>44</volume>
<fpage>327</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="doi">10.1590/S0037-86822011005000023</pub-id>
<?supplied-pmid 21537796?><pub-id pub-id-type="pmid">21537796</pub-id></element-citation></ref><ref id="B238-molecules-22-00058"><label>238.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riad</surname><given-names>N.H.A.</given-names></name><name><surname>Fares</surname><given-names>N.H.</given-names></name><name><surname>Mostafa</surname><given-names>O.M.S.</given-names></name><name><surname>Mahmoud</surname><given-names>Y.</given-names></name></person-group>
<article-title>The Effect of Garlic on Murine Schistosomiasis Mansoni: A Histological and Ultrastructural Study on the Ileum</article-title>
<source>Res. J. Med. Med. Sci.</source>
<year>2008</year>
<volume>3</volume>
<fpage>188</fpage>
<lpage>201</lpage>
</element-citation></ref><ref id="B239-molecules-22-00058"><label>239.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riad</surname><given-names>N.H.A.</given-names></name><name><surname>Fares</surname><given-names>N.H.</given-names></name><name><surname>Mostafa</surname><given-names>O.M.S.</given-names></name><name><surname>Mahmoud</surname><given-names>Y.</given-names></name></person-group>
<article-title>The Effect of Garlic on Some Parasitological Parameters and On Hepatic Tissue Reactions in Experimental Schistosomiasis Mansoni</article-title>
<source>J. Appl. Sci. Res.</source>
<year>2007</year>
<volume>3</volume>
<fpage>949</fpage>
<lpage>960</lpage>
</element-citation></ref><ref id="B240-molecules-22-00058"><label>240.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koshimizu</surname><given-names>K.</given-names></name><name><surname>Ohigashi</surname><given-names>H.</given-names></name><name><surname>Huffman</surname><given-names>M.A.</given-names></name></person-group>
<article-title>Use of Vernonia amygdalina by wild chimpanzee: Possible roles of its bitter and related constituents</article-title>
<source>Physiol. Behav.</source>
<year>1994</year>
<volume>56</volume>
<fpage>1209</fpage>
<lpage>1216</lpage>
<pub-id pub-id-type="doi">10.1016/0031-9384(94)90368-9</pub-id>
<pub-id pub-id-type="pmid">7878093</pub-id></element-citation></ref><ref id="B241-molecules-22-00058"><label>241.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jisaka</surname><given-names>M.</given-names></name><name><surname>Kawanaka</surname><given-names>M.</given-names></name><name><surname>Sugiyama</surname><given-names>H.</given-names></name><name><surname>Takegawa</surname><given-names>K.</given-names></name><name><surname>Huffman</surname><given-names>M.A.</given-names></name><name><surname>Ohigashi</surname><given-names>H.</given-names></name><name><surname>Koshimizu</surname><given-names>K.</given-names></name></person-group>
<article-title>Antischistosomal activities of sesquiterpene lactones and steroid glucosides from Vernonia amygdalina, possibly used by wild chimpanzees against parasite-related diseases</article-title>
<source>Biosci. Biotechnol. Biochem.</source>
<year>1992</year>
<volume>56</volume>
<fpage>845</fpage>
<lpage>846</lpage>
<pub-id pub-id-type="doi">10.1271/bbb.56.845</pub-id>
<?supplied-pmid 1368347?><pub-id pub-id-type="pmid">1368347</pub-id></element-citation></ref><ref id="B242-molecules-22-00058"><label>242.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wiegrebe</surname><given-names>W.</given-names></name><name><surname>Kramer</surname><given-names>W.J.</given-names></name><name><surname>Shamma</surname><given-names>M.</given-names></name></person-group>
<article-title>The emetine alkaloids</article-title>
<source>J. Nat. Prod.</source>
<year>1984</year>
<volume>47</volume>
<fpage>397</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1021/np50033a001</pub-id>
</element-citation></ref><ref id="B243-molecules-22-00058"><label>243.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akinboye</surname><given-names>E.S.</given-names></name></person-group>
<article-title>Biological Activities of Emetine</article-title>
<source>Open Nat. Prod. J.</source>
<year>2011</year>
<volume>4</volume>
<fpage>8</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.2174/1874848101104010008</pub-id>
</element-citation></ref><ref id="B244-molecules-22-00058"><label>244.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grollman</surname><given-names>A.P.</given-names></name></person-group>
<article-title>Structural Basis for Inhibition of Protein Synthesis By Emetine and Cycloheximide Based on an Analogy between Ipecac Alkaloids and Glutarimide Antibiotics</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1966</year>
<volume>56</volume>
<fpage>1867</fpage>
<lpage>1874</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.56.6.1867</pub-id>
<?supplied-pmid 16591432?><pub-id pub-id-type="pmid">16591432</pub-id></element-citation></ref><ref id="B245-molecules-22-00058"><label>245.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grollman</surname><given-names>A.P.</given-names></name></person-group>
<article-title>Inhibitors of Protein Biosynthesis V. Effects of Emetine on Protein and Nucleic Acid Biosynthesis in HeLa Cells</article-title>
<source>J. Biol. Chem.</source>
<year>1968</year>
<volume>243</volume>
<fpage>4089</fpage>
<lpage>4094</lpage>
<?supplied-pmid 4299101?><pub-id pub-id-type="pmid">4299101</pub-id></element-citation></ref><ref id="B246-molecules-22-00058"><label>246.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lietman</surname><given-names>P.S.</given-names></name></person-group>
<article-title>Mitochondrial protein synthesis: Inhibition by emetine hydrochloride</article-title>
<source>Mol. Pharmacol.</source>
<year>1971</year>
<volume>7</volume>
<fpage>122</fpage>
<lpage>128</lpage>
<?supplied-pmid 4399461?><pub-id pub-id-type="pmid">4399461</pub-id></element-citation></ref><ref id="B247-molecules-22-00058"><label>247.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blanc</surname><given-names>F.</given-names></name><name><surname>Nosny</surname><given-names>Y.</given-names></name></person-group>
<article-title>[Treatment of schistosomiasis with injections of 2-dehydro-emetine]</article-title>
<source>Presse Med.</source>
<year>1968</year>
<volume>76</volume>
<fpage>1419</fpage>
<lpage>1420</lpage>
<?supplied-pmid 5659882?><pub-id pub-id-type="pmid">5659882</pub-id></element-citation></ref><ref id="B248-molecules-22-00058"><label>248.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alonso</surname><given-names>D.F.</given-names></name><name><surname>Farina</surname><given-names>H.G.</given-names></name><name><surname>Skilton</surname><given-names>G.</given-names></name><name><surname>Gabri</surname><given-names>M.R.</given-names></name><name><surname>de Lorenzo</surname><given-names>M.S.</given-names></name><name><surname>Gomez</surname><given-names>D.E.</given-names></name></person-group>
<article-title>Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis</article-title>
<source>Breast Cancer Res. Treat.</source>
<year>1998</year>
<volume>50</volume>
<fpage>83</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1023/A:1006058409974</pub-id>
<?supplied-pmid 9802623?><pub-id pub-id-type="pmid">9802623</pub-id></element-citation></ref><ref id="B249-molecules-22-00058"><label>249.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>J.L.</given-names></name><name><surname>Brown</surname><given-names>M.S.</given-names></name></person-group>
<article-title>Regulation of the mevalonate pathway</article-title>
<source>Nature</source>
<year>1990</year>
<volume>343</volume>
<fpage>425</fpage>
<lpage>430</lpage>
<pub-id pub-id-type="doi">10.1038/343425a0</pub-id>
<?supplied-pmid 1967820?><pub-id pub-id-type="pmid">1967820</pub-id></element-citation></ref><ref id="B250-molecules-22-00058"><label>250.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>G.Z.</given-names></name><name><surname>Foster</surname><given-names>L.</given-names></name><name><surname>Bennett</surname><given-names>J.L.</given-names></name></person-group>
<article-title>Antischistosomal action of mevinolin: Evidence that 3-hydroxy-methylglutaryl-coenzyme a reductase activity in Schistosoma mansoni is vital for parasite survival</article-title>
<source>Naunyn. Schmiedebergs. Arch. Pharmacol.</source>
<year>1990</year>
<volume>342</volume>
<fpage>477</fpage>
<lpage>482</lpage>
<pub-id pub-id-type="doi">10.1007/BF00169467</pub-id>
<?supplied-pmid 2123968?><pub-id pub-id-type="pmid">2123968</pub-id></element-citation></ref><ref id="B251-molecules-22-00058"><label>251.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.M.</given-names></name><name><surname>Coultas</surname><given-names>K.A.</given-names></name></person-group>
<article-title>Identification of plumbagin and sanguinarine as effective chemotherapeutic agents for treatment of schistosomiasis</article-title>
<source>Int. J. Parasitol. Drugs Drug Resist.</source>
<year>2013</year>
<volume>3</volume>
<fpage>28</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijpddr.2012.12.001</pub-id>
<?supplied-pmid 23641325?><pub-id pub-id-type="pmid">23641325</pub-id></element-citation></ref><ref id="B252-molecules-22-00058"><label>252.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prasad</surname><given-names>K.B.</given-names></name><name><surname>Reddy</surname><given-names>G.A.K.</given-names></name><name><surname>Joy</surname><given-names>J.M.</given-names></name><name><surname>Rasheed</surname><given-names>A.</given-names></name><name><surname>Dalith</surname><given-names>D.</given-names></name></person-group>
<article-title>Natural antifilarial drugs: A review</article-title>
<source>Int. J. Pharmacol. Toxicol.</source>
<year>2011</year>
<volume>1</volume>
<fpage>1</fpage>
<lpage>10</lpage>
</element-citation></ref><ref id="B253-molecules-22-00058"><label>253.</label><element-citation publication-type="webpage">
<article-title>Lymphatic Filariasis</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.webcitation.org/6mVkfD6pl">http://www.webcitation.org/6mVkfD6pl</ext-link></comment>
<date-in-citation>(accessed on 4 December 2016)</date-in-citation>
</element-citation></ref><ref id="B254-molecules-22-00058"><label>254.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bulman</surname><given-names>C.A.</given-names></name><name><surname>Bidlow</surname><given-names>C.M.</given-names></name><name><surname>Lustigman</surname><given-names>S.</given-names></name><name><surname>Cho-Ngwa</surname><given-names>F.</given-names></name><name><surname>Williams</surname><given-names>D.</given-names></name><name><surname>Rasc&#x000f3;n</surname><given-names>A.A.</given-names></name><name><surname>Tricoche</surname><given-names>N.</given-names></name><name><surname>Samje</surname><given-names>M.</given-names></name><name><surname>Bell</surname><given-names>A.</given-names></name><name><surname>Suzuki</surname><given-names>B.</given-names></name><etal/></person-group>
<article-title>Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis</article-title>
<source>PLoS Negl. Trop. Dis.</source>
<year>2015</year>
<volume>9</volume>
<elocation-id>e0003534</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0003534</pub-id>
<?supplied-pmid 25700363?><pub-id pub-id-type="pmid">25700363</pub-id></element-citation></ref><ref id="B255-molecules-22-00058"><label>255.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Misra</surname><given-names>N.</given-names></name><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Raj</surname><given-names>K.</given-names></name><name><surname>Dangi</surname><given-names>A.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Misra-Bhattacharya</surname><given-names>S.</given-names></name></person-group>
<article-title>Chemical constituents and antifilarial activity of Lantana camara against human lymphatic filariid Brugia malayi and rodent filariid Acanthocheilonema viteae maintained in rodent hosts</article-title>
<source>Parasitol. Res.</source>
<year>2007</year>
<volume>100</volume>
<fpage>439</fpage>
<lpage>448</lpage>
<pub-id pub-id-type="doi">10.1007/s00436-006-0312-y</pub-id>
<?supplied-pmid 17061115?><pub-id pub-id-type="pmid">17061115</pub-id></element-citation></ref><ref id="B256-molecules-22-00058"><label>256.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mathew</surname><given-names>N.</given-names></name><name><surname>Misra-Bhattacharya</surname><given-names>S.</given-names></name><name><surname>Perumal</surname><given-names>V.</given-names></name><name><surname>Muthuswamy</surname><given-names>K.</given-names></name></person-group>
<article-title>Antifilarial lead molecules isolated from Trachyspermum ammi</article-title>
<source>Molecules</source>
<year>2008</year>
<volume>13</volume>
<fpage>2156</fpage>
<lpage>2168</lpage>
<pub-id pub-id-type="doi">10.3390/molecules13092156</pub-id>
<?supplied-pmid 18830147?><pub-id pub-id-type="pmid">18830147</pub-id></element-citation></ref><ref id="B257-molecules-22-00058"><label>257.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>G.</given-names></name><name><surname>Wei</surname><given-names>D.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name></person-group>
<article-title>An alternative total synthesis of solamargine</article-title>
<source>Sci. China Chem.</source>
<year>2012</year>
<volume>55</volume>
<fpage>1247</fpage>
<lpage>1251</lpage>
<pub-id pub-id-type="doi">10.1007/s11426-011-4476-7</pub-id>
</element-citation></ref><ref id="B258-molecules-22-00058"><label>258.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Misra</surname><given-names>S.</given-names></name><name><surname>Verma</surname><given-names>M.</given-names></name><name><surname>Mishra</surname><given-names>S.K.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Lakshmi</surname><given-names>V.</given-names></name><name><surname>Misra-Bhattacharya</surname><given-names>S.</given-names></name></person-group>
<article-title>Gedunin and photogedunin of Xylocarpus granatum possess antifilarial activity against human lymphatic filarial parasite Brugia malayi in experimental rodent host</article-title>
<source>Parasitol. Res.</source>
<year>2011</year>
<volume>109</volume>
<fpage>1351</fpage>
<lpage>1360</lpage>
<pub-id pub-id-type="doi">10.1007/s00436-011-2380-x</pub-id>
<?supplied-pmid 21523424?><pub-id pub-id-type="pmid">21523424</pub-id></element-citation></ref><ref id="B259-molecules-22-00058"><label>259.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sharma</surname><given-names>R.</given-names></name><name><surname>Petare</surname><given-names>S.</given-names></name><name><surname>Shinda</surname><given-names>G.</given-names></name><name><surname>Goswami</surname><given-names>K.</given-names></name><name><surname>Reddy</surname><given-names>M.V.R.</given-names></name></person-group>
<article-title>Novel drug designing rationale against B rugia malayi microfilariae using herbal extracts</article-title>
<source>Asian Pac. J. Trop. Dis.</source>
<year>2010</year>
<fpage>846</fpage>
<lpage>850</lpage>
<pub-id pub-id-type="doi">10.1016/S1995-7645(10)60204-0</pub-id>
</element-citation></ref><ref id="B260-molecules-22-00058"><label>260.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>L.</given-names></name><name><surname>Mathew</surname><given-names>N.</given-names></name><name><surname>Muthuswamy</surname><given-names>K.</given-names></name></person-group>
<article-title>In vitro antifilarial activity of glutathione S-transferase inhibitors</article-title>
<source>Parasitol. Res.</source>
<year>2009</year>
<volume>105</volume>
<fpage>1179</fpage>
<lpage>1182</lpage>
<pub-id pub-id-type="doi">10.1007/s00436-009-1534-6</pub-id>
<?supplied-pmid 19562376?><pub-id pub-id-type="pmid">19562376</pub-id></element-citation></ref><ref id="B261-molecules-22-00058"><label>261.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahajan</surname><given-names>R.S.</given-names></name><name><surname>Goswami</surname><given-names>K.</given-names></name><name><surname>Hande</surname><given-names>S.</given-names></name><name><surname>Bhoj</surname><given-names>P.</given-names></name></person-group>
<article-title>Evolution of anti-filarial therapeutics&#x0202f;: An overview</article-title>
<source>J. Microbiol. Antimicrob. Agents</source>
<year>2015</year>
<volume>1</volume>
<fpage>16</fpage>
<lpage>22</lpage>
</element-citation></ref><ref id="B262-molecules-22-00058"><label>262.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoerauf</surname><given-names>A.</given-names></name><name><surname>Specht</surname><given-names>S.</given-names></name><name><surname>B&#x000fc;ttner</surname><given-names>M.</given-names></name><name><surname>Pfarr</surname><given-names>K.</given-names></name><name><surname>Mand</surname><given-names>S.</given-names></name><name><surname>Fimmers</surname><given-names>R.</given-names></name><name><surname>Marfo-Debrekyei</surname><given-names>Y.</given-names></name><name><surname>Konadu</surname><given-names>P.</given-names></name><name><surname>Debrah</surname><given-names>A.Y.</given-names></name><name><surname>Bandi</surname><given-names>C.</given-names></name><etal/></person-group>
<article-title>Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: A randomized placebo-controlled study</article-title>
<source>Med. Microbiol. Immunol.</source>
<year>2008</year>
<volume>197</volume>
<fpage>295</fpage>
<lpage>311</lpage>
<pub-id pub-id-type="doi">10.1007/s00430-007-0062-1</pub-id>
<?supplied-pmid 17999080?><pub-id pub-id-type="pmid">17999080</pub-id></element-citation></ref><ref id="B263-molecules-22-00058"><label>263.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lakshmi</surname><given-names>V.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Kumar Mishra</surname><given-names>S.</given-names></name><name><surname>Misra</surname><given-names>S.</given-names></name><name><surname>Verma</surname><given-names>M.</given-names></name><name><surname>Misra-Bhattacharya</surname><given-names>S.</given-names></name></person-group>
<article-title>In vitro and in vivo antifilarial potential of marine sponge, Haliclona exigua (Kirkpatrick), against human lymphatic filarial parasite Brugia malayi: Antifilarial activity of H. exigua</article-title>
<source>Parasitol. Res.</source>
<year>2009</year>
<volume>105</volume>
<fpage>1295</fpage>
<lpage>1301</lpage>
<pub-id pub-id-type="doi">10.1007/s00436-009-1555-1</pub-id>
<?supplied-pmid 19626340?><pub-id pub-id-type="pmid">19626340</pub-id></element-citation></ref><ref id="B264-molecules-22-00058"><label>264.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gupta</surname><given-names>J.</given-names></name><name><surname>Misra</surname><given-names>S.</given-names></name><name><surname>Mishra</surname><given-names>S.K.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Srivastava</surname><given-names>M.N.</given-names></name><name><surname>Lakshmi</surname><given-names>V.</given-names></name><name><surname>Misra-Bhattacharya</surname><given-names>S.</given-names></name></person-group>
<article-title>Antifilarial activity of marine sponge Haliclona oculata against experimental Brugia malayi infection</article-title>
<source>Exp. Parasitol.</source>
<year>2012</year>
<volume>130</volume>
<fpage>449</fpage>
<lpage>455</lpage>
<pub-id pub-id-type="doi">10.1016/j.exppara.2012.01.009</pub-id>
<?supplied-pmid 22306280?><pub-id pub-id-type="pmid">22306280</pub-id></element-citation></ref><ref id="B265-molecules-22-00058"><label>265.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dhananjeyan</surname><given-names>M.R.</given-names></name><name><surname>Milev</surname><given-names>Y.P.</given-names></name><name><surname>Kron</surname><given-names>M.A.</given-names></name><name><surname>Nair</surname><given-names>M.G.</given-names></name></person-group>
<article-title>Synthesis and activity of substituted anthraquinones against a human filarial parasite, Brugia malayi</article-title>
<source>J. Med. Chem.</source>
<year>2005</year>
<volume>48</volume>
<fpage>2822</fpage>
<lpage>2830</lpage>
<pub-id pub-id-type="doi">10.1021/jm0492655</pub-id>
<?supplied-pmid 15828820?><pub-id pub-id-type="pmid">15828820</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="molecules-22-00058-f001" position="float"><label>Figure 1</label><caption><p>Antitrypanosomal drugs in clinical use.</p></caption><graphic xlink:href="molecules-22-00058-g001"/></fig><fig id="molecules-22-00058-f002" position="float"><label>Figure 2</label><caption><p>Trypanocidal alkaloids, saponins, and peroxides isolated from marine organisms.</p></caption><graphic xlink:href="molecules-22-00058-g002"/></fig><fig id="molecules-22-00058-f003" position="float"><label>Figure 3</label><caption><p>Trypanocidal phenolic and quinone derivatives.</p></caption><graphic xlink:href="molecules-22-00058-g003"/></fig><fig id="molecules-22-00058-f004" position="float"><label>Figure 4</label><caption><p>Trypanocidal terpenes and other metabolites.</p></caption><graphic xlink:href="molecules-22-00058-g004"/></fig><fig id="molecules-22-00058-f005" position="float"><label>Figure 5</label><caption><p>Trypanocidal semisynthetic compounds based on natural product scaffolds.</p></caption><graphic xlink:href="molecules-22-00058-g005"/></fig><fig id="molecules-22-00058-f006" position="float"><label>Figure 6</label><caption><p>Currently used antileishmanial drugs.</p></caption><graphic xlink:href="molecules-22-00058-g006"/></fig><fig id="molecules-22-00058-f007" position="float"><label>Figure 7</label><caption><p>Antileishmanial flavonoids, sterols, chalcones, coumarins, tannins and aurones.</p></caption><graphic xlink:href="molecules-22-00058-g007"/></fig><fig id="molecules-22-00058-f008" position="float"><label>Figure 8</label><caption><p>Antileishmanial iridoid, naphtoquinone, quinolines, and alkaloids.</p></caption><graphic xlink:href="molecules-22-00058-g008"/></fig><fig id="molecules-22-00058-f009" position="float"><label>Figure 9</label><caption><p>Anti-leishmanial saponins.</p></caption><graphic xlink:href="molecules-22-00058-g009"/></fig><fig id="molecules-22-00058-f010" position="float"><label>Figure 10</label><caption><p>Lignans, taxoids, anthranoids, terpenes and other leishmanicidal metabolites.</p></caption><graphic xlink:href="molecules-22-00058-g010"/></fig><fig id="molecules-22-00058-f011" position="float"><label>Figure 11</label><caption><p>Marine-derived antileishmanial natural products.</p></caption><graphic xlink:href="molecules-22-00058-g011"/></fig><fig id="molecules-22-00058-f012" position="float"><label>Figure 12</label><caption><p>Natural product-based synthetic/semisynthetic antileishmanial compounds.</p></caption><graphic xlink:href="molecules-22-00058-g012"/></fig><fig id="molecules-22-00058-f013" position="float"><label>Figure 13</label><caption><p>Clinically established antischistosomal drugs.</p></caption><graphic xlink:href="molecules-22-00058-g013"/></fig><fig id="molecules-22-00058-f014" position="float"><label>Figure 14</label><caption><p>Antischistosomal alkaloids and ginger-derived metabolites.</p></caption><graphic xlink:href="molecules-22-00058-g014"/></fig><fig id="molecules-22-00058-f015" position="float"><label>Figure 15</label><caption><p>Antischistosomal phloroglucinols, curcumin, and phytol.</p></caption><graphic xlink:href="molecules-22-00058-g015"/></fig><fig id="molecules-22-00058-f016" position="float"><label>Figure 16</label><caption><p>Antischistosomal cinchona alkaloids and derivatives.</p></caption><graphic xlink:href="molecules-22-00058-g016"/></fig><fig id="molecules-22-00058-f017" position="float"><label>Figure 17</label><caption><p>Artemisinin derivatives with antischistosomal potency.</p></caption><graphic xlink:href="molecules-22-00058-g017"/></fig><fig id="molecules-22-00058-f018" position="float"><label>Figure 18</label><caption><p>Structures of allicin, vernodalin, emetine and dehydroemetine.</p></caption><graphic xlink:href="molecules-22-00058-g018"/></fig><fig id="molecules-22-00058-f019" position="float"><label>Figure 19</label><caption><p>Structures of Mevinolin (lovastatin), plumbagin and sanguinarine.</p></caption><graphic xlink:href="molecules-22-00058-g019"/></fig><fig id="molecules-22-00058-f020" position="float"><label>Figure 20</label><caption><p>Naturally derived antifilarial compounds.</p></caption><graphic xlink:href="molecules-22-00058-g020"/></fig><fig id="molecules-22-00058-f021" position="float"><label>Figure 21</label><caption><p>Synthetic antifilarial quinones based on natural product scaffolds.</p></caption><graphic xlink:href="molecules-22-00058-g021"/></fig></floats-group></article>